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ABSTRACT 
____________________________________________________ 
 
Medroxyprogesterone acetate (MPA) and norethisterone (NET) and its 
derivatives (norethisterone enanthate (NET-EN); norethisterone acetate (NET-
A)), are used by millions of women as contraceptives and in hormone 
replacement therapy (HRT). Although both progestins are widely used, very 
little is known about their mechanism of action at the molecular level. In this 
thesis, the differential regulation of gene expression and molecular 
mechanism of action via different steroid receptors by these synthetic 
progestons, as compared to progesterone (Prog) was investigated in human 
cell lines. In the first part of the study, the effect of Prog, MPA and NET-A on 
the expression of endogenous cytokine genes was investigated in two 
epithelial cell lines of the human female genital tract, Ect1/E6E7 (an 
ectocervical cell line) and Vk2/E6E7 (a vaginal cell line). Quantitative realtime 
RT-PCR (QPCR) showed ligand-specific and cell-specific regulation of the 
interleukin (IL)-6, IL-8 and RANTES (Regulated-upon-Activation, Normal T cell 
Expressed and Secreted) genes with Prog, MPA and NET-A. Moreover, the 
repression of the TNFα-induced RANTES gene by MPA in the Ect1/E6E7 cell 
line was found to be mediated by the androgen receptor (AR). The second 
part of the study focused on elucidating the androgenic activities of these two 
progestins, in comparison to Prog. Competitive binding in whole cells revealed 
that Prog, MPA and NET-A have a similar binding affinity for the hAR as the 
natural androgen dihydrotestosterone (DHT). Both transactivation and 
transrepression transcriptional assays demonstrate that, unlike Prog, MPA 
and NET-A are efficacious AR agonists, with activities comparable to DHT. 
Using a mammalian two-hydrid assay, it was shown that MPA and NET-A 
exert their androgenic actions by different mechanisms. NET-A, like DHT and 
other well-characterised androgens, induces the ligand-dependent interaction 
between the NH2- and COOH-terminal domains (N/C-interaction) of the AR 
independent of promoter-context, while MPA does this in a promoter-
dependent manner. In the third part of this study, competitive binding revealed 
that MPA and NET-A have a similar binding affinity to each other, but about a 
100-fold lower affinity than Prog for the human mineralocorticoid receptor 
(hMR), while RU486 has an even lower affinity for the hMR. Promoter-reporter 
assays showed that MPA, NET-A and RU486 are all antagonists of the hMR, 
but unlike Prog, they have weak antagonistic activity. However, on the 
endogenous MR-regulated Orm-1 (α-glycolytic protein or orosomucoid-1) 
gene expressed in a rat cardiomyocyte cell line, NET-A and RU486, but not 
MPA, has similar antagonistic activity as Prog. This study is the first to show 
that, NET-A and RU486, but not MPA, can dissociate between 
transrepression and transactivation via the hMR. Taken together, these 
results show that natural Prog and the synthetic progestins, MPA and NET-A 
display differential promoter-, cell- and receptor-specific effects on gene 
expression. Furthermore they may have important implications for 
cervicovaginal immune function, cardiovascular and other physiological 
functions. 
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OPSOMMING 
_____________________________________________________ 
 
Medroksieprogesteroon asetaat (MPA), noretisteroon (NET) en derivate 
daarvan (noretisteroon enantaat (NET-EN); noretisteroon asetaat (NET-A), 
word deur miljoene vroue gebruik as voorbehoedmiddels en vir hormoon 
vervangingsterapie (HVT). Tenspyte daarvan dat beide hierdie progestiene 
algemeen gebruik word, is min bekend oor hulle meganisme van werking op 
molekulêre vlak. In hierdie proefskrif word die differensiële regulering van 
geenuitdrukking asook die molekulêre meganisme van werking deur middel 
van steroïedreseptore van beide hierdie sintetiese progestiene, ondersoek, en 
vergelyk met progesteroon (Prog), in menslike sellyne. In die eerste deel van 
die studie is die effek van Prog, MPA en NET-A op die uitdrukking van 
endogene sitokinien gene ondersoek in twee epiteel sellyne van die menslike 
vroulike geslagskanaal, Ect1/E6E7 (‘n ektoservikale sellyn) en Vk2/E6E7 (‘n 
vaginale sellyn). Kwantitatiewe intydse RT-PKR het ligand-spesifieke en sel-
spesifieke regulering van interleukien (IL)-6, IL-8 en RANTES (Regulering-na-
Aktivering, Normale T-sel Uitgedrukte en Afgeskei) gene getoon met Prog, 
MPA en NET-A. Verder is gevind dat die onderdrukking van die TNF-α-
geïnduseerde RANTES geen deur MPA in die Ect1/E6E7 sellyn bemiddel 
word deur die androgeen reseptor (AR). Die tweede deel van die studie het 
gefokus op die toeligting van die androgeniese aktiwiteit van die twee 
progestiene in vergelyking met Prog. Kompeterende binding in volselle het 
getoon dat Prog, MPA en NET-A ‘n soortelyke bindings affiniteit vir die 
menslike AR as die natuurlike androgeen dehidrotestosteroon (DHT) vir die 
menslike AR het. Beide transaktiverings en transonderdrukkings 
transkripsionele analieses toon dat, anders as Prog, MPA en NET-A 
effektiewe AR agoniste is met aktiwiteite wat vergelykbaar is met die van 
DHT. Deur die gebruik van ‘n soogdier twee-hibried toets, kon gewys word dat 
MPA en NET-A hul androgeniese effekte uitoefen deur verskillende 
meganismes. NET-A, soos DHT en ander goed gekarakteriseerde androgene, 
induseer die ligand-afhanklike interaksie tussen die NH2- en COOH-terminale 
domeine (N/C-interaksie) van die AR, onafhanklik van die promoter-konteks. 
MPA, aan die ander kant, doen dit op ‘n promoter-afhanklike manier. In die 
derde deel van die studie het kompeterende binding getoon dat MPA en NET-
A soortelyke relatiewe bindings affiniteite vir die menslike mineralokortikoïed 
reseptor (hMR) het, maar dat hierdie affiniteit ongeveer 100-voud laer is as 
die van Prog en dat die affiniteit van RU486 vir hMR selfs nog laer is. 
Promoter-rapporteerder toetse het getoon dat MPA, NET-A en RU486 almal 
antagoniste van die hMR is, maar anders as Prog, is hierdie ‘n swak 
antagonistiese aktiwiteit. Nietemin, op die endogene MR-gereguleerde Orm-1 
(α-glikolitiese proteïen of orosomukoïed-1) geen, uitgedruk in ‘n rot 
kardiomiosiet sellyn, het NET-A en RU486, maar nie MPA nie, ‘n soortgelyke 
antagonistiese aktiwiteit as Prog. Hierdie studie is die eerste om te wys dat 
NET-A en RU486, maar nie MPA nie, kan onderskei tussen transrepressie en 
transaktivering deur middel van die hMR. Samevattend toon die resultate dat 
natuurlike Prog en die sintetiese progestiene, MPA en NET-A, ‘n differentiële 
promoter-, sel- en reseptor-spesifieke effek op geenuitdrukking het. Verder 
mag die resultate belangrike implikasies vir servikovaginale immuunfunksie, 
asook kardiovaskulêre en ander fisiologiese funksies, inhou. 
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THESIS OUTLINE 
_____________________________________________________ 
This thesis consists of five chapters. Chapters 1, 2, 3 and 4 are written up in 
manuscript format. Chapters 2, 3 and 4 include a brief introduction to the 
specific aims of the particular studies, report and discuss the undertaken 
experiments and the results obtained. These chapters will shortly be 
submitted for publication. The references for all the chapters are included in 
one section following Chapter 5.  
 
1. Chapter 1: Literature review. This chapter gives a detailed overview of 
the relevant knowledge currently available in the literature, with a 
particular focus on directly comparing the molecular mechanism of 
action of medroxyprogesterone acetate (MPA) and norethisterone 
enanthate (NET-EN)/norethisterone acetate (NET-A). The review was 
written by the candidate. Nicolette Verhoog also works on the progestin 
project, and contributed in the exchange of information and ideas. 
Dominique Koubovec previously reviewed the topic in her PhD thesis 
and this material was used as a guideline for the current review. 
2. Chapter 2: Differential regulation of endogenous pro-inflammatory 
cytokine genes by MPA and NET-A in cell lines of the female 
genital tract. This chapter contains the results of a study investigating 
and comparing the regulation of endogenous cytokine genes by Prog, 
MPA and NET-A in Ect1/E6E7 (human ectocervical) and Vk2/E6E7 
(human vaginal) cell lines. All experiments were performed by the 
candidate, except for the maintenance of the cell lines, which was 
performed by Carmen Langeveldt.  
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3. Chapter 3: A comparative study of the androgenic properties of 
progesterone and the synthetic progestins, medroxyprogesterone 
acetate (MPA) and norethisterone acetate (NET-A). This chapter 
includes the results of a study into the molecular mechanism of action 
of MPA and NET-A, as compared to Prog, via the hAR in the COS-1 
cell line. All experiments were performed by the candidate, except for 
the maintenance of the COS-1 monkey kidney cell line, which was 
performed by Carmen Langeveldt.   
4. Chapter 4: Investigating the anti-mineralocorticoid properties of 
synthetic progestins used in hormone replacement therapy. This 
chapter reports on the findings of a study investigating whether MPA 
and NET-A, like Prog, can act via the MR. This study was performed in 
COS-1 (monkey kidney) as well as H9C2 cell lines (rat 
cardiomyocytes). All experiments were performed by the candidate, 
except for the maintenance of the cell lines, which was performed by 
Carmen Langeveldt.   
5. Chapter 5: Conclusions and Future Perspectives. In this final 
chapter, the results of the overall study are discussed and conclusions 
drawn in the context of the larger body of work.  
 
The appendices (A-D), found at the back of the thesis, include data not 
shown, but referred to as supplementary material within the manuscripts, as 
well as additional results not included in the chapters and definitions. 
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The literature review presented in Chapter 1 will be submitted to Endocrine 
Reviews. The manuscript presented in Chapter 2 will be submitted to 
Contraception, while the manuscripts presented in Chapter 3 and Chapter 4 
will be submitted to the Journal of Steroid Biochemistry and Molecular Biology 
and Molecular and Cellular Endocrinology, respectively. 
 
Consistent with manuscript format, the collective term “we” and “our” is often 
used in the thesis. However, all the experimental work was performed by the 
candidate, barring the figure in Appendix B5 which was performed by Tamzin 
Tanner (MSc thesis) previously from the Hapgood laboratory. 
 xvi 
TABLE OF CONTENTS 
_____________________________________________________ 
LIST OF ABBREVIATIONS                viii 
THESIS OUTLINE          xv 
 
CHAPTER 1 
REVIEWING THE MOLECULAR MECHANISM OF ACTION OF 
MEDROXYPROGESTERONE ACETATE AND 
NORETHISTERONE ENANTHATE/ACETATE      1 
Abstract             2 
1.1 Introduction            3 
1.2 Therapeutic applications          7 
1.2.1 Contraception            7 
1.2.1.1 Female contraception         7 
1.2.1.2 Male contraception          9 
1.2.2 Hormone replacement therapy       10 
1.2.3 Other applications         13 
1.3 Physiological effects of MPA and NET-EN/NET-A/NET  14 
1.3.1 Reproduction          14 
1.3.2 Adrenal function         18 
1.3.3 Skeletal function         20 
1.3.4 Brain function          24 
1.3.5 Reproductive cancers        27 
 1.3.5.1 Breast cancer        27 
 xvii 
 1.3.5.2 Endometrial, ovarian and cerviCal cancers    31 
1.3.6 Cardiovascular function        33 
1.3.7 Immune function         41 
 
1.4 Mechanism of action        48 
1.4.1 Serum binding globulins        49 
1.4.2 Steroid receptors         52 
1.4.3 Effects of MPA and NET on target genes via the:    56 
1.4.3.1 Progesterone receptor (PR)      56 
1.4.3.2 Glucocorticoid receptor (GR)      62 
1.4.3.3 Androgen receptor  (AR)       68 
1.4.3.4 Mineralocorticoid receptor  (MR)      73 
1.4.3.5 Estrogen receptor  (ER)       74 
1.5 Conclusion          75 
 
  
HYPOTHESES AND AIMS                 78 
 
CHAPTER 2 
DIFFERENTIAL REGULATION OF ENDOGENOUS PRO-
INFLAMMATORY CYTOKINE GENES BY MPA AND NET-A IN 
CELL LINES OF THE FEMALE GENITAL TRACT    80 
Abstract           81 
Introduction          83 
Materials and methods        86 
 xviii 
Inducing compounds         86 
Cell culture            87 
Plasmids           88 
Isolation of total RNA and realtime quantitative RT-PCR (QPCR) 
analysis of representative genes        88 
Western blotting          89 
Whole cell binding assays to determine steroid receptor contentt in  
the Ect1/E6E7 and Vk2/E6E7 cell line       90 
Luciferase reporter assays         91 
 
Data manipulation and statistical analysis      92 
Results           92 
MPA and NET-A, unlike Prog, exhibit differential patterns of gene  
regulation on pro-inflammatory chemokine       92 
The PR, AR and GR are expressed in both ectocervical and vaginal  
cell lines           93 
Receptor-specific antagonists indicate a role for the AR in the  
downregulation of the RANTES pro-inflammatory chemokine gene by  
MPA in the ectocervical cell line        98 
Only the GR was transcriptionally active in promoter-reporter  
Transactivation  assays in both ectocervical and vaginal cell lines           100 
Discussion                105 
 
 
 xix 
CHAPTER 3 
A COMPARATIVE STUDY OF THE ANDROGENIC 
PROPERTIES OF PROGESTERONE AND THE SYNTHETIC 
PROGESTINS, MEDROXYPROGESTERONE ACETATE (MPA) 
AND NORETHISTERONE ACETATE (NET-A)          112 
Abstract                 113 
Introduction                114 
Materials and methods              120 
Inducing compounds               120 
Plasmids                  120 
Cell culture                  121 
Whole cell binding assays                121 
Transient transfection assays                 123 
Mammalian two-hybrid assays                124 
Data manipulation and statistical analysis              124 
Results                 125 
MPA and NET-A have a similar binding affinity for the AR            125 
MPA and NET-A display androgen agonist activity that is similar to  
that of DHT for transactivation                126 
MPA, but not NET-A, induces the ligand-dependent interaction  
between the amino- and carboxyl-terminals of the androgen receptor  
in a promoter-dependent manner                132 
MPA and NET-A display similar androgenic properties for transrepression 137 
 xx 
Discussion                142 
 
CHAPTER 4 
INVESTIGATING THE ANTI-MINERALOCORTICOID 
PROPERTIES OF SYNTHETIC PROGESTINS USED IN 
HORMONE REPLACEMENT THERAPY           152 
Abstract                 153 
Introduction                155 
Materials and methods              159 
Plasmids                   159 
Inducing compounds                  160 
Cell culture                    160 
Whole cell binding assays                  161 
Luciferase reporter assays                 162 
Mammalian two-hybrid assays                164 
Isolation of total RNA and realtime quantitative RT-PCR  
analysis of representative genes                164 
Western blotting                  166 
Data manipulation and statistical analysis              166 
Results                 167 
MPA and NET-A have a similar binding affinity for the MR            167 
Unlike Prog, MPA and NET-A display weak MR antagonist activity  
and no mineralocorticoid agonist activity for transactivation            169 
Unlike MPA and NET-A, Prog and Dex induce the  
 xxi 
ligand-dependent interaction between the amino- and carboxyl-terminals  
of the mineralocorticoid receptor                172 
MPA and NET-A display dissimilar mineralocorticoid properties  
for transrepression on the AP-1 promoter              175 
Unlike, MPA Prog, NET-A and RU486 do inhibit the aldosterone- 
induced upregulation of the endogenous Orm-1 gene             179 
Discussion                183 
 
CHAPTER 5 
CONCLUSIONS AND FUTURE PERSPECTIVES          194 
REFERENCES                218 
 
APPENDIX A: DATA NOT INCLUDED IN CHAPTER 2         269 
A1: Hydroxyflutamide does not inhibit the effects of Prog, MPA or NET-A on 
RANTES gene expression in the human vaginal cell line (Vk2/E6E7)          270 
 
APPENDIX B: DATA NOT INCLUDED IN CHAPTER 3         271 
B1: Optimisation of [3H]-MIB concentration for the determination of Kd or Ki 
values of ligands for overexpressed hAR.              272 
B2: Time course to establish equilibrium time for binding of 0.2 nM [3H]-MIB to 
overexpressed hAR.                                                                                      273 
B3: Transrepression assay in COS-1 cells in the absence and presence of 
overexpressed hAR.                 274 
B4: MPA and NET-A lack AR antagonist activity.             275 
 xxii 
B5: MPA, but not NET-A, antagonizes the DHT-induced N/C-interaction of the 
AR.                                        276 
 
APPENDIX C: DATA NOT INCLUDED IN CHAPTER 4         277 
C1: Optimisation of [3H]-Ald concentration for the determination of Kd or Ki 
values of ligands via overexpressed hMR.               278 
C2: Time course to establish equilibrium time for binding of 0.2 nM [3H]-Ald to 
overexpressed hMR.                                              279 
C3: Transrepression assay in COS-1 cells in the absence and presence of 
overexpressed hR.                                                                                      280 
C4: Prog displays weak partial agonist activity for transactivation via 
overexpressed MR in COS-1 cells                  281 
C5: Similar induction of the MR N/C-interaction by aldosterone and cortisol.
                    282 
C6: Antagonist activity of NET-A via the hGR in COS-1 cells.            283 
 
APPENDIX D: DEFINITIONS AND EXTRA DATA NOT 
INCLUDED IN CHAPTERS                      284 
D1: Binding parameters and calculations                                                      285 
D2: Pharmacological definitions                                                                    288 
D3: Transactivation in COS-1 cells in the absence and presence of 
overexpressed MR, AR or GR                290 
D4: Effects of Dex, MPA and NET-A on IL-6 protein production in human 
monocytes                   291 
 
 
 1 
Chapter 1 
_____________________________________________________ 
 
Reviewing the molecular mechanism of action of 
medroxyprogesterone acetate and norethisterone enanthate/acetate 
 
Donita Africander1, Nicolette Verhoog*, Dominique Koubovec1 and Janet Hapgood* 
 
1Department of Biochemistry, University of Stellenbosch, Private Bag X1, Matieland, 
7602, South Africa. 
* Department of Molecular and Cell Biology, University of Cape Town, Private Bag, 
Rondebosch, 7700, South Africa. 
 
 
 
 
 
 
 
 
 
 
 
Manuscript in preparation for submission to Endocrine Reviews. 
 
 2 
Abstract 
Medroxyprogesterone acetate (MPA) and norethisterone (NET) and its derivatives 
(norethisterone enanthate (NET-EN); norethisterone acetate (NET-A)), are used by 
millions of women as contraceptives and in hormone replacement therapy (HRT).  In 
addition, both MPA and NET-acetate (NET-A) are used in cancer therapy and in the 
treatment of gynaecological disorders such as endometriosis and premenstrual 
dysphoria. Although both progestins are widely used, very little is known about their 
mechanism of action at the molecular level. The importance of investigating these 
mechanisms, as compared to those of progesterone (Prog), has recently been 
highlighted by clinical evidence showing that MPA increases the risk of the 
development of breast cancer and coronary heart disease in HRT users. In addition, 
use of MPA as a contraceptive has also been shown to increase viral shedding, 
which raises concern as to its impact on the spread of viral diseases. There are 
currently no reviews in the literature other than one of our own, comparing the 
mechanism of action of MPA and NET-A or NET-EN (Hapgood et al., 2004). Here we 
review the physiological effects of these two progestins, as well as their regulation of 
and/or binding to serum-binding proteins and steroidogenic enzymes. In addition, as 
it is known that both MPA and NET can bind not only to the progesterone receptor, 
but also to the glucocorticoid, androgen, mineralocorticoid, and possibly the estrogen 
receptors, it is plausible that MPA and NET exert therapeutic actions as well as side-
effects via some of these receptors. We thus also review the molecular mechanism of 
action of both MPA and NET via each of the above steroid receptors on various 
target genes.  
 
 
 3 
1.1 Introduction 
Progestins are a class of synthetically developed compounds. Their development 
was based on similarity of biological actions to that of the endogenous ovarian 
hormone progesterone, which plays a pivotal role in female reproduction. These 
progestins have many therapeutic applications in female reproductive medicine, and 
are used instead of progesterone because of their longer biological half-life (Speroff, 
1996). A wide variety of progestins are available, that in addition to their common 
progestogenic effects, exhibit a range of biological effects that differ not only from 
each other, but also from that of progesterone (Schindler et al., 2003). The synthetic 
progestins, medroxyprogesterone acetate (MPA) and norethisterone enanthate 
(NET-EN), are two highly effective injectable progestogen-only contraceptives that 
have been available in many countries for over 40 years (Westhoff, 2003), including 
South Africa. In fact, in South Africa, MPA and NET-EN are the most commonly used 
contraceptives (Draper et al., 2006). These progestins are not only used as 
contraceptive agents, but also in hormone replacement therapy (HRT) (also referred 
to as hormone therapy (HT)), as well as a number of other non-contraceptive 
therapies. 
 
Progestins are chemically derived from parent compounds such as testosterone 
resulting in the 19-nortestosterone derivatives or from progesterone, resulting in the 
17-hydroxy (17-OH) progesterone derivatives and 19-norprogesterone derivatives. 
MPA (6α-methyl-17-acetoxy pregn-4-ene-3, 20-dione) (also referred to as Depo-
Provera®, depot medroxyprogesterone acetate (DMPA) or Petogen®, the latter 
locally manufactured in South Africa) is a 17-OH progesterone derivative (21-carbon 
series steroid) containing the pregnane nucleus, while NET-EN (17α-ethynyl-17β-
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heptanoyloxy-4-estren-3-one) (also referred to as either norethindrone enanthate, 
norethisterone enanthate or Nur-Isterate®) is a 19-nortestosterone derivative (19-
carbon series steroid) containing the androstane nucleus (structures depicted in 
Figure 1). Due to the aforementioned structures, MPA is often referred to as a true 
progestin, while NET-EN, which retains its androgenic activity, is referred to as an 
androgenic progestin (Darney, 1995).  
 
As with most drugs, a number of side-effects, some more severe than others, have 
been reported with the clinical use of MPA and NET. Interestingly, the World Health 
Organization (WHO) classifies MPA and NET-EN in the same category of medical 
eligibility, and makes no distinction between the two with regard to their side-effects 
or contra-indications (WHO, 2004). Similarly, Haider and Darney (2007) recently 
reported that NET-EN has the same mechanism of action as MPA in terms of 
contraceptive action and efficacy, with the same advantages and disadvantages. The 
advantages refered to the convenient and effective contraceptive method, the fact 
that it can be used by women with contra-indications to estrogen, as well as some 
therapeutic benefits, while the disadvantages refer to the side-effect profile. Similarly, 
the Cochrane comparative review on the contraceptive effectivity, reversibility and 
side-effects of MPA and NET-EN, also reported that MPA and NET-EN are similar, 
barring the slower return to fertility with MPA (Draper et al., 2006). While clinical 
studies have not identified significant differences between the side-effect profile of 
MPA and NET in patients, given the enormous spectrum of possible side-effects, and 
the specific circumstances under which these may manifest, it is possible that 
differences may yet be identified, especially given the differences in their activity 
recently identified at a cellular level (Koubovec et al., 2005; Sasagawa et al., 2008). 
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Interestingly, these studies observed differences in mechanism of action not only 
between MPA and NET, but also as compared to Prog. These observed differences 
in activity are a matter of concern, especially since these progestins are usually 
reported to act in a similar manner. A number of factors may account for the 
differential effects of MPA vs. NET, such as their differences in molecular structure, 
metabolism, bio-availibility, and binding affinities to different steroid receptors or 
receptor isoforms (Stanczyk et al., 2003; Schindler et al., 2003). It is thus clear that 
additional comparative studies between these two progestins, relative to each other 
and Prog, are needed at the cellular level. The objective of the present review is thus 
to highlight the differences between MPA and NET-EN/NET-A1, as compared to 
Prog, in terms of (1) therapeutic applications, observed side-effects and physiological 
effects, (2) their interaction with serum proteins, and (3) their mechanism of action via 
different steroid receptors.  
 
 
 
 
 
 
 
                                                    
1
 NET-EN is a derivative of NET used in injectable contraception; NET-A is the acetate ester of NET and is used 
in oral contraception or HRT; the derivatives, NET-EN and NET-A, have to be metabolically converted to NET 
in order to become biologically active.  At times, NET will be used generically to include all derivatives. 
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Figure 1. The chemical structures of (A) progesterone (Prog), (B) medroxyprogesterone acetate 
(MPA) and (C) norethisterone (NET) (R=OH), norethisterone acetate (NET-A) (R=OCOCH3) and 
norethisterone enanthate (NET-EN) [R=OCO(CH2)5CH3]. Note that ‘norethisterone’ is the same as 
‘norethindrone’. Basic ring structures are composed of 17 carbon arranged in four rings conventionally 
denoted by the letters A, B, C and D (adapted from Hapgood et al., 2004). 
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1.2 Therapeutic applications 
1.2.1 Contraception 
1.2.1.1 Female contraception  
When used as injectable contraceptives in women, both MPA and NET-EN 
formulations are administered as intramuscular injections, however, they differ in 
dosage and frequency of administration. MPA is administered as a 150 mg aqueous 
suspension every three months (Mishell, 1996), whereas NET-EN is administered as 
a 200 mg oily suspension every two months (Garza-Flores et al., 1991). Interestingly, 
a new formulation of MPA, at a 30% lower dose (104 mg), has recently been 
approved in the United States for subcutaneous administration every 3 months (Jain 
et al., 2004), and is referred to as Depo-Sub Q.  
 
After injection, MPA is fairly stable and is itself the active contraceptive compound 
(Speroff, 1996), whereas NET-EN and NET-A are hydrolysed to 
norethindrone/norethisterone (NET) and other metabolites, which together have 
contraceptive action (Stanczyk and Roy, 1990). Women receiving the 150 mg 
intramuscular injection of MPA, typically have serum concentrations of about 2.6-3.9 
nM for the duration of contraceptive treatment (Mathrubutham and Fotherby, 1981; 
Mishell, 1996), while the 200 mg dose of NET-EN has been reported to result in 
serum concentrations of about 1.5-59 nM (Fotherby et al., 1983).  
 
MPA mediates its contraceptive action by inhibiting the secretion of the pituitary 
gonadotropins, luteinizing hormone (LH) and follicle-stimulating hormone (FSH), 
thereby preventing follicular maturation and ovulation (Mishell, 1996; Kaunitz, 2000; 
Greydanus et al., 2001). MPA also alters the endometrial lining and reduces 
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glycogen secretion, thus preventing a blastocyst from entering the endometrial cavity 
(Mishell, 1996). In addition, MPA thickens the cervical mucus, which interferes with 
sperm penetration into the uterus (Greydanus et al., 2001). Although NET-EN has 
also been shown to block ovulation, (Bhowmik and Mukherjea, 1988), its primary 
contraceptive action involves altering the content of cervical mucus thus preventing 
sperm movement into the uterine cavity (Bhowmik and Mukherjea, 1987). MPA and 
NET-EN therefore have multiple sites of action, and are thus both highly effective 
contraceptive agents in women. 
 
Despite the effectiveness of MPA and NET-EN in preventing pregnancy, there are 
several side-effects associated with their use. The side-effect profile of both these 
progestins includes irregular bleeding, amenorrhea, breast tenderness, headaches, 
weight gain, acne and vaginal discharge (Kaunitz, 2000; Greydanus et al., 2001; 
Benagiano et al., 1978; Darney, 1995; Tyler, 1970; Schwallie, 1976; El-Mahgoub and 
Karim, 1972; Westhoff, 2003; Haider and Darney, 2007; Spencer et al., 2009). 
Interestingly, in a community-based cross-sectional household survey to determine 
perceived side-effects of MPA and NET-EN in KwaZulu-Natal in South Africa, many 
women reported vaginal wetness as a side-effect (Smit et al., 2002). It is unclear 
whether this vaginal wetness is the same as the previously reported side-effect of 
vaginal discharge. In addition, side-effects such as dizziness, fatigue, bloating of the 
abdomen or breasts, behavioural changes, reduced libido and decreased bone 
mineral density (BMD) have also been reported for MPA (Kaunitz, 2000; Greydanus 
et al., 2001). Although the side-effect profile of NET-EN is not as well defined as that 
of MPA, it is assumed to be similar to, but less severe than MPA, with a more rapid 
return to fertility after termination of treatment (Benagiano et al., 1978; Fraser and 
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Weisberg 1982; Koetsawang, 1991, Draper et al., 2006). This difference in time 
before return to fertility has been challenged by Bigrigg and co-workers (1999), as 
they report that there is in fact, no statistically significant delay in return to fertility by 
MPA users.  
 
1.2.1.2 Male contraception 
Male contraception involves the administration of synthetic analogues of 
testosterone, which functions as a contraceptive by suppressing the secretion of the 
gonadotropins, LH and FSH, from the pituitary (Amory and Bremner, 1998; Morse et 
al., 1973). The suppression of LH and FSH deprives the testes of the stimulatory 
signals required for spermatogenesis, leading to decreased sperm counts and 
reversible infertility in most men. However, the administration of testosterone 
derivatives alone does not completely suppress sperm production in all men (Amory 
and Bremner, 1998; McLachlan et al., 2002). For this reason, recent research has 
been investigating the use of testosterone analogues in combination with progestins. 
Testosterone esters, combined with injections of MPA or NET-EN, show severe 
suppression of spermatogenesis, due to the synergistic suppression of gonadotropin 
levels (Kamischke et al., 2000a; Kamischke et al., 2000b; Turner et al., 2003; 
reviewed by Nieschlag et al., 2003; Gu et al., 2004, reviewed by Amory, 2008). Thus, 
combined treatment with testosterone and progestins, holds promise for an effective 
male contraceptive. However, as observed in women, the use of synthetic progestins 
causes certain side-effects in men. For example, the use of NET-EN in male 
contraception has been shown to decrease the levels of high-density lipoprotein 
(HDL) and lipoprotein, which may lead to negative effects on the cardiovascular 
system (Zitzmann et al., 2002). Current research in male hormonal contraception, as 
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with female contraception, is thus focusing on producing an effective contraceptive 
agent, while minimizing side-effects. 
 
1.2.2 Hormone replacement therapy 
Hormone replacement therapy (HRT/HT) is commonly prescribed to alleviate 
symptoms experienced by women after menopause. These symptoms, including hot 
flushes, urogenital atrophy, bone loss and vaginal dryness, are due to a decrease in 
estrogen levels (Hickey et al., 2005; Greendale, 1999). HRT includes administration 
of either estrogen alone, or estrogen combined with a progestin, such as MPA or 
NET-EN (Greendale, 1999). The latter treatment is used for menopausal women with 
an intact uterus so as to counteract the proliferative effects of estrogen on the uterine 
epithelium, thereby preventing estrogen-induced endometrial hyperplasia (Gambrell 
Jr et al., 1980; Taitel and Kafrissen, 1995; Brunelli et al., 1996; Palacios et al., 2006). 
The progestin may be administered either continuously (every day) or sequentially 
(for a part of each month). It has been reported that, in the longterm, continuous 
therapy may be more protective against endometrial hyperplasia than sequential 
therapy (reviewed by Lethaby et al., 2004).  
 
Whether MPA or NET is used as the progestin of choice for HRT differs 
internationally. In the United States, the most commonly used progestin is MPA, 
generally combined with conjugated equine estrogens (CEE) in formulations for oral 
administration (Newcomb et al., 2002). Similarly, in France, MPA or cyproterone 
acetate is mainly used (Fournier et al., 2005). In contrast, only a small percentage of 
women in the United Kingdom and Northern Europe use MPA (≤ 20%) (Beral, 2003; 
Magnusson et al., 1999; Jernstrom et al., 2003; Stahlberg et al., 2004), while the 
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majority use NET-A or other 19-nortestosterone-derivatives (Campagnoli et al., 2005; 
Fournier et al., 2005).  
 
Originally, the dose of MPA employed in HRT was a sequential dosage of 10 mg/day 
for about 11 days per month, but subsequently the dose has been reduced to 2.5 to 5 
mg/day (Brunelli et al., 1996; Van de Weijer, 2007; Archer and Pickar, 2000). HRT 
doses of NET range from about 0.35 to 2.1 mg/day (Taitel and Kafrissen, 1995). 
Women receiving the Activelle HRT regime (0.5 mg NET-A, 1 mg estradiol) are 
reported to have peak serum concentrations of NET ranging between 3.64 and 17.7 
nM (Activelle package insert reg. no. 33/21.8.2/0532, Novo Nordisk Inc.), while 
serum levels of MPA for HRT range between 0.02 and 0.2 nM (Ghatge et al., 2005). 
 
Side-effects of MPA and NET used in HRT include changes in the levels of lipids and 
lipoproteins, as well as adverse effects on vasomotion, which may increase 
cardiovascular risk in postmenopausal women (Sitruk-Ware, 2000). In addition, MPA 
and NET have been implicated in increased risk of breast cancer development (Riis 
et al., 2002; Stahlberg et al., 2003). Although these side-effects have long been 
recognized, it had always been assumed that the benefits of HRT for 
postmenopausal women outweighed the risks. However, the Women’s Health 
Initiative (WHI) trial in the USA of a combined estrogen and progestin (MPA) HRT 
regime in healthy postmenopausal women highlighted several side-effects such as 
increased risk of breast cancer, coronary heart disease (CHD), venous 
thromboembolism, stroke and dementia (Rossouw et al., 2002). In addition, data by 
investigators working on the same trial (estrogen plus MPA) also suggested an 
increase in the risk for ovarian cancer (Anderson et al., 2003). These side-effects 
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were deemed so severe that the trial was terminated two years earlier than planned. 
This caused much confusion and alarm amongst HRT users, and as a result many 
postmenopausal women have stopped using HRT (Ettinger et al., 2004). It is 
noteworthy that a similar trial on the use of estrogen alone also indicated an 
increased risk of stroke, but no increase in breast cancer risk or cardiovascular 
disease (CVD) (Anderson et al., 2004), thus implicating the MPA component in 
breast cancer and CVD side-effects. The Women’s International Study of Long 
Duration Oestrogen after the Menopause (WISDOM) investigation (Vickers et al., 
2007) was prematurely stopped following publication of the results of the WHI study. 
Their results were consistent with the WHI study in indicating increased 
cardiovascular and thromboembolic risk when HRT (estrogen plus MPA) was started 
a considerable time after menopause (Vickers et al., 2007). The ‘Million Women 
Study’ found that both MPA and NET substantially increased the risk of breast cancer 
in long-term HRT users (Beral; 2003). Taken together, results from these studies 
indicate that usage of MPA may result in increased risk of breast cancer. In addition, 
all studies except the Million Women Study which did not investigate cardiovascular 
effects, indicate that MPA may have increased risk of CVD. NET usage has also 
been implicated, in the Million Women Study, in an increase of breast cancer risk.  
 
The controversy surrounding the risk/benefit ratio of progestins in HRT has resulted 
in a trend towards prescription of HRT with lower doses of progestin, and different 
routes of administration such as gels, sprays, vaginal rings, intrauterine systems or 
transdermal patches (Nath and Sitruk-Ware, 2009). In this way, the potentially 
harmful effects of estrogen on the endometrium are still counteracted by MPA, while 
the progestin-induced side-effects on the breast and heart may possibly be 
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minimized (Sitruk-Ware, 2007). However, the safety of these new systems (low 
dosage, parenterally administered) vs. the old (higher dosage, oral therapy) needs to 
be evaluated. 
 
1.2.3 Other applications 
In addition to the use of MPA and NET-EN/NET-A/NET in contraception and HRT, 
they are also used in a number of other therapeutic applications. MPA is used in the 
treatment of gynaecological disorders such as dysmenorrhea, menorrhagia 
(excessively heavy menstrual bleeding), ovulatory pain, pain associated with ovarian 
disease, premenstrual dysphoria, perimenopausal symptoms (Kaunitz, 1998) and 
endometriosis, a complex disorder causing pelvic pain and infertility (Irahara et al., 
2001; Harrison and Barry-Kinsella, 2000; Muneyyirci-Delale and Karacan, 1998; 
Vercellini et al., 2003). NET can also be used in the treatment of endometriosis 
(Vercellini et al., 2003), and the dosage used for both MPA and NET is about 50-100 
mg/day (Harrison and Barry-Kinsella, 2000; Telimaa et al., 1989). MPA has also 
been associated with haematological improvement in women with sickle cell disease 
(Grimes, 1999), as well as reduced seizure frequency in women with seizure 
disorders (Kaunitz, 2000). A recent study, however, observed increased seizure 
occurrences with the use of CEE/MPA in HRT, suggesting that MPA may not be the 
optimal progestin for HRT in postmenopausal women with epilepsy (Harden et al., 
2006).  
 
In cancer therapy, MPA is used at very high doses (Etienne et al., 1992; Yamashita 
et al., 1996), typically between 500 and 1500 mg/day taken orally for about 12 weeks 
(Blossey et al., 1984). At these high cancer therapy doses, serum levels of MPA are 
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approximately 0.14-1.7 µM (Thigpen et al., 1999; Focan et al., 2001), and potent 
glucocorticoid-like side-effects such as inhibition of adrenal function (Blossey et al., 
1984; Papaleo et al., 1984; Lang et al., 1990) and immunosuppression (Yamashita et 
al., 1996; Mallmann et al., 1990; Scambia et al., 1988), have been observed.  
 
Finally, MPA is also prescribed for mentally handicapped women who have 
menstrual hygiene problems (Elkins et al., 1986). Furthermore it is also used in the 
treatment of deviant sexual behaviors in men such as pedophilia, exhibitionism, 
transvestism, and voyeurism (Kravitz et al., 1995; Bradford, 1999). Although NET is 
not as widely used as MPA, with the exception of use for HRT and contraception, it 
has been used in the treatment of acne (Zouboulis and Piquero-Martin, 2003) and in 
treating gastrointestinal symptoms of women with colorectal endometriosis (Ferrero 
et al., 2009). 
 
1.3 Physiological effects of MPA and NET-EN/NET-A/NET  
1.3.1 Reproduction  
Hypothalamic gonadotropin-releasing hormone (GnRH) is the key hormone 
responsible for regulating reproduction. It is secreted by the hypothalamus and 
travels via the blood to the anterior pituitary where it binds to the GnRH receptor on 
the cell surface of gonadotrope cells. Intracellular signal transduction pathways are 
subsequently activated, stimulating the synthesis and release of the gonadotropins, 
LH and FSH. These gonadotropins then enter the systemic circulation to regulate 
gonadal function, including steroidogenesis and gametogenesis. MPA mediates its 
contraceptive action by inhibiting the secretion of LH and FSH, thereby preventing 
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follicular maturation and preventing ovulation (Mishell, 1996; Kaunitz, 2000). The 
inhibition of the gonadotropins results in suppression of ovarian estradiol production.  
 
Although the effect of MPA and NET on GnRH synthesis and release has not yet to 
our knowledge been determined, a few studies have investigated the effects of MPA 
and to a lesser extent NET, on LH, FSH and steroid hormone levels, in an attempt to 
fully understand the contraceptive mechanism of action of these two progestins. An 
early study showed that MPA and NET-EN inhibits the mid-cycle surge of FSH and 
LH, but that the release of these gonadotropins continues at luteal phase levels 
(Mishell et al., 1977; Franchimont et al., 1970). Another early study measured the 
peripheral blood levels of LH, FSH, and estradiol after intramuscular injection of a 
contraceptive dose of MPA in normal women (Jeppsson and Johansson, 1976). The 
levels of all three hormones remained in the range of the early follicular phase of a 
normal menstrual cycle (low levels) and ovulation was suppressed due to 
suppression of the LH peak. Interestingly, no suppression of basal LH and FSH 
levels was reported in any of the women, an effect which likely contributes to the lack 
of menopausal-like symptoms in women receiving contraceptive doses of MPA. In 
another study using contraceptive doses, normal menstruating women showed a 
decline in plasma levels of estradiol, progesterone and 17α-hydroxyprogesterone to 
early follicular phase levels sixteen days after MPA administration (Aedo et al., 
1981). In addition, no LH surge or ovulation was detected in patients receiving 1 mg 
of NET over a 5-day period in in vitro fertilisation studies (Letterie, 2000).  
 
For male contraception, MPA or NET-EN, combined with testosterone esters, show 
severe suppression of spermatogenesis, due to the synergistic suppression of 
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gonadotropin (LH and FSH) levels (Kamischke et al., 2000; Turner et al., 2003; 
reviewed by Nieschlag et al., 2003; Gu et al., 2004; reviewed by Amory 2008). 
Similarly, it has been shown that MPA effectively suppresses spermatogenesis by 
inhibiting testosterone and gonadotropin production in rats (Lobl et al., 1983; 
Flickinger, 1977).  
 
MPA and to a much lesser extent NET, has been shown to influence expression of a 
number of genes involved in reproductive functions. Examples of such genes include 
tissue factor (TF) (Krikun et al., 2000), decidual cell-expressed plasminogen activator 
inhibitor-1 (PAI-1) (Lockwood, 2001), transforming growth factor-β (TGF-β), (Arici et 
al., 1996b), vascular endothelial growth factor (VEGF) (Sugino et al., 2001), c-fos 
and prolactin (PRL) (Reis et al., 1999), and the metalloproteinases (MMPs) (Bruner-
Tran et al., 2006). Tissue factor, a cell membrane-bound glycoprotein, is responsible 
for the initiation of hemostasis during implantation and placentation, and is 
associated with decidualisation (differentiation) in the uterus. Decidualisation is an 
adaptation of the uterus to enable implantation of the embryo, and may occur as a 
result of hormonal contraception. MPA at 100 nM was shown to significantly enhance 
TF gene transcription in human endometrial stromal cells (HESCs) (the progenitors of 
decidual cells) (Krikun et al., 2000). Furthermore, decidual cell-expressed PAI-1 plays 
a role in preventing haemorrhage during human pregnancy implantation. MPA, in the 
absence and presence of estradiol, was shown to enhance PAI-1 expression in 
HESCs (Schatz and Lockwood, 1993; Schatz et al., 1995; Lockwood, 2001). It is 
noteworthy that estradiol is ineffective alone, but enhances the MPA-mediated 
effects.  
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Another MPA-regulated gene involved in endometrial functions is transforming 
growth factor beta (TGF-β), which is believed to play a role in the predecidualisation 
of HESCs and in the completion of decidualisation after blastocyst implantation. 
Treatment of cultured HESCs with 1 nM MPA resulted in reduced levels of TGF-β3 
mRNA, and a small increase in TGF-β1 mRNA levels (Arici et al., 1996b). In contrast, 
in endometrial samples from women having received higher doses of MPA (10 
mg/day), TGF-β3 expression was enhanced, with no observable change in TGF-β1 
levels (Reis et al., 2002). On the other hand, in a comparative study of MPA and NET 
in MCF-7 breast cancer cell lines, MPA did not affect TGF-β2 and TGF-β3 mRNA 
levels, whereas a highly significant decrease was observed with NET (Jeng and 
Jordan, 1991). Collectively, the data by Reis et al. (2002) and Jeng and Jordan 
(1991), suggest that MPA acts in a cell-specific manner, and moreover suggest that 
MPA and TGF-β3 may together mediate endometrial differentiation. 
 
VEGF and its receptors play important roles in implantation and maintenance of 
pregnancy. Expression of VEGF and one of its receptors, kinase insert domain-
containing region (KDR), was significantly increased by MPA (1 µM) and estrogen 
(10 nM) in human endometrial stromal cells isolated from proliferative phase 
endometrium (Sugino et al., 2001). Another study in human endometrium showed 
that MPA inhibited c-fos gene expression, and enhanced the expression of PRL 
(Reis et al., 1999). The authors suggested that inducing similar c-fos and PRL 
expression levels to those in secretory endometrium may be the mechanism by 
which MPA exerts its anti-proliferative effects. In addition, MPA, NET-A and Prog 
were shown to differentially regulate pro-matrix metalloproteinase (pro-MMP)-3 and 
pro-MMP-7 protein expression in stromal cells isolated from normal endometrial 
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tissue donors and endometriosis patients, in the absence and presence of the pro-
inflammatory cytokine IL-1α (Bruner-Tran et al., 2006). MMP expression is crucial for 
endometrial growth and remodeling, but failure to suppress MMPs may impair 
implantation and promote the development of endometriosis (Bruner et al., 1997; 
Osteen et al., 2005). MPA and Prog suppressed pro-MMP-3 and pro-MMP-7 in both 
healthy tissue donors and endometriosis patients regardless of IL-1α challenge, while 
NET-A could do so only in normal cells and in the absence of IL-1α challenge. The 
fact that NET could not suppress these MMP’s in the presence of IL-1α induced 
inflammation, or in endometriosis (inflammatory disease) patients (Podgaec et al., 
2007), suggests that NET is a weaker anti-inflammatory agent as compared to MPA 
and natural Prog, and thus may not be an optimal treatment for women with 
endometriosis.  
 
1.3.2 Adrenal function and steroidogenesis 
Surprisingly little research appears to have been carried out in humans on the effects 
of MPA on adrenal function, and to our knowledge, there is only one report on the 
effects of NET (Amatayakul et al., 1988). 
 
Jones and co-workers (1974) reported lowered baseline plasma cortisol levels in 
contraceptive users of MPA. Similarly, a later study also showed that administration 
of a single dose of MPA resulted in a slight but significant reduction of cortisol in 
normal menstruating women (Aedo et al., 1981). However, healthy, non-lactating 
Thai women who received long-term MPA and NET treatment were found to have no 
significant change in adrenal function as measured by cortisol levels (Amatayakul et 
al., 1988).  
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At higher doses (up to 1500 mg orally per day), MPA has been shown to cause 
significant inhibition of adrenal function (Hellman et al., 1976; Blossey et al., 1984; 
Papaleo et al., 1984; Lang et al., 1990), which may be attributed to its glucocorticoid 
activity (van Veelen et al., 1985). Furthermore, a study evaluating the adrenal 
function of postmenopausal breast cancer patients treated with MPA (300 mg), 
reported no difference in adrenocorticotropic hormone (ACTH) levels, but significantly 
lower cortisol, androstenedione and dehydroepiandrosterone sulphate (DHEA-S) 
levels, when compared to a control group (van Veelen et al., 1984). Androstenedione 
is the main precursor of estrogens in postmenopausal women and this reduction in 
its levels could be the cause of hypoestrogenism induced by MPA. Earlier studies, 
however, observed reduction in both ACTH and cortisol levels by MPA (Matthews et 
al., 1970; Hellman et al., 1976). In addition, MPA used in the treatment of abnormal 
sexual behaviors in males (100 to 1000 mg weekly by intramuscular injection) 
significantly reduced mean serum concentrations of total testosterone and cortisol 
(Guay, 2008).  
 
MPA directly inhibits multiple steps in human sex steroid biosynthesis. Studies using 
cultured rodent Leydig cells and testicular homogenates showed that MPA (1 µM) 
inhibited the activities of three key enzymes involved in steroidogenesis: 17α-
hydroxylase (P450c17), 3β-hydroxysteroid dehydrogenase/D5-D4-isomerase 
(3βHSD) and 17β-hydroxysteroid dehydrogenase (17βHSD) (Barbieri and Ryan, 
1980). These enzymes are responsible for the synthesis of estradiol and Prog, in the 
ovary, in response to LH and FSH. Prog is synthesized from pregnenolone by the 
3βHSD, while estradiol is synthesized from testosterone by aromatase, or from 
estrone by 17β-HSD. Furthermore, Prog is a precursor for testosterone via the action 
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of P450c17 and 17β-HSD. In a study evaluating the effect of MPA as a substrate for, 
or inhibitor of the enzymes mediating the early steps common to both human adrenal 
and gonadal steroidogenesis, namely cholesterol side-chain cleavage enzyme 
(P450scc), 17α-hydroxylase/17,20-lyase (P450c17) and type II 3βHSD (3βHSDII), 
MPA showed no effect on P450c17 or P450scc, whereas it competitively inhibited 
3βHSDII (Lee et al.,1999). Since 3βHSDI shares 93.5% amino acid identity with 
3βHSDII (Rhéaume et al., 1991), it is likely that 3βHSDI may also be inhibited by 
MPA. Since MPA is structurally similar to 17-hydroxyprogesterone, the mechanism 
by which MPA inhibits 3βHSD is likely to be product inhibition.  
 
In summary, most studies on the effect of MPA on adrenal function focus on high 
doses such as those used in cancer therapy. More research on the effects of lower 
doses of MPA, and particularly of NET, on adrenal function is thus necessary for a 
better understanding of side-effects of contraceptive and HRT doses.  
 
1.3.3 Skeletal function  
Bone mineral density (BMD) is an important indicator of skeletal health in 
postmenopausal women. A number of studies have reported that long-term 
contraceptive use of MPA has a negative effect on BMD (refs), although the 
mechanism is poorly understood. However, it has been postulated that this occurs as 
a consequence of estrogen deficiency, which is induced by MPA due to inhibition of 
secretion of the pituitary gonadotropins by MPA (Jeppsson et al., 1982). Indeed, in a 
study by Cundy et al. (2003), it was shown that supplemental estrogen therapy 
arrested MPA-related bone loss in premenopausal women treated for a minimum of 
two years with MPA and with a below average baseline lumbar spine BMD. Similarly, 
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in another randomized trial comparing estrogen supplementation with placebo among 
adolescents, increases in BMD were observed in the group receiving estrogen 
supplements, and decreases in the placebo group (Cromer et al., 2005). Notably, the 
decrease in bone density tends to be most significant in women who start MPA use 
at an early age, and in those whose duration of use exceeds 15 years (Cundy et al., 
1991; Cromer et al., 1996; Cundy et al., 1998; Paiva et al., 1998; Gbolade et al., 
1998; Scholes et al., 1999; Tang et al., 1999; Cundy et al., 2003; Cromer et al., 
2005). These findings are significant as the peak bone mass attained during 
adolescence is one of the primary determinants of osteoporosis risk in post-
menopausal women. Thus, the main reason for concern for women using MPA in 
adolescence is the potential risk for future osteoporosis and osteoporotic fractures.  
 
A substantial number of studies evaluating the potential association between MPA 
usage and changes in BMD, indicate decreases in BMD among MPA users (Cundy 
et al., 1998; Cundy et al., 1994; Scholes et al., 2002; Scholes et al., 2004; Berenson 
et al., 2004; Clark et al., 2004; Busen et al., 2003; Cromer et al., 1996; Lara-Torre et 
al., 2004; Cromer et al., 2004; Scholes et al., 2005). In contrast, a few studies have 
showed positive effects of MPA on BMD. For example, premenopausal women with 
amenorrhea or abnormal menstrual cycles treated with MPA (10 mg/day for 10 days 
per month) were shown to have improved spinal bone density (Prior et al., 1994). 
However, a study investigating the effect of MPA (20 mg/day) on BMD in 
postmenopausal women showed that MPA therapy could not arrest spinal bone loss. 
However, when postmenopausal women were treated with MPA (10 mg/day) 
combined with estrogen (0.3 mg/ day), bone loss was reduced (Gallagher et al., 
1991). Similarly, results from the Postmenopausal Estrogen/Progestin Interventions 
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trial (PEPI) showed that postmenopausal women receiving estrogens (0.625 mg/day) 
in combination with MPA (10 mg/day for 12 days/month) exhibited an increase in 
bone mass (Writing Group for the PEPI trial, 1996). In addition, results from the 
Women’s Health Initiative trial demonstrated that conjugated equine estrogen (CEE) 
(0.625 mg/day) plus MPA (2.5 mg/day) increased bone BMD and reduced the risk of 
fracture in postmenopausal women (Cauley et al., 2003). Furthermore, a cross-
sectional study among postmenopausal women showed that the mean BMD of past 
users of MPA (median length of use ~3 years), was comparable to non-users (Orr-
Walker et al., 1998), indicating that bone loss occurring with MPA use is reversible. 
Similarly, a study following up on adolescent users of MPA following discontinuation, 
showed a significant increase in BMD (Scholes et al., 2005). Consistent with these 
latter two studies, three prospective studies indicated that BMD tended towards 
baseline values following MPA discontinuation in women of all ages (Clark et al., 
2004; Clark et al., 2006; Kaunitz et al., 2006). In addition, recovery in BMD was seen 
as early as 24 weeks after cessation of therapy, and the BMD in past MPA users was 
similar to that in nonusers, 2-3 years after discontinuation of contraceptive injections 
(Rosenberg et al., 2007). Taken together, most studies have found that women lose 
BMD while using MPA, but regain it after discontinuation of MPA use. 
 
Studies on the effects of NET on BMD are limited. Oral administration of 
contraceptive doses of NET (0.35 mg/day) was reported to protect against loss of 
bone mass in breast-feeding women (Caird et al., 1994). In addition, clinical studies 
have shown that an oral contraceptive containing 20-35 µg/day of ethinyl estradiol in 
combination with NET resulted in the optimal bone-sparing effect in premenopausal 
women (DeCherney, 1996). Similarly, women receiving a NET-containing oral 
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contraceptive pill showed a 2.33% gain in BMD (Berenson et al., 2001). Furthermore, 
the effect of NET in HRT has also been investigated and appears to be controversial. 
NET-A has been reported to have positive effects on postmenopausal bone 
metabolism, and has been shown to increase bone mass more than alendronate, an 
effective candidate for both the prevention and treatment of osteoporosis (Riis et al., 
2002). Similarly, in the review by Taitel and Kafrissen (1995), a number of studies 
reported increased bone mass and BMD in postmenopausal women treated with 
estradiol and NET-A. In addition, NET (5 mg/day) for 4 months was also shown to 
prevent bone loss in postmenopausal osteoporosis by decreasing bone turnover 
(Horowitz et al., 1993). Conversely, another study was unable to show a consistent 
increase in markers of bone formation in postmenopausal women treated with 5 
mg/day NET-A for 9 weeks (Onobrakpeya et al., 2001), indicating that NETA does 
not have short-term anabolic effects on bone. 
 
In contrast to the effects seen with the majority of studies on the oral contraceptive 
formulation of NET, limited data with injectable NET-EN indicate a negative effect on 
BMD in adolescent (Beksinska et al., 2007; Beksinska et al., 2009) and adult users 
(Rosenburg et al., 2007). Consistent with the reversal of negative BMD effects 
following the discontinuation of injectable MPA use, the recovery of BMD was also 
seen when usage of injectable NET was stopped (Rosenburg et al., 2007; Beksinska 
et al., 2009). However, according to Sarfati and de Vernejoul (2009), bone loss does 
not occur with injectable NET, and NET exerts anabolic effects on bone. These 
authors also report that bone formation with NET may reflect peripheral conversion to 
ethinylestradiol or direct androgenic effects on bone tissue. In addition, Ishida et al. 
(2008) reported that postmenopausal women who have been diagnosed with 
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osteoporosis, should preferably use NET-A, rather than MPA, in HRT so as to 
prevent the possibility of fractures. It has been speculated that the positive effect of 
NET-A on BMD may be attributed to its androgenic activity (Sarfati and de Vernejoul, 
2009), and/or its lack of glucocorticoid activity (Ishida et al., 2008). The latter would 
be consistent with the proposal that bone loss associated with MPA, at contraceptive 
doses or higher, is due to its glucocorticoid activity (Ishida and Heersche, 2002).  
 
In summary, studies to date provide sufficient evidence to support a link between 
MPA usage and reduction of BMD, although the benefits of MPA as a contraceptive 
may outweigh the risk of decreased BMD. Whether NET has such negative effects 
on BMD is controversial. Nevertheless, concern still remains for adolescent users, as 
maximal BMD is obtained during adolescence. Further studies are thus needed to 
establish whether, after stopping the use of MPA and NET as injectable 
contraceptives, BMD remains at lower levels long-term, and how the risk of future 
fractures is affected. Additional research is also needed to address the role of MPA 
vs. NET on bone metabolism in HRT users. Finally, many factors, such as dosage, 
age of onset of usage, duration of usage, peak BMD at adolescence, and even the 
level of exercise, may contribute to the effect of the progestins on BMD. Thus, these 
factors need to be considered in future research assessing the impact of MPA vs. 
NET on BMD.  
 
1.3.4 Brain function 
The role of Prog or synthetic progestins in the brain has recently been under much 
scrutiny, after a number of studies reported differences in neurological effects of Prog 
and MPA in cell culture models (Nilsen and Brinton, 2002a; Nilsen and Brinton, 
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2002b; Nilsen and Brinton, 2003). Both Prog and MPA can cross the blood-brain 
barrier (Lanthier and Patwardhan, 1986; Skatrud et al., 1978), while Prog is also 
synthesized in the brain de novo (Baulieu et al., 2001). Two clinical trials showed that 
MPA abrogated beneficial effects of longterm estrogen replacement therapy on 
cognitive function (Ohkura et al., 1995; Rice et al., 2000). Similarly, analysis from the 
Women’s Health Initiative Memory Study (WHIMS) clinical trial reported that estrogen 
plus progestin (MPA) therapy did not improve cognitive function in older women, and 
resulted in a doubling of the diagnosis of Alzheimer’s disease (Rapp et al., 2003). 
This finding could possibly be explained by the results of the study by Nilsen and 
Brinton (2002a), which suggest that MPA may counteract the beneficial effects of 
estrogen on cognitive function and prevention of Alzheimer’s disease.The authors 
showed that 17β-estradiol and Prog, but not MPA, protect hippocampal neurons 
against glutamate neurotoxicity. In addition, unlike MPA, progesterone results in 
nuclear translocation of mitogen-activated protein kinase (MAPK) in hippocampal 
neurons, which appears to be linked to the neuroprotective profile of progesterone 
(Nilsen and Brinton, 2003). In addition, a study in rats reports that Prog, but not MPA, 
is neuroprotective in vivo (Ciriza et al., 2006). In contrast to MPA, Prog is 
metabolised to 5α-dihydroprogesterone (DHP), which is subsequently reduced to 3α, 
5α-tetrahydroprogesterone (THP), in the nervous system. The authors show that the 
observed neuroprotective effects of Prog are due to these metabolites. Prog can also 
be metabolised to allopregnenalone (AP) (3α-5α–tetrahydroprogesterone), which is a 
potent modulator of the GABAA receptor, and also plays a role in neuroprotection 
(Hosie et al., 2006). Most progestins used in HRT, like MPA and NET, contain the 
typical steroidal backbone (Figure 1). The potential thus exists for MPA and NET to 
be metabolised into neuroactive steroids that may modulate the GABAA receptor. 
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Winneker et al. (2003) used rat behavioural models to assess the potential GABAA 
receptor activity of MPA and NET. Both these progestins were shown to produce 
some anxiolytic-like effects, supporting the concept of their metabolism into 
neuroactive steroids (Pluchino et al., 2009). However, a recent study indicated that 
unlike Prog, MPA could not downregulate the mRNA expression of the α4 subunit of 
GABAA receptors in the CA1 hippocampus of female rats (Pazol et al., 2009). 
Changes in the α4 subunit expression in the CA1 hippocampus have important 
implications for the regulation of anxiety (Shen et al., 2005). Further clinical studies 
are needed to establish the eventual functional consequences of the differential 
regulation of gene expression by Prog, MPA and NET.  
 
In summary, the above data indicates opposing effects of Prog and MPA on 
neuroprotection. Thus it is evident that MPA cannot be used as a simple substitute 
for Prog in the brain. Indeed, the WHIMS clinical trial found that estrogen combined 
with MPA showed an increased risk for dementia in women aged 65 and older 
(Shumaker et al., 2003). On the other hand, a recent study in primary cultures of 
cortical neurons indicates that Prog and MPA exert similar protective effects on 
neurons, and that the effects depend strictly on the previous hormonal status of the 
neurons and timing of exposure (Mannella et al., 2009). In addition, the authors 
showed that the activation of nitric oxide synthase (NOS) is critical for the 
neuroprotective effects by Prog and MPA. Finally, there is paucity in the research on 
the effects of NET on neuroendocrine function, which needs to be addressed 
considering current knowledge that the type of progestin is likely to be critical for 
achieving therapeutic benefits, preventing neurodegenerative disease and sustaining 
cognitive function throughout the menopausal years. Clearly, additional research is 
 27 
needed to explore the neurobiology of progesterone vs. different synthetic 
progestins. 
 
1.3.5 Reproductive cancers 
1.3.5.1 Breast cancer 
There is evidence in the literature to suggest that the use of MPA as a contraceptive 
does not increase breast cancer risk (reviewed by Kaunitz, 1996; Dillis and 
Schreiman, 2003). Based on comparative mammograms of two patients while using 
injectable MPA vs. after discontinuation, Dillis and Schreiman (2003) suggested that 
MPA has a suppressive effect on breast density in women receiving contraceptive 
injections. In contrast, recent clinical evidence suggests that MPA in HRT use 
increases the risk of breast cancer (2003) suggested a suppressive effect of MPA on 
breast density in women receiving contraceptive injections. In contrast, recent clinical 
evidence suggests that MPA in HRT use increases the risk of breast cancer 
(Rossouw et al., 2002; Beral, 2003). This raises the question of whether the addition 
of MPA, or NET, to estrogen replacement therapy is more harmful than beneficial. 
Indeed, although the use of NET in HRT has been implicated in increased risk of 
breast cancer in clinical studies (Beral, 2003; Colditz, 2005), it has also been 
reported to significantly inhibit breast cancer cell proliferation in vitro (Seeger et al., 
2003). Thus reports on the effects of progestins at a cellular level do not concur with 
studies conducted at a systemic level.  
 
The above-mentioned trials confirmed results from numerous observational studies 
demonstrating that MPA, and NET are associated with an increase in breast cancer 
risk (de Lignières, 2002; Newcomb et al., 2002; Lee et al., 2005; Ross et al., 2000; 
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Ewertz et al., 2005). In the study by Newcomb and co-workers (2002), 
postmenopausal women using estrogen-only HRT showed a significant increase in 
breast cancer risk, and this risk was increased by the addition of MPA. Furthermore, 
Ross et al. (2000) compared the risk for breast cancer in women on combined 
estrogen and MPA therapy, to women on estrogen alone therapy, and demonstrated 
that the use of MPA increased the risk for breast cancer compared with estrogen 
alone. Observations from a population-based cohort study (Ewertz et al., 2005), and 
a meta-analysis of 61 studies (Lee et al., 2005), showed that both MPA and NET 
were associated with increased risk of breast cancer, with increased duration of use 
of MPA and NET in HRT.  
 
In a study in the MCF-7 breast cancer cell line, MPA was shown to have no effect on 
TGF-β2 and TGF-β3 mRNA levels, whereas a dramatic decrease was observed with 
NET (Jeng and Jordan, 1991). This effect seen with NET was accompanied by cell 
growth stimulation, which suggested that the differential regulation of TGF-β 
expression by NET might be partly responsible for the growth stimulation induced by 
NET. These results are consistent with a role for NET in contraception that might 
facilitate the development of breast cancer. In a study in a normal human breast 
epithelial cell line (MCF10A), the effects of Prog, MPA and NET on proliferation and 
apoptosis were investigated. The results showed that MPA significantly increased the 
growth factor-induced stimulation of MCF10A cells, while Prog and NET had no 
effect, thus implying an enhanced proliferative effect by MPA (Krämer et al., 2006). In 
a human cancerous breast cancer cell line (HCC1500) however, MPA and NET 
enhanced the initial growth factor-induced proliferative effect, while Prog had no 
effect in these cells. Collectively, these data indicate differences between Prog, MPA 
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and NET in terms of breast cancer risk in the same in vitro model, and moreover 
raises the concern that MPA may increase the mitotic rate of normal epithelial breast 
(Seeger and Mueck, 2008). 
 
MPA and NET may also enhance the conversion of weaker endogenous estrogens 
into more potent estrogens (Coldham et al., 1990; Seeger et al., 2000; Campagnoli et 
al., 2005; Xu et al., 2007), which could potentially contribute to their carcinogenic 
effects. For example, Seeger et al. (2000) showed that NET-A, used by 
postmenopausal women for HRT, may promote the formation of the genotoxic 
estrogen metabolite 16-hydroxyestrone. In human breast cancer cell lines, MPA but 
not NET was shown to stimulate the conversion of inactive estrone sulfate into active 
estrone by stimulating sulfatase, as well as increasing 17-beta-hydroxysteroid 
reductase activity (Xu et al., 2007). Other studies demonstrated an increase in the 
activity of 17-beta-hydroxysteroid reductase by both MPA and NET (Campagnoli et 
al., 2005; Coldham et al., 1990). Increased activity of this enzyme may increase the 
intracellular production of more potent estrogens, and possibly increase breast 
cancer risk.  
 
MPA has also been implicated in breast cancer cell migration and invasion (Birrell et 
al., 2007; Fu et al., 2008]. In the study by Fu et al. (2008), both MPA and Prog, alone 
or in combination with 17β-estradiol (E2), increased breast cancer cell migration and 
invasion by a mechanism involving the activation of the actin-binding protein moesin, 
and the initiation of actin remodelling. The authors suggest that MPA may play a role 
in the development of PR+ breast cancer by changing the ability of cancer cells to 
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interact with the extracellular environment, and ultimately their ability to move or 
invade the surrounding environment.  
On the other hand, results from some in vitro studies investigating the effects of MPA 
and NET on breast cancer, do not correlate with the recently available clinical 
evidence suggesting an increased risk of breast cancer for HRT users. MPA has 
been shown to significantly decrease parathyroid hormone related peptide (PTHrP) 
expression in breast tissue (Sugimoto et al., 1999). The level of PTHrP expressed in 
breast cancer tissue is closely associated with the incidence of bone metastasis. This 
result is consistent with the therapeutic effect of MPA when used as second line 
hormonal therapy for the treatment of metastatic breast cancer. Similarly, MPA has 
been shown to induce the expression of the metastasis suppressor gene, Nm23-H1, 
in a metastatic breast cancer cell line, thereby decreasing metastatic colonization 
(Palmieri et al., 2005).  
 
MPA also inhibits the E2-stimulated growth of the MCF-7 cell line (Lippert et al., 2001; 
Schoonen et al., 1995), while another study MCF-7 cells showed that both MPA and 
NET displayed significant inhibition of cell proliferation (Seeger et al., 2003). The 
above in vitro studies, in contrast to recent clinical evidence for MPA and NET, seem 
to indicate that both these progestins may reduce the risk of breast cancer. Cyclin 
D1, which is required for cell cycle progression in G1, has been implicated in the 
pathogenesis of breast cancer. When the T47-D breast cancer cell line was treated 
with MPA, increased expression of cyclin D1 mRNA and protein was observed after 
24 hours, while a decrease was observed after 72 hours (Thuneke et al., 2000). In 
contrast to the recent clinical evidence, the authors suggest that long-term MPA 
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administration may therefore have an inhibitory influence on the proliferative activity 
of breast cancer cells.  
 
Taken together, the evidence in the literature indicates that the role of MPA in breast 
cancer development is not straightforward. At high dosages such as those in cancer 
therapy, MPA has anti-proliferative effects on breast cancer cells, elucidating its 
therapeutic effects in the treatment of metastatic cancer. In contrast, the role of MPA 
in breast cancer development becomes blurred when used for contraception and 
HRT. Some studies indicate that MPA enhances the development of breast cancer 
(Ganzina et al., 1979, Etienne et al., 1992; Bentel et al., 1999; Hofseth et al., 1999; 
Thuneke et al., 2000; Cavalli et al., 1984), while others show that does not increase 
breast cancer risk (reviewed by Kaunitz, 1996; Dillis and Schreiman, 2003; Palmieri 
et al., 2005; Lippert et al., 2001; Schoonen et al., 1995; Thuneke et al., 2000). 
Similarly, NET has also been shown to significantly inhibit cell proliferation at a 
concentration range of 0.01 nM to 10 µM (Seeger et al., 2003), but also to increase 
breast cancer proliferation at HRT doses (Millions women’s study collaborators). 
Further investigation is therefore required to determine the conditions under which 
MPA or NET (in contraceptive or HRT use) facilitates the development of breast 
cancer in women, in order to minimize the risk to users.  
 
1.3.5.2 Endometrial, ovarian and cervical cancers 
The use of MPA as an injectable contraceptive is associated with an 80% reduction 
of endometrial adenocarcinoma (Kaunitz, 1996). Further in vitro evidence for the 
protective effect of MPA on the endometrium involves a study on regularly cycling 
women treated with MPA (10 mg/day), which showed suppression of c-fos 
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expression in the human endometrial samples (Reis et al., 1999). The proto-
oncogene, c-fos is one of the putative mediators of estrogen-induced endometrial 
proliferation.  
 
A number of studies have been undertaken in cell lines and tissue samples to further 
determine the effects and mechanisms of action of MPA and NET on uterine 
(endometrial) cancer. Consistent with the clinical evidence suggesting no deleterious 
effect of MPA on the development of uterine cancers, MPA, unlike estradiol, did not 
increase the expression of PD-ECGF, an angiogenic factor, in the Ishikawa cell line 
(Aoki et al., 2003). Similarly, NET combined with estrogen in HRT has been reported 
to protect against the hyperplastic effects of estrogen treatment on the endometrium 
(Riis et al., 2002). 
 
Although NET in HRT use has been shown to have protective effects on the 
endometrium, its A-ring (figure 1) reduced derivatives were able to significantly 
increase mRNA levels of c-fos in ovariectomized rats. These results indicate that 
NET administration might indirectly induce estrogenic effects through the action of its 
5α-dihydro and 3β, 5α-tetrahydro derivatives, an activity that may facilitate the 
development of uterine cancer (Mendoza-Rodriguez et al., 1999). In contrast to the 
above study, and consistent with its protective effects on the endometrium, in vitro 
studies showed upregulation of Wnt-7a gene expression by NET-A in normal 
estrogen treated endometrial epithelial cells. This upregulation of Wnt-7a is thought 
to be associated with the antineoplastic effects of progestins on the endometrium 
(Oehler et al., 2002). Taken together, the in vitro studies are consistent with the 
clinical evidence that neither MPA nor NET increase the risk of endometrial cancer. 
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However, the study by Mendoza-Rodriguez et al. (1999) suggests that NET 
metabolites may increase the risk of endometrial cancer under certain conditions. 
 
The use of MPA as contraceptive has been reported to have no effect the risk of 
epithelial ovarian cancer or cervical neoplasia (Kaunitz, 1996, Shapiro et al., 2003). 
In contrast, recent evidence suggests that MPA in HRT use increases the risk of 
ovarian cancers (Anderson et al., 2003). To our knowledge, nothing is known on the 
effects of contraceptive or HRT doses of NET on the development of ovarian and 
cervical cancers. Further investigation is therefore required to determine whether 
NET (in contraceptive or HRT use) facilitates the development of these reproductive 
cancers in women. 
 
1.3.6 Cardiovascular function 
 Cardiovascular disease (CVD) is the main cause of death in both men and women of 
the developed world (ESHRE Capri Workshop Group, 2006). Pre-menopausal 
women are considered more protected from CVD than men due to the presence of 
endogenous estrogen. When estrogen levels start declining after the onset of 
menopause, the relative cardioprotective effect by estrogen also wanes. In a study by 
Bairey Merz et al. (2003), it was shown that disruption of the ovulatory cycle in 
premenopausal women, indicated by estrogen deficiency and hypothalamic 
dysfunction, is associated with an increased risk of coronary atherosclerosis and 
adverse cardiovascular events (Bairey Merz et al., 2003). Furthermore, lipid and 
lipoprotein profiles have been shown to deteriorate following menopause, resulting in 
increased risk of coronary heart disease (CHD), which is known to be reversed by 
estrogen therapy (Dubey et al., 2005).  
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Synthetic progestins, including MPA and NET, have been shown to negate the 
cardioprotective effects of estrogen, in addition to producing negative cardiovascular 
effects when used alone (Farish et al., 1986; LaRosa, 1994; Kim et al., 1994; Levine 
et al., 1996; Adams et al., 1997; Register et al., 1998; Chen et al., 1998; Spencer et 
al., 2000; Mishra et al., 2005; Jeanes et al., 2006, Fernandes et al., 2008). 
Consistent with this, recent randomised clinical trials have suggested that estrogen 
plus MPA in HRT regimes does not confer cardiac protection, and may increase the 
risk of coronary heart disease in postmenopausal women (Rossouw et al., 2002; 
Manson et al., 2003). In contrast, a trial on estrogen alone did not show increased 
risk of CVD (Women’s health initiative steering committee, 2004). 
 
The PEPI study, which compared a variety of cardiovascular effects, including lipid 
effects, of usage of both MPA and Prog in combination with CEE, indicated that all 
regimens were associated with clinically significant improvements in lipoprotein 
levels, but that many of estrogen’s beneficial effects on HDL-cholesterol (HDL-C) 
were reversed with the addition of MPA, but not Prog (Writing group for the PEPI trial, 
1995). These results are consistent with other studies, showing that MPA, and also 
NET, reduces HDL levels (Ottosson et al., 1985; Hirvonen et al., 1981; Saarikoski et 
al., 1990; Miller et al., 1991), while progesterone either maintains or increases 
estrogen’s positive lipid and HDL effects (Ottosson et al., 1985; Saarikoski et al., 
1990). Ottosson et al. (1985) compared the lipid effects in menopausal women 
receiving estrogen combined with MPA or Prog, and demonstrated that those 
receiving estrogen combined with MPA had a significant reduction in HDL and HDL 
subfraction 2, while no significant changes were seen in those women receiving 
estrogen combined with Prog. Furthermore, a randomized trial which compared the 
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lipid effects in women using Prog and NET, indicated that women using NET had a 
significantly decreased HDL, whereas those using Prog showed no decrease in HDL. 
 
In addition to the effects of Prog, MPA and NET on lipids, their effects on other risk 
factors of CVD such as atherosclerosis, vasoconstriction/vasodilation, and 
carbohydrate metabolism, have also been examined. The lack of correct endothelial 
function (endothelial dysfunction) is the initial event in the development of 
atherosclerosis and an early marker of cardiovascular disease (CVD) (Abdu et al., 
2001). It starts with injury of the vascular endothelium and results in an increase of 
monocytes and macrophages in the subendothelium by increasing the expression of 
cellular adhesion molecules such as intercellular adhesion molecule (ICAM-1), 
vascular and cell adhesion molecule-1 (VCAM-1) and E-selectin, as well as 
increased production of chemokines like monocyte attracting protein (MCP-1) 
(Seeger et al., 2007). Consequently, smooth muscle cells migrate and proliferate 
resulting in remodeling of the vascular wall. When a further buildup of inflammatory 
cells and lipids occurs, atherosclerotic plaques form. When these plaques rupture, it 
may cause myocardial infarction or stroke. A number of studies have shown that 
unlike Prog, which inhibits atherosclerotic plaque formation, MPA promotes plaque 
formation and also prevents the plaque-inhibiting and lipid-lowering actions of 
estrogen (Levine et al., 1996; Adams et al., 1997; Register et al., 1998). 
 
Both MPA and NET-A have been shown to have deleterious effects on the 
vasculature by dose dependently increasing the expression of the adhesion 
molecules, ICAM-1 and VCAM-1, in human umbilical venous endothelial cells 
(HUVECs) (Tatsumi et al., 2002). Similarly, a study in human vascular endothelial 
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cells, showed that unlike Prog, MPA did not inhibit the expression of VCAM-1 (Otsuki 
et al., 2001). As already mentioned, monocyte adhesion to endothelial cells is an 
important initial event at the onset of atherosclerosis, thus the above data suggests 
that MPA and NET may contribute unfavourably to this disease (Tatsumi et al., 
2002). Furthermore, treatment of vascular smooth muscle cells with MPA, in contrast 
to NET, upregulated PAR-1 expression, which markedly potentiated the vascular 
procoagulent effects of thrombin, an effect thought to be due to the glucocorticoid-like 
activity of MPA (Herkert et al., 2001). In addition, long-term administration of MPA to 
ovariectomised rats increased PAR-1 protein levels in the arterial wall, which resulted 
in increased responsiveness of isolated aortic rings to thrombin (Herkert et al., 2001). 
Interestingly however, MPA unlike NET antagonised the estradiol-induced significant 
reduction of MCP-1 in human female coronary endothelial cell cultures (Mueck et al., 
2002). Taken together, a large number of studies indicate that unlike Prog, MPA and 
NET-A have adverse effects on early stages of atherosclerosis, while the study by 
Mueck et al. (2002) infers that MPA and NET-A may differ in their effects, and that 
NET-A may be protective under some conditions. 
 
Two recent studies have also indicated that MPA promotes endothelial dysfunction 
(Meendering et al., 2008; Lizarelli et al., 2009), which could subsequently lead to 
increased stroke risk. Meendering et al. (2008) demonstrated that MPA counteracts 
the beneficial effects of estradiol on endothelium-dependent vasodilation in young 
women. In particular, their data suggests that the decrease of the vasoconstrictor, 
endothelin-1, by estradiol is reversed by MPA. A study in isolated human endothelial 
cells as well as in ovariectomized rat aortas, demonstrated that MPA has no effect on 
endothelial nitric oxide (NO) production, while Prog increases its production 
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(Simoncini et al., 2004). Production of NO, a vasodilatory agent, is essential for 
normal vascular endothelial functioning, and impaired synthesis of NO would result in 
atherosclerosis (Yasa and Türkseven, 2005). Thus, the study by Simoncini et al., 
2004, implies that Prog would have beneficial effects on the vasculature, while MPA 
would not. In addition, that study showed that MPA inhibits the expression of 
leukocyte adhesion molecules and moreover, when MPA was used in combination 
with estradiol, it hinders the favorable estradiol signaling, while Prog enhances the 
effects of estradiol. Overall, these results highlight the fact that Prog and MPA have 
distinct biological effects, with MPA generally having a more negative effect on the 
vascular system.  
 
A number of studies have shown that coronary artery spasm, which increases the 
risk for heart attack and stroke, is reduced with the use of estrogen and/or Prog, 
while the addition of MPA to estrogen has the opposite effect, resulting in 
vasoconstriction, thus increasing the risk for ischemic heart disease (Miyagawa et al., 
1997; Minshall et al., 1998; Mishra et al., 2005). For example, Miyagawa and co-
workers (1997) showed that primates pretreated with estradiol combined with Prog, 
did not experience vasospasm, while all of those treated with MPA showed 
significant vasospasm. Similarly, Mishra et al. (2005) recently also showed that Prog 
protected against coronary hyperreactivity, while MPA had the opposite effect and 
induced coronary constriction. A study investigating the effects of MPA and NET-A in 
an animal model of the human menopause (ovariectomised New Zealand white 
rabbits), indicated that potassium and endothelin-1 induced higher contractile 
responses in the distal coronary artery from animals treated with MPA compared to 
animals treated with NET-A (Pedersen et al., 2004). Furthermore, another study by 
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this group, investigating vascular function in coronary arteries of hyperlipidemic 
rabbits, showed that when estradiol is combined with MPA or NET-A, the beneficial 
effects of estradiol on NO and Ca2+-mediated vascular reactivity are negated by 
MPA, but not by NET-A (Pedersen et al., 2006). Taken together, the results of the 
two latter studies show adverse effects with MPA but not NET-A, clearly indicating 
that MPA and NET-A cause different vascular effects, emphasizing that the choice of 
progestin is crucial in HRT. 
 
An increase in insulin resistance and subsequent deterioration in glucose tolerance 
(associated with menopause) could result in type 2 diabetes as well as CVD. MPA 
and NET-A have been shown to significantly increase insulin resistance (Wagner et 
al., 1996; Godsland et al., 1992; Christodoulakos et al., 2005; 1993; Spencer et al., 
2000; Fernandes et al., 2008) when compared with estrogen and progesterone 
(Godsland et al., 1993; Spencer et al., 2000). Christodoulakos et al. (2005), 
comparing insulin resistance in postmenopausal women receiving different regimens 
of HRT, demonstrated that estrogen combined with NET-A showed no association 
with insulin resistance, while when estrogen was combined with MPA, increased 
insulin resistance was found. Similarly, a placebo-controlled trial showed that a 6-
month treatment with estrogen and NET-A, did not affect insulin sensitivity (Walker et 
al., 2001). Conversely, Fernandes et al. (2008) showed that in postmenopausal 
women receiving HRT, estrogen alone caused an improvement insulin resistance, 
while when combined with NET-A, this positive effect was no longer seen. Taken 
together, these data indicate that MPA may worsen glucose tolerance causing insulin 
resistance, thereby increasing risk of CVD. However, the effects of NET are 
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controversial, and more research is needed to establish the effect of NET on glucose 
metabolism. 
 
Hypertension is one of the greatest risk factors of CVD (Mueck and Seeger, 2004). 
When used in HRT, synthetic progestins, such as MPA and NET-A, that are reported 
to lack the anti-mineralocorticoid activity of Prog (Winneker et al., 2003; Palacios et 
al., 2006), could lead to cardiovascular complications, as they are not able to 
antagonize the salt-retaining and blood pressure raising effects of estrogens. 
Estrogen acts on the renin-angiotensin-aldosterone system (RAAS), leading to 
increased synthesis of angiotensinogen, which subsequently increases aldosterone 
levels thereby promoting sodium and water retention (Oelkers, 1996). Thus estrogen 
indirectly leads to increases in weight and blood pressure. On the other hand, Prog is 
a potent antagonist of aldosterone (Wambach et al., 1979; Rafestin-Oblin et al., 
1992; Quinkler et al., 2002) via binding to the mineralocorticoid receptor (MR). Thus 
Prog, acting via the MR, will cause increased sodium excretion and prevent sodium 
retention, conferring potential blood pressure benefits. As MPA and NET-A are 
unable to antagonize the salt-retaining and blood pressure raising effects of 
estrogens, it would lead to weight gain and increased blood pressure, which may 
subsequently lead to cardiovascular complications.  
 
Consistent with the above effects of Prog on the RAAS, Rylance et al. 1985 observed 
no changes in blood pressure with progesterone in normotensive postmenopausal 
women, but a slight reduction in blood pressure was observed in hypertensive 
women. In contrast, NET-A in combination with estradiol in HRT has been reported to 
result in increases in blood pressure (Activelle package insert reg. no. 
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33/21.8.2/0532, Novo Nordisk). Similarly, Rosano et al. (2001) showed that estradiol 
associated with a high dose of NET-A (10 mg) increased blood pressure in 
hypertensive postmenopausal women. In another study, NET-A in HRT was 
associated with an increased risk of stroke among hypertensive but not normotensive 
women. The authors thus suggested that hypertensive postmenopausal women 
should not use HRT regimes containing NET-A (Lokkegaard et al., 2003). A study in 
ovariectomized female Wistar rats treated with Ald and salt to induce renal injury, 
showed that estradiol in combination with MPA, increased the development of kidney 
injury, sodium retention and increased blood pressure (Arias-Loza et al., 2009). In 
contrast to the risk for HRT users, contraceptive usage of MPA or NET-EN is 
reported to have a relatively minor effect on blood pressure. The Cochrane 
comparative review on these two progestins reported similar relatively small changes 
in blood pressure, which are not clinically relevant, for both MPA and NET-EN 
(Draper et al., 2006). 
 
In contrast to the studies showing negative effects of MPA on CVD, and variable 
effects for NET (negative and positive), a study in human vascular coronary cells 
demonstrated that estrogen in combination with MPA and NET significantly reduced 
the inflammatory markers, monocyte chemoattractant protein-1 (MCP-1), E-Selectin 
and ICAM-1, as well as the plaque marker PAI-1 (Seeger et al., 2007), suggesting 
that MPA and NET can also positively influence the vasculature. PAI-1, synthesized 
by the endothelium, is an independent risk factor for the development of CVD and a 
promoter of thrombosis after plaque rupture. Similarly, a prospective randomized 
study investigating the pro-coagulant and fibrinolytic activity of HRT showed that 
estrogen combined with MPA or NET, reduced PAI-1 levels (Taner et al., 2006). MPA 
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and NET also enhanced the positive effect of estradiol on the precursor of matrix 
metalloproteinase-1 human female coronary endothelial cell cultures (Mueck et al., 
2002). Consistent with positive effects on the vasculature with MPA usage, but in 
contrast to previous studies, a recent study showed that MPA combined with 
estrogen does not impair the improvement in flow-mediated dilatation in resistance 
arteries of postmenopausal women, and that MPA alone has no effect (Kublickiene et 
al., 2008). These data suggest that use of MPA or NET, either alone or in 
combination with estrogen, has a positive effect on the function of resistance arteries, 
and may prevent endothelial dysfunction. 
 
Understanding the effects of MPA and NET on cardiovascular mechanisms and how 
they translate into clinical risk, together with the current epidemiological knowledge, 
should thus be considered when prescribing the optimal progestin for HRT, 
especially in women susceptible to cardiovascular disease.  
 
1.3.7 Immune function  
The possibility that MPA, and to a lesser extent NET, can exert immunosuppressive 
effects on a physiological level was raised many years ago by Hulka et al. (1965). In 
their study in rabbits, they observed that MPA treatment (5 mg daily) suppressed 
circulating antibody production to the same extent as observed with cortisol treatment 
(50 mg twice a week). Similarly, MPA was shown to suppress the primary humoral 
antibody response in rabbits and also to extend survival of dogs with renal allografts 
as well as survival of rabbits with skin allografts (Turcotte et al., 1968). In the guinea 
pig, MPA decreased expression of splenic macrophage Fcgamma receptors, which 
play a critical role in host defence against infection (Gomez et al., 1998). In contrast, 
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MPA was shown to enhance antibody production in mice in vivo and in vitro in 
cultures of splenocytes, bone marrow cells or lymph node cells (Vermeulen et al., 
2001).  
 
Surprisingly, little research appears to have been carried out in humans on the 
effects of contraceptive doses of MPA on immune function. Two early findings show 
that MPA increases cell-mediated immune reactivity in the skin (Gerretsen et al., 
1979) and has a profound effect on the efferent phase of the immune response 
(Gerretsen et al., 1980). However, MPA was found to compromise cell-mediated 
immune status in Bangladeshi women receiving these compounds as injectable 
contraceptives (Majumder et al., 1987). Doses of MPA used in HRT also modulate 
human immune function, selectively affecting various immune cell subsets (Brunelli et 
al., 1996, Malarkey et al., 1997). Furthermore, MPA has been shown to have anti-
inflammatory activity, by decreasing the levels of the plasma proinflammatory 
markers, C-reactive protein and serum amyloid A protein, that are increased by 
estrogen, in postmenopausal women using the CEE/MPA HRT treatment (Wakatsuki 
et al., 2002). In addition, MPA used together with estrogen, has been shown to 
downregulate release of the pro-inflammatiry cytokines interleukin-2 (IL-2) and 
interferon gamma (IFN-γ) by phytohemaglutinin (PHA)-stimulated peripheral blood 
mononuclear cells (PBMCs) isolated from postmenopausal women using HRT 
therapy (Stopińska-Głuszak et al., 2006). The authors propose that the use of 
estrogen combined with MPA in HRT may affect cell-mediated immunity which could 
lead to the development of neoplastic disease.  
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At higher doses (up to 1500 mg orally per day), MPA has been shown to cause 
significant immunosuppression in patients (Brunelli et al., 1996; Malarkey et al., 
1997; Yamashita et al., 1996; Mallmann et al., 1990; Scambia et al., 1988; 
Kurebayashi et al., 2003; Naglieri et al., 2002). Mallman et al. (1990) observed 
decreased T cell numbers in breast cancer patients receiving high doses of MPA, 
while another group showed that MPA could inhibit lymphocyte proliferation in vitro 
(Kontula et al., 1983). Furthermore, MPA treatment of PBMCs from cancer patients 
was shown to significantly reduce the proliferative response to PHA (Mantovani et al., 
1997). Similarly, MPA at 100 ng/ml was shown to exert a significant inhibitory effect 
on lymphocyte response to mitogens in healthy volunteers (Corsini and Puppo, 1982-
1983). In contrast, Grönroos and Eskola (1984) showed no effect of MPA on 
lymphocyte proliferation, or in the proportion of T and B cells in endometrial cancer 
patients. Furthermore, MPA at 0.2 µg/ml has been shown to decrease the levels of 
IL-1β, IL-6, tumor necrosis factor-alpha (TNFα) and serotonin (5-HT) produced in 
culture by PHA-stimulated PBMCs from cancer patients (Mantovani et al., 1997). 
Moreover, treatment of serotonin-induced myometrial smooth muscle cells with MPA 
resulted in a marked decrease in the expression of IL-1α mRNA and protein (Lan et 
al., 1999). Similarly, IL-1 and IL-6 were strongly suppressed by MPA (≥ 100 nM), but 
not Prog, in normal human lymphocytes (Bamberger et al., 1999). Koubovec et al. 
(2005) showed, using promoter-reporter assays, that MPA elicited more potent 
transrepression of the IL-8 promoter than Prog, while NET-A only repressed the 
reporter by 22% at a concentration of 10 µM. Furthermore, studies have shown that 1 
µM MPA could inhibit IL-8 production in endometrial explants and chorion cells (Kelly 
et al., 1994), as well as β-chemokine production in choriodecidual cells (Kelly et al., 
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1997). In contrast Arici et al. (1996a) found that 100 nM MPA increased the 
expression of IL-8 mRNA in HESCs. 
 
Interestingly, MPA is widely used to facilitate infection of sexually transmitted 
diseases in animal models. Kaushic et al. (2003) showed that MPA treatment (up to 2 
mg/mouse) changed susceptibility and local immune responses to genital herpes 
simplex virus type 2 (HSV-2) infections. Similarly, longer exposure to MPA lead to 
poor innate and adaptive immune responses to HSV-2 that failed to protect mice 
from subsequent genital challenges (Gillgrass et al., 2003). Progesterone implants, 
which could mimic hormonally based contraceptives like MPA, were shown to thin the 
vaginal epithelium and enhanced SIV vaginal infection in monkeys (Cohen, 1996; 
Marx et al., 1996). Interestingly, a recent animal study showed increased 
susceptibility to vaginal simian-human immunodeficiency virus (SHIV) transmission 
and suppression of the antiviral cellular immune response in SHIV-infected rhesus 
macaques administered the injectable MPA contraceptive (Trunova et al., 2006), 
indicating an immune- rather than transmission-based mechanism. In addition, the 
use of MPA at contraceptive doses has been associated with increased acquisition of 
cervical chlamydial and gonococcal infections (Morrison et al., 2004). This increase 
could be related to significant changes observed in the vaginal intraepithelial 
leukocyte population of MPA contraceptive users, which was thought to reflect 
altered local immune capacity (Ildgruben et al., 2003). In contrast, in a retrospective 
cohort study among HIV-infected women, MPA contraceptive use did not appear to 
enhance the risk of sexually transmitted infection (STI) acquisition (Overton et al., 
2008). With the exception of the latter study, the above-mentioned studies suggest 
that MPA may exert a negative influence on local defence mechanisms in the human 
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female genital tract, which is the primary route for heterosexual transmission of HIV. 
During male-to-female transmission, it is thought that virus in the semen enters the 
stratified squamous epithelium of the vagina or the columnar epithelium of the 
endocervix to infect cells within or below the epithelium (reviewed in Pope and 
Haase, 2003). It is not clear which cells are the first to interact with, and to be 
infected with the virus, whether environmental factors in the reproductive tract tissues 
may influence the infection, or whether there are local immune-system responses 
directed at the virus. Understanding these processes is critical, particularly for 
developing effective prophylactic microbiocides and vaccines (Boggiano and Littman, 
2007). 
 
When used as a contraceptive, MPA was found to increase HIV viral shedding 
(Mostad et al., 1997) and HSV cervical shedding in HIV-infected women (Mostad et 
al., 2000). Although Mostad et al. (1997) did not investigate the molecular 
mechanism of these effects, they postulate that the effects may be mediated by 
factors such as direct effects on the virus, effects on local genital tract physiology or 
effects on immune modulation of viral replication, or a combination of these effects. 
Similarly, MPA used as a contraceptive causes a modest but significant increase in 
shedding of HIV-1 DNA in humans (Wang et al., 2004). Moreover, MPA users 
infected with HIV have more viral variants and higher viral loads than women who are 
not on hormonal contraception (Lavreys et al., 2004). Female sex workers in Kenya 
who used MPA were found to have an increased incidence of HIV-1 infection (Martin 
et al., 1998). Taken together, the above studies raise concern, as they suggest that 
MPA exerts not only systemic but also local immunosuppressive side-effects in vivo, 
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and when used as injectable contraception has deleterious effects on HIV viral 
shedding. 
 
In contrast to the above studies, recent data suggest that MPA as a contraceptive 
does not increase the risk of HIV infectability in women (Myer et al., 2007; 
Kleinschmidt et al., 2007; Morrison et al., 2007). Although the results from the study 
by Morrison et al. (2007), called the Hormonal Contraception and Risk of HIV 
Acquisition (HC-HIV) study, found no overall increased risk of HIV acquisition among 
MPA users in Uganda and Zimbabwe, they observed a link between HIV, MPA and 
herpes simplex virus-2 (HSV-2). They indicated that whether or not women were 
infected with HSV-2, was a determining factor for whether women using MPA were at 
risk of HIV infection. They reported that women using MPA only had increased risk of 
HIV infection if they were not already infected with HSV-2 (Morrison et al., 2007), 
indicating that HSV-2 infection appears to protect against HIV infection in MPA users. 
This result is surprising, as there is some evidence that genital tract shedding of HSV 
increases rather than decreases HIV acquisition and also other STIs (Ramaswamy et 
al., 2007; Corey et al., 2007). However, whether MPA influences susceptibility to HIV 
remains a controversial issue. 
 
In contrast to what is known for MPA, very little is known about the effects of NET on 
immune function. Early studies in animal models on the effects NET (5 mg daily) on 
the immune system reported significantly prolonged survival of skin allografts and a 
moderate suppression of antibody production (Hulka et al., 1965). Similary to MPA, 
NET also decreases splenic macrophage Fcgamma receptor expression in the 
guinea pig, thereby impairing the clearance of IgG-coated erythrocytes (Gomez et al., 
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1998). Furthermore, in humans, NET like MPA compromised cell-mediated immune 
status in Bangladeshi women receiving these compounds as injectable 
contraceptives (Majumder et al., 1987). In a study in men, contraceptive doses of 
NET-EN upregulated IL-6 (proinflammatory cytokine), while downregulating IL-10 
(anti-inflammatory cytokine), implying an inflammatory profile in healthy men 
(Zitzmann et al., 2005). In a study in healthy postmenopausal women however, NET-
A in combination with estrogen, similarly to estrogen only therapy, had no effect on 
IL-6 levels (Žegura et al., 2006). Whether or not NET is associated with an increased 
risk of HIV/HSV acquisition and shedding and viral load and viral diversity remains to 
be determined. In this regard, two recent studies in a cohort of South African women, 
showed no association between risk of HIV infection and NET-EN at contraceptive 
doses (Myer et al., 2007; Kleinschmidt et al., 2007). 
 
To date, very little is known about the molecular mechanisms of action of MPA and 
NET on immune function, in particular the target cells, target genes and dose 
responses. In this regard, MPA has been reported to modulate transcription of a 
number of genes via the glucocorticoid receptor (GR), such as IL-2 in normal human 
lymphocytes (Bamberger et al., 1999), IL-6 and IL-8 in mouse fibroblast cells 
(Koubovec et al., 2004) and the nm-23 tumor suppressor gene in breast cancer cells 
(Ouatas et al., 2003). In contrast, MPA’s suppression of the RANTES gene in 
endometrial cells was progesterone receptor (PR)-mediated (Zhao et al., 2002). 
Thus, the above results suggest that the immune suppression manifested by MPA is 
mostly mediated by its glucocorticoid rather than progestogenic actions (Kurebayashi 
et al., 2003; Koubovec et al., 2004). Consistent with this idea is the finding that MPA, 
but not Prog, possesses potent anti-inflammatory properties that contribute to its 
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ability to prevent inflammation-induced pre-term birth in mice (Elovitz and Wang, 
2004), indicating that MPA has more pronounced immunosuppressive effects than 
Prog.  
 
Considering the above data, it is clear that more research on the effects of MPA and 
NET on target genes involved in immune function in specific target cells, is needed at 
the molecular level.  
 
1.4 Mechanism of action 
There are many unanswered questions about the relative actions of MPA and NET at 
the cellular level. It is known, however, that both these progestins bind to, as well as 
regulate, serum levels of steroid-binding proteins such as corticosteroid-binding 
globulin (CBG) (Pugeat et al., 1981; Misao et al., 1998a; van der Vange et al., 1990) 
and sex hormone-binding globulin (SHBG) (Pugeat et al., 1981; Misao et al., 1998b; 
Rodriguez-Aleman et al., 2000; Onobrakpeya et al., 2001; Fotherby, 1988; Biglia et 
al., 2003; Ylikorkala et al., 2003). This means that they could possibly alter serum 
concentrations, and thus the bioavailability, of endogenous steroids to various target 
tissues. Moreover, it is known that the intracellular effects of MPA and NET, are 
mediated via binding to not only the progesterone receptor (PR), but also other 
steroid receptors such as the GR, MR, androgen (AR), and possibly the estrogen 
(ER) receptor, thereby regulating an array of genes. In the sections below, we briefly 
review what is known at the molecular level about the effects of MPA and NET on 
serum-binding proteins, followed by a detailed review on the known effects of MPA 
and NET via the different members of the steroid receptor family.  
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1.4.1 Serum binding globulins 
When steroids enter the bloodstream, they interact with several serum-binding 
proteins, and their biological activity depends on the ratio of bound to free steroid. 
Steroids that are bound to serum-binding proteins are unavailable to tissues, 
whereas steroids that are unbound are free to diffuse from the blood into the cells of 
target tissues where they either get metabolised or interact with specific steroid 
receptors. CBG and SHBG are low abundance serum-binding proteins with high 
steroid-binding affinity and specificity (Hammond, 2002). They are the main 
transporter proteins that carry steroid hormones in the plasma. SHBG preferentially 
binds to testosterone, while CBG preferentially binds to cortisol (Pugeat et al., 1981). 
Once MPA and NET-EN reach the bloodstream, they demonstrate very different 
binding properties towards these serum proteins, resulting in different effects on their 
free (bioavailable) concentrations and those of endogenous steroids which compete 
for binding to serum proteins (Schindler, 2003; Pugeat et al., 1981).  
  
CBG is a glycoprotein synthesized mainly in the liver (Scrocchi et al., 1993), with high 
affinity for glucocorticoids and progestins, and low affinity for androgens, estrogens 
and mineralocorticoids (Breuner and Orchinik, 2002). It is the major transport protein 
for natural glucocorticoids (GCs) in all mammalian species including humans 
(Hammond, 1990). The main function of CBG is to transport and regulate the 
bioavailability of GCs to a range of target tissues (Hammond, 1990). In this way, CBG 
may be protecting tissues against potentially harmful effects of elevated GCs 
(Breuner and Orchinik, 2002). CBG has also been shown to influence metabolic 
clearance rates of GCs as the greater the fraction of bound hormone, the slower the 
metabolic clearance (Siiteri et al., 1982). Although CBG is reported to have high 
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binding affinity for progestins, Schindler et al. (2003) have previously reported that 
MPA has no binding affinity for CBG. Similarly, a recent study observed very low 
relative binding affinities (RBAs) of Prog, MPA, as well as NET, for human CBG (less 
than 1%, compared to 100% for cortisol) (Sasagawa et al., 2008). This result for MPA 
and NET-A is in agreement with an earlier study showing that these progestins could 
not compete with cortisol for binding to CBG (Ottosson et al., 1985). In contrast to the 
study by Sasagawa et al. (2008), Ottosson et al. (1985) showed that Prog could 
compete with cortisol for binding to CBG. Thus there are a number of inconsistencies 
in the literature, which should be addressed by further research. 
 
Little is known on the effects of MPA or NET on CBG gene regulation. One study 
showed that MPA at 1 µM suppressed CBG mRNA expression in an endometrial 
cancer cell line (Misao et al., 1998a), which could influence bioavailability of GCs to 
target tissues. In contrast, oral contraceptive doses of NET resulted in an increase in 
serum CBG levels in healthy women (van der Vange et al., 1990).  
 
SHBG is a homodimeric glycoprotein produced by hepatocytes (Jänne et al., 1998) 
that binds testosterone and estradiol with high affinity (Hammond, 2002). Its primary 
function is to transport these two biologically active steroids in the blood, thus playing 
an important role in regulating the levels of free fraction of testosterone and estradiol 
available to target cells (Siiteri et al., 1982). Furthermore, several reports have shown 
that SHBG can exit the blood circulation and enter the extravascular compartments 
of various tissues (Bordin and Petra, 1980; Sinnecker et al., 1988). This may regulate 
the local access of testosterone and estradiol to target cells that are not in the 
immediate vicinity of the blood supply.  
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MPA, NET and NET-A have been shown to influence SHBG levels in a number of 
studies. In the Ishikawa cell line (human endometrial cancer cells), low MPA 
concentrations (0.1 nM) added together with estradiol (10 nM) were found to increase 
SHBG mRNA expression, whereas the addition of high concentrations (1-10 µM) of 
MPA with or without estradiol (10 nM) suppressed it (Misao et al., 1998b). Similarly, 
serum SHBG concentrations investigated in postmenopausal women decreased 58% 
with a daily treatment of 60 mg MPA for two weeks (Saaresranta et al., 2000). This 
decrease in SHBG concentrations in response to MPA is significant, as low levels of 
circulating SHBG may predict diabetes and cardiovascular diseases (Pugeat et al., 
1995; Hajamor et al., 2003). In contrast, serum SHBG levels were significantly 
increased in postmenopausal women treated with MPA at 2.5- to 10 mg daily in 
combination with 2 mg per day estradiol valerate (Rodriguez-Aleman et al., 2000). 
Furthermore, postmenopausal women using the CEE/MPA regimen for HRT 
exhibited 2.5-fold higher SHBG levels, with a consequent corresponding 3.5-fold 
lower free androgen level, compared to non-users (Christodoulakos et al., 2005).  
 
Postmenopausal women treated with NET-A (5 mg/day) for 9 weeks showed a 
significant decrease in SHBG levels (Onobrakpeya et al., 2001). Similarly, increasing 
concentrations of NET antagonised the stimulatory effect of estrogen and resulted in 
a reduction of serum SHBG concentrations (Fotherby, 1988). However, in another 
study of postmenopausal women receiving E2/NET-A this regimen increased SHBG 
levels and decreased free testosterone (Dören et al., 2001). Consistent with this 
study, SHBG levels increased in osteoporotic elderly women receiving 1 mg NET-A 
in combination with 2 mg estradiol over a period of one year (Ylikorkala et al., 2003). 
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In contrast to these studies showing either decreased or increased SHBG levels, 
some studies have shown no variations in serum levels of SHBG in postmenopausal 
women receiving NET-A in combination with estradiol (Biglia et al., 2003; 
Christodoulakos et al., 2005).  
 
In addition to regulating SHBG levels, NET, to a greater extent than MPA, has been 
shown to bind to and displace [3H]-testosterone from SHBG (Pugeat et al., 1981; 
Fotherby, 1988; Darney, 1995; Activelle package insert reg. no. 33/21.8.2/0532, 
Novo Nordisk). The results from a recent study showing RBAs of NET for human 
SHBG as 19.5%, and less than 1% for both MPA and Prog, relative to testosterone = 
100%, are consistent with this (Sasagawa et al., 2008). This may result in the 
displacement of endogenous steroids from SHBG such as testosterone and 
estrogen, which may increase their bioavailability to target tissues.  
 
1.4.2 Steroid receptors 
The effects of steroid hormones are mediated through binding to intracellular steroid 
receptors, a subfamily of the nuclear receptor superfamily. The steroid receptor 
family comprises the PR, GR, MR, AR, and ER. These receptors are hormone-
activated transcription factors that share a high level of similarity with regards to their 
structure (Figure 2), as well as their mechanism of action. The receptors all contain a 
variable amino-terminal transactivation domain (NTD), followed by the well conserved 
DNA-binding domain (DBD) and the moderately conserved carboxy-terminal domain, 
containing the ligand-binding domain (LBD) (Mangelsdorf et al., 1995). Furthermore, 
they have two major transcriptional activation domains i.e. activation function 1 (AF-
1) and activation function 2 (AF-2) located in the NTD and LBD, respectively. Co-
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activators bind to the AF-2 site, and are thus important for the induction of 
transcriptional activity of the receptor, while the AF-1 site is required for optimal 
transcriptional activity. In the absence of hormone, steroid receptors are mostly 
associated with heat-shock proteins.  
 
 
 
 
 
 
 
Figure 2. A schematic representation of the general structural and functional domains of steroid 
hormone receptors. 
 
Although all steroid receptors function by essentially identical mechanisms, their 
target genes and also target tissues, may differ (McKenna and O’Malley, 2002). The 
inactive receptor is activated by hormone binding after which the hormone receptor-
complex translocates to the cell nucleus where it binds to specific DNA sequences, 
called hormone response elements (HREs), in the promoter regions of target genes, 
and subsequently regulates gene expression (reviewed in Evans, 1988 and Beato, 
1989). For example, the GR binds to HREs called glucocorticoid response elements 
(GREs). When receptors bind directly to the DNA of target genes, expression of 
specific target genes is modulated by activating (transactivation) or repressing 
(transrepression) transcription. Transrepression can take place without direct DNA 
binding by the receptor but rather via protein-protein interactions with other 
transcription factors such as nuclear factor-kappa B (NFκB) or activator protein-1 
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(AP-1) (McEwan et al., 1997; Webster et al., 1999). By far the best-studied in terms 
of transrepression is the GR (De Bosscher et al., 2003; Koubovec et al., 2005). GCs 
may inhibit other genes by transcriptional cross-talk where the GR mutually interferes 
with other signalling pathways such as those involving AP-1, NFκB, C/EBP, CREB, 
p53 and Smad (De Bosscher et al., 2003). This may require direct or indirect binding 
of the GR monomer to these transcription factors, and as this effect does not require 
direct binding of the GR to DNA, the term “tethering GRE” is often used to describe 
these elements (Newton, 2000). Many genes involved in the inflammatory response 
such as cytokines and chemokines have been reported to be repressed in this way 
(De Bosscher et al., 2003).  
 
Many genes contain GREs in their promoters, including lipocortin-1 (also known as 
annexin I), p11/calpactin binding protein (Flower and Rothwell, 1994; Pitzalis et al., 
2002; Yao et al., 1999), tyrosine aminotransferase (TAT) (Sassi et al., 1998), and the 
mouse mammary tumour virus (MMTV) gene (Scheidereit et al., 1983). The 
consensus sequence for GRE binding is the palindromic 15bp sequence 
GGTACAnnnTGTTCT, where n is any nucleotide (Adcock, 2000). This element may 
also mediate induction by progesterone, androgens and mineralocorticoids, via the 
PR, AR and MR, respectively (Beato, 1989).  
 
Much less is known about the mechanisms by which the AR, PR and MR repress 
genes, but given the similar mechanism of action established thus far for 
transactivation, it is likely that these receptors repress genes by mechanisms similar 
to those of the well-studied GR. Indeed, the AR and PR have also been shown to 
mediate transrepression of genes via the same mechanism as the GR by tethering to 
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other transcription factors. For example, NFκB can be antagonised by the PR 
(Kalkhoven et al., 1996) and the AR (Palvimo et al., 1996; Bellido et al., 1995), 
resulting in repression of genes. This antagonism involves direct protein-protein 
interactions between the steroid receptors and NFκB (Palvimo et al., 1996; 
Kalkhoven et al., 1996). Not much is known about the transrepression of genes via 
the MR. Early work by Pearce and Yamamoto (1993) showed that the MR could not 
repress AP-1 activity in response to aldosterone (Ald), while a later report suggested 
that the MR could exert repressive effects on NFĸB (Liden et al., 1997).  
 
The prediction of the physiological effects of MPA and NET is not straightforward. 
These effects may be influenced by the fact that different cells have different levels, 
as well as different isoforms, of steroid receptors. A cell’s response to a particular 
progestin may thus differ depending on which receptor or receptor isoform it binds. In 
addition, receptor density in a specific cell has also been reported to determine the 
biological character (agonist or antagonist) of steroids, as well as the transcriptional 
activity (transactivation versus transrepression) of steroids (Zhao et al., 2003). 
Another level of complexity is the presence of plasma membrane steroid receptors 
that signal by rapid non-genomic mechanisms and crosstalk between various 
signalling pathways (Turgeon et al., 2004). For these reasons, recent research has 
begun to address the cell-specific effects of MPA and NET. In the following section, 
we will thus review what is known of the mechanism of action of MPA and NET via 
steroid receptors, and their subsequent effects on target genes. 
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1.4.3 Effects of MPA and NET on target genes via the: 
1.4.3.1 Progesterone receptor (PR) 
The physiological effects of progestins in target tissues are assumed to be mediated 
by binding to the classic intracellular PR. Indeed, both MPA and NET have been 
shown to bind to the PR in a number of studies (MacLaughlin and Richardson, 1979; 
Bergink et al., 1983; Feil and Bardin, 1979; Zhang et al., 2000; Selman et al., 1996; 
Bergink et al., 1983; Deckers et al., 2000; Chavez et al., 1985; Kontula et al., 1975), 
with almost equal affinity (Kontula et al., 1975; Bergink et al., 1983). It is noteworthy 
that although Bergink and co-workers (1983) observed similar relative binding 
affinities for both MPA and NET for the PR (44- and 38% respectively, relative to 
100% binding by the synthetic progestin, Org 2058) in cytosolic fractions of the MCF-
7 breast cancer cell line, MPA had a higher binding affinity (65%) for the PR than 
NET (41%) relative to 100% binding by Org 2058, in intact MCF-7 cells. It is unclear 
from the above data whether the relative binding activity was determined from Kd 
values or from EC50 curves.  
 
There are two functional isoforms of the PR, PR-A and PR-B, which are transcribed 
from two promoters of a single gene (Kastner et al., 1990). The ratios of the 
individual isoforms vary in reproductive tissues (Shyamala et al., 1990), and they 
have different physiological functions. Considering that MPA is a progesterone 
derivative and NET-EN, a testosterone derivative, it is likely that they may have 
different binding affinities for the PR-A and PR-B isoforms, as well as different 
biological activities depending on the target cell. In normal human breast tissue, the 
ratio of the PR isoforms, PR-A:PR-B is approximately 1:1, while in a large percentage 
of breast cancer cells, this ratio is changed, and constitutes a risk for breast cancer 
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(Mote et al., 2002). In a study evaluating the effects of CEE and MPA on the 
expression of PR-A and PR-B in breast tissue of castrated female monkeys, it was 
found that CEE combined with MPA decreased PR-A and increased PR-B levels, 
while treatment with conjugated estrogen alone increased the expression of both PR 
isoforms (Isaksson et al., 2003). Interestingly, MPA alone did not affect the levels of 
either isoform. These findings suggest that MPA, when used together with estrogen 
in HRT, upregulates PR-B, which is responsible for both proliferation and 
differentiation of the mammary tissue (Sitruk-Ware and Plu-Bureau, 2004). This 
alteration of the normal PR-A:PR-B ratio has also been shown in another study 
(Vereide et al., 2006), and may be a putative mechanism by which MPA, and 
possibly NET, when used together with estrogen in HRT, increase the risk for breast 
cancer.  
 
MPA has also been shown to be a PR agonist for transactivation via synthetic HRE 
sequences as well as via natural promoter-reporter constructs for several target 
genes involved in different physiological processes such as tumour development 
(Bamberger et al., 1999). In a study in Ishikawa endometrial adenocarcinoma cells 
co-transfected with either hPRA or hPRB, MPA has been shown to increase vascular 
endothelial growth factor (VEGF) promoter construct activity via three functional 
progesterone response elements (PREs) identified in the VEGF promoter (Mueller et 
al., 2003). These results raise the possibility that increased angiogenesis in response 
to progestins may play a role in cell growth or metastasis in some human tumours 
(Hyder et al., 1998). However, the role of MPA in cancer development is 
controversial. MPA effectively inhibited estrogen-induced growth of the T47D cell 
line, and also inhibited growth of the Ishikawa endometrial cancer cell line stably 
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transfected with PR-B in a dose-dependent manner, irrespective of the presence or 
absence of estrogen in the culture medium. Neither the parental Ishikawa cell line, 
which is PR negative, nor the cell line stably transfected with PR-A, showed growth 
inhibition during culture in the presence of MPA. When the PR-B cell line was 
cultured with MPA in the presence of RU486 (antiprogestin), the MPA-induced 
growth inhibition was impaired (Smid-Koopman et al., 2003). In contrast, MPA 
induces human breast cancer cell proliferation by increasing cyclin D1 promoter 
activity via PR-B, but not PR-A (Saitoh et al., 2005). As the cyclin D1 promoter does 
not have progesterone-response element-related sequences, this appears to be a 
nongenomic mechanism which entails activation of the PI3K/Akt/NFκB signalling 
cascade (Saitoh et al., 2005).  
 
A study comparing the transcriptional effects of MPA and Prog in human breast 
cancer cell lines expressing either PR-A or PR-B, transiently transfected with a PRE2-
luciferase construct, indicated that MPA and Prog were equally effective through both 
PR-isoforms (Ghatge et al., 2005). Interestingly, when co-transfecting exogenous 
PR-isoforms individually with the PRE2-luciferase construct, MPA had lower 
transcriptional activity than Prog, at all doses, via both PR-A and PR-B. In contrast, 
expression profiling of endogenous PR-regulated genes comparing Prog and MPA, in 
the wild type T47Dco breast cancer cell line stably expressing equimolar levels of 
PR-A and PR-B, indicated that MPA and Prog have similar transcriptional activity 
(Ghatge et al., 2005).  
 
MPA has been shown in many studies to play a significant role in various endometrial 
functions via the PR. MPA was shown to increase the promoter activity of insulin-like 
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growth factor binding proteins-1 (IGFBP-1) in HESCs co-transfected with either hPR-
A or hPR-B. IGFBP’s regulate insulin-like growth factor action, which is believed to 
play a role in endometrial differentiation. In contrast, IGFBP3 (the major binding 
protein of IGF-1) is downregulated by MPA in the Ishikawa endometrial cell line 
stably transfected with the PR-B, but not in the parental Ishikawa cells or those stably 
transfected with PR-A (Smid-Koopman et al., 2003). Relatively high plasma IGF-1 
and low IGFBP3 levels have been independently associated with an increased risk of 
prostate-, breast- (in premenopausal women), colorectal epithelium-, and possibly 
lung cancer development (Renehan et al., 2005). It thus stands to reason that as the 
levels of IGFBP3 decrease, the amount of freely available IGF-1 consequently 
increases, resulting in an increased risk of cancer development.  
 
MPA has also been shown to increase the promoter activity of a deleted glycodelin-A 
(GdA) promoter-reporter construct in the HEC-1B cell line (a human endometrial 
adenocarcinoma cell line originally derived from the glandular component of the 
endometrium) via the PR. The timing of expression of GdA in the glandular cells of 
the human endometrium is critical for the regulation of fertilisation, as it potentially 
inhibits fertilisation but enhances implantation (Gao et al., 2001). Thus, this increase 
in GdA expression by MPA may possibly participate in its contraceptive mechanism 
of action. Furthermore, MPA at 10 mg/day also significantly enhanced decidual 
prolactin (PRL) gene expression (mRNA and protein) in the human endometrium in 
vivo (Reis et al., 1999). Similar results were obtained in HESCs, where MPA was 
shown to enhance PRL gene activation in the presence of elevated intracellular 
cAMP levels (Brosens et al., 1999). PRL is a marker of decidualisation, which is a 
critical process in the preparation of the uterus for blastocyst implantation and which 
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involves stromal cell differentiation. This synergy between MPA and cAMP on PRL 
expression was postulated to be dependent upon cellular levels of PR, and facilitated 
by transient expression of steroid receptor co-activator 1e (SRC-1e) but not SRC-1a. 
An additional study revealed an increase in STAT5 in response to cAMP/MPA 
treatment, which enhanced PRL expression in human endometrial stromal (ES) cells 
(Mak et al., 2002). Furthermore, MPA acts via the PR to suppress functional long 
form leptin receptor (OB-R (L)) mRNA expression by 50% in human organ-cultured 
proliferative endometrial samples, as indicated by the inhibition of MPA-induced 
suppression by the addition of the PR antagonist, RU486 (Koshiba et al., 2001). MPA 
may therefore alter the sensitivity of the endometrium to leptin, which is involved in 
the stimulation of reproductive functions and possibly in early development.  
 
NET has also been shown to have agonist activity for transactivation via the PR on 
synthetic and natural promoter constructs of genes involved in various physiological 
functions. NET was shown to induce a PRE2-TATA-CAT reporter vector transiently 
transfected in the CV-1 cell line stably transfected with the rabbit PR, and this activity 
was inhibited by RU486 (Pasapera et al., 2001). In the CHO cell line transfected with 
the MMTV-luciferase reporter, NET showed about 12% transactivation activity 
relative to 100% agonist activity of Org 2058 (Schoonen et al., 2000; Deckers et al., 
2000). As was observed with MPA, NET also increased VEGF release into the media 
of cultured T47-D breast cancer cells (Hyder et al.,1998), an effect likely mediated via 
the three functional PRE elements located in the promoter (Mueller et al.,2003). 
Furthermore, NET (like MPA) was shown to increase the promoter activity of IGFBP-
1 in endometrial cells co-transfected with hPRA via PRE sites present in the promoter 
(Gao et al., 2000). A study using Affymetrix GeneChip U133A expression arrays, 
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demonstrated that the effects of MPA, NET-A and Prog on PR-regulated gene 
expression in the PR-positive T47Dco breast cancer cell line, were similar to each 
other (Bray et al., 2005). Similarly, a recent study reported EC50 values for MPA, NET 
and Prog for the PR in the COS-1 cell line transiently co-transfected with PRE2-tk-
luc, as 0.1, 0.2 and 0.4-0.8 nM, respectively (Sasagawa et al., 2008). Furthermore, in 
the CHO cell line stably transfected with either human PR-A or PR-B, and a MMTV-
luciferase reporter, Dijkema and co-workers (1998) reported similar rank order of 
MPA, NET-A and Prog for both the PR-A and PR-B. Upon closer inspection of their 
data however, it appears that the rank order for potency for PR-A is MPA > NET-A > 
Prog, while for PR-B, MPA = NET-A > Prog. 
 
Both MPA and NET-A were shown to dose-dependently (0.1 to 10 nM) increase 
expression of two markers of vascular inflammation, intracellular adhesion molecule-
1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1) (Tatsumi et al., 2002). 
This increase was moderately blocked by the addition of RU486, but not by 
hydroxyflutamide, an AR antagonist, and the authors conclude that this stimulation 
was mediated to some extent via the PR. Considering that RU486 is also an 
antagonist of the GR it may be that the GR also plays a role. However, the authors 
do not comment on such a possibility. In human ES cells, prolonged MPA exposure 
(100 nM for 8 days) was shown to repress the transcription and protein levels of 
RANTES (Regulated-upon-Activation, Normal T cell Expressed and Secreted) via the 
PR (Zhao et al., 2002). RANTES is a critical chemokine in the pathogenesis of 
endometriosis and has been suggested to play an early role in the inflammatory 
response (Khorram et al., 1993; Hornung et al., 1997) 
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Although the above studies shed some light on the mechanism of action of MPA and 
NET via the PR on various physiological functions, further pharmacological 
investigation into the relative binding affinity, relative agonist potency and mechanism 
of action of MPA and NET for both transactivation and transrepression via PR-A and 
PR-B are required.  
 
1.4.3.2 Glucocorticoid receptor (GR) 
A large number of studies have indicated that MPA interacts with the GR (Bojar et al., 
1979; Winneker and Parsons, 1981; Teulings et al., 1980; Kontula et al., 1983; 
Selman et al., 1996; Bamberger et al., 1999; Simoncini et al., 2004; Koubovec et al., 
2004; Koubovec et al., 2005; Ronacher et al., 2009). One study, in human 
mononuclear leukocytes, found that MPA displays considerable binding affinity 
towards the GR (42%, relative to 100% binding by the synthetic glucocorticoid (GC) 
Dexamethasone (Dex), calculated from EC50 curves at the 50% competition level) 
(Kontula et al., 1983). Interestingly, the relative binding affinity of the naturally 
occurring ligand, cortisol, was significantly lower (25%) than that of MPA. Similar 
results were obtained in human renal carcinoma cells (Bojar et al., 1979) and human 
breast cancer cells (Teulings et al., 1980). In addition, our recent study in the COS-1 
monkey kidney cell line transfected with the hGR indicated a relative binding affinity 
of 19 nM for MPA, compared to 14 nM for Dex (Ronacher et al., 2009). Kontula and 
co-workers also obtained a Kd value (31 nM), which is a more accurate measure of 
binding affinity, for MPA binding to the GR in human mononuclear leukocytes, which 
was shown to be only 3 times higher than that of Dex (Kd = 10 nM) (Kontula et 
al.,1983). An additional study by our group revealed a Ki value of 10.8 nM for MPA, 
only about 2.5 times higher than the Kd of 4.2 nM for Dex , for the hGR in a human 
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lung carcinoma cell line (A549) expressing endogenous GR (Koubovec et al., 2005). 
Furthermore, MPA’s high affinity for the GR was also demonstrated in the beagle 
dog, with a calculated Ki value of 3.7 nM for MPA, which was shown to be 4-5 times 
higher than that of Dex (Selman et al., 1996). In another study, the affinity of the rat 
GR for MPA (Kd = 5.0 nM) was observed to be similar to that of Dex (Kd = 4.1 nM) 
(Winneker and Parsons, 1981).  
 
In contrast to MPA, NET has been shown to bind with very low affinity to the hGR 
(0.1% relative to 100% binding by Dex, calculated from EC50 curves) and was also 
unable to displace [3H]-MPA from the human GR in human mononuclear leukocytes 
(Kontula et al., 1983). These results are consistent with a later study in a human 
leukemic IM-9 cell line, indicating binding activity of NET towards the human GR to 
be below 1% relative to Dex = 100% (Schoonen et al., 2000). Our results obtained 
from a study in the COS-1 cell line transfected with a human GR expression vector 
also indicate that NET has a low affinity for the GR (RBA for NET=1688 nM, Dex=14 
nM) (Ronacher et al., 2009). In addition, we have directly compared the relative 
binding affinities of MPA and NET-A to each other, and to Prog, for the GR in the 
A549 cell line, and subsequently determined precise Ki values for MPA (10.8 nM), 
NET (270 nM) and Prog (215 nM) (Koubovec et al., 2005).  
 
Since many of the side-effects of conventional GCs used to treat inflammatory or 
autoimmune diseases may be attributed to transactivation of GRE-driven promoters 
(Imai et al., 1993; Brasier and Li, 1996), an important goal of pharmacological and 
clinical research has been to identify GCs that discriminate between transactivation 
and transrepression. The transrepressive effect of MPA, and to a much lesser extent 
NET, on in vitro functions of human lymphocytes via the GR has previously been 
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investigated. Results indicate that MPA (at 2.5x10-7 M) acts as a dissociated GC, 
since it efficiently (same extent as Dex) transrepresses phorbol-ester-stimulated IL-2 
and IL-6 transcription, but only minimally activates transcription via GREs 
(Bamberger et al., 1999). These observed effects of MPA are likely to be mediated 
by the GR, as Dex, the synthetic GR ligand, showed similar effects, and moreover 
human lymphocytes express GR, very low levels of AR, and no PR. In addition, MPA 
was also shown to repress transcription of the IL-2 promoter construct stimulated with 
tetradecanoyl phorbol acetate (TPA) and ionomycin, via co-transfected GR in the 
Jurkat T-lymphocyte cell line (Bamberger et al., 1999). Furthermore, the dose-
dependent (10 nM to 10 µM) decrease in the secretion and mRNA expression of IL-6 
by MPA in a human thyroid cancer cell line (KTC-2 cells), was also suggested to be 
GR-mediated (Kurebayashi et al., 2003).  
 
Although NET has previously been shown to display no transactivation activity 
towards the GR in the leukemic IM-9 cell line (Schoonen et al., 2000), it had not been 
established whether it displays dissociative GC properties until the work by our 
group. We pharmacologically characterised the effects of MPA compared to NET and 
Prog on GR-mediated gene regulation for both transrepression and transactivation in 
the human embryonic kidney (HEK293) cell line stably transfected with a rat GR 
expression vector, and transiently transfected with a glucocorticoid response element 
(GRE)-driven reporter construct or with an IL-8 promoter-reporter construct 
(Koubovec et al., 2005). In contrast to the minimal transcriptional activity observed 
via GREs in human lymphocytes, our study showed that MPA displayed 
transcriptional activity via GREs. In fact, MPA displayed much greater glucocorticoid 
agonist potency than Prog for both transactivation (MPA: EC50 = 7.2 nM; Prog: EC50 
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= 280 nM) and transrepression (MPA: EC50 = 2.7 nM; Prog: EC50 = 26 nM). In 
contrast to MPA, NET-A did not transactivate even at 10 µM, and only marginally 
(22%) transrepressed the IL-8 reporter at this concentration. We observed similar 
results in a COS-1 cell system, transiently transfected with hGR and a GRE-driven 
reporter construct (pTAT-GRE-E1b) or an AP-1 or NFκB promoter–reporter construct, 
respectively (Ronacher et al., 2009). In this system, NET-A was shown to antagonize 
GR-mediated transactivation (Appendix C6). Interestingly, results from another recent 
study in the COS-1 cell line co-transfected with the GR and the PRE2-tk-luc 
promoter-reporter, corroborates the results indicating that MPA is an agonist for 
transactivation via the GR (EC50 = 23.3 nM is about 11.5 times higher than the 2 nM 
observed by Ronacher et al., 2009), but this study did not show antagonist activity for 
NET up to 3 x 10-6M (Sasagawa et al., 2008).  
 
Consistent with agonist activity of MPA via the GR as discussed above, there are 
several reports of GR-mediated MPA effects on target genes in different tissues and 
cells. It has been suggested that MPA, but not Prog, can exert negative effects in 
kidney cells via the GR. MPA increased α-subunit of epithelial Na channel (α-ENaC) 
mRNA levels in the kidney cortex in vivo (in adrenalectomized mice), while MPA, but 
not Prog, dose dependently increased endogenous α-ENaC, as well as serum and 
glucocorticoid-regulated kinase 1 (sgk1) mRNA expression via the GR in two mouse 
cortical collecting duct (CCD) cell lines, M-1 and MDCK-C7 (Thomas et al.,2006). In 
addition, MPA was unable to stimulate an α-ENaC promoter-reporter construct where 
the GRE had been mutated, indicating that the stimulation of α-ENaC is mediated via 
the GRE in its 5’-flanking region. Furthermore, the dose-dependent (10 nM to 1µM) 
elevation of Nm23-H1 (metastasis suppressor) protein expression by MPA in 
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metastatic human breast carcinoma cells via the GR was thought to involve GREs 
(Ouatas et al., 2003). Recently, it was shown that MPA downregulates endothelial 
nitric oxide synthase (eNOS) mRNA expression and the formation of nitric oxide 
levels in human umbilical vein endothelial cells (HUVECs) via the GR (Zerr-Fouineau 
et al., 2007), thereby reducing the anti-aggregatory effect of endothelial cells.  
 
Several studies indicate that the GR may play a role in the effects of MPA on the 
immune system. MPA, unlike NET, has been shown to induce GC-like effects 
including inhibition of the proliferative responses to the T-cell mitogens concanavalin 
A and phytohaemagglutinin (Kontula et al., 1983). We have also previously  
demonstrated that the GR partly mediates MPA repression of IL-6 and IL-8 promoter-
reporter activity at the transcriptional level, most likely via interference with NFκB and 
AP-1 transcription factors, in murine fibrosarcoma L929sA (Koubovec et al.,2004). 
Since GCs impact on virtually every aspect of the immune and inflammatory 
response (Spangelo and Gorospe, 1995; Galon et al., 2002) MPA, and possibly NET, 
may exert side-effects due to their GC-like repressive action on target genes involved 
in immune function, other than those reviewed above.  
 
In addition to genes involved in immune function, several genes involved in 
reproduction are negatively regulated by GCs, and may also be targets for MPA, 
such as the genes for the α-subunit of glycoprotein hormones (Chatterjee et al., 
1991) and PRL (Sakai et al., 1988). Furthermore, physiological concentrations of 
GCs have been proposed to be essential and optimal for osteoblast proliferation and 
differentiation. It has recently been proposed that bone loss associated with MPA 
administration, at contraceptive doses or higher, is caused by decreased osteoblast 
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differentiation as a likely result of MPA occupying the GR, since increasing GR 
occupancy beyond that reached at normal GC concentrations reduces osteoblast 
differentiation (Ishida and Heersche, 2002).  
 
Taken together, MPA, unlike NET-A and Prog, has high affinity for the GR (Koubovec 
et al., 2005; Ronacher et al., 2009). MPA represses cytokine genes in vitro 
(Koubovec et al., 2004, Bamberger et al., 1999) and displays greater GR agonist 
potency and efficacy than progesterone or NET-A for both transactivation and 
transrepression of synthetic promoter-reporter constructs (Koubovec et al,. 2005). In 
addition, MPA protected the GR from partial trypsin digestion in vitro to a much 
greater extent than NET-A or Prog at saturating concentrations, suggesting that the 
differences in biological activity of the progestins are not only due to differences in 
their affinity for the GR, but also due to the induction of different conformational 
changes in the liganded-GR (Koubovec et al., 2005). Furthermore, the findings that 
GR levels can determine whether MPA acts as a GR agonist or antagonist in some 
systems, and can also influence its dissociative properties (extent of transactivation 
versus transrepression activity), could have major implications for the physiological 
effects of MPA, and maybe even NET-A, via the GR (Bamberger et al., 1999, Zhao et 
al., 2003). Finally, the glucocorticoid-like actions of MPA may cause side-effects in 
women using MPA for contraception, as well as other reproductive therapies via 
transactivation and transrepression of GC-responsive target genes, and in particular 
may compromise immune function via transrepression of cytokine genes. The above-
mentioned data all indicate that MPA and NET-A display very different GC-like 
properties compared to each other and to Prog, confirming that all progestins are not 
the same as each other, and very rarely the same as Prog. 
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1.4.3.3 Androgen Receptor (AR) 
As for the GR, a multitude of studies show that MPA binds to and is an agonist for 
transactivation via the AR (MacLaughlin and Richardson, 1979; Teulings et al., 1980; 
Perez-Palacios et al., 1981a; Perez-Palacios et al., 1981b; Perez-Palacios et al., 
1983; Bergink et al., 1983; Hackenberg et al., 1993; Bentel et al., 1999; Bamberger 
et al., 1999; Kemppainen et al., 1999). In the study by Perez-Palacios and co-
workers (1983), the Kd of MPA for the cytosolic AR from rat pituitary and 
hypothalamus was determined as 1.7 nM and 2.9 nM, respectively. Similarly, the Kd 
of MPA for the AR in MFM-223 human mammary carcinoma cells was determined as 
3.6 nM, compared with a Kd of 0.18 nM for the natural androgen dihydrotestosterone 
(DHT) (Hackenberg et al., 1993). In addition, NET has also been shown to bind to 
and have agonist activity for transactivation via the AR (Perez-Palacios et al., 1981a; 
Bergink et al., 1983; Chavez et al., 1985; Bergink et al., 1985; Schoonen et al., 2000; 
Deckers et al., 2000). However, in two different studies (Schoonen et al., 2000; 
Deckers et al., 2000), the relative binding and relative agonist activity values for 
transactivation of NET for the AR were shown to be low: 3.2% and 1.1% of DHT 
(100%), respectively. Similarly, the Kd of NET for the AR was determined as 19 nM 
(8.1% relative binding compared to 100% binding by the synthetic androgen, R1881) 
in rat prostrate cytosol (Chavez et al., 1985). Furthermore, when comparing MPA and 
NET, both progestins showed similar relative binding affinities (8- and 7% 
respectively, relative to 100% binding for DHT) for the endogenously expressed AR 
in intact human breast cancer (MCF-7) cells, yet in cytosol fractions of the same cells 
MPA showed a higher binding affinity (29%) relative to NET (17%) for the AR 
(Bergink et al., 1985). It is unclear from some of the above data whether the relative 
binding activity was determined from equilibrium dissociation constant (Kd or Ki) 
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values or from relative binding affinity (RBA) values (EC50 values). This is relevant as 
Kd or Ki values are a constant value for a particular receptor, that cannot be 
influenced by different experimental conditions, and thus represent a more accurate 
measure of relative binding affinity of a ligand for its receptor than EC50 values. In 
contrast, the EC50 value is a relative number, which is influenced by receptor levels 
and radiolabeled ligand concentration (further explanation in Appendix D1). The 
possibility also exists that the results reported by Bergink et al. (1985) may be 
inaccurate, as these cells express steroid receptors other than the AR, to which 
these progestins may bind. 
 
Several reports in the literature show that MPA acts as an agonist for transactivation 
via the AR on several different synthetic reporter genes as well as on endogenous 
genes. For example, MPA (at 0.1 nM) was shown to induce transcriptional activation 
of a MMTV-luciferase reporter construct in the CV-1 cell line via the AR. However, 
100-fold more MPA was required to achieve the same agonist activity as DHT, and 
the synthetic AR agonists, mibolerone and R1881. Similarly, the androgenic activity 
of MPA was also confirmed in the HeLa cervical carcinoma cell line transiently co-
transfected with an AR expression vector and two different promoter-reporter 
constructs (PRE2-luc and MMTV-luc) (Ghatge et al., 2005). In another study, MPA (at 
2.5 x 10-7 M) was reported to transactivate a GRE-driven reporter construct, via co-
transfected AR in the Jurkat T lymphoma cell line (Bamberger et al., 1999). NET, as 
well as its A-ring reduced derivative, 5α-NET, have also been shown to have AR-
mediated transcriptional activation in the HeLa cervical cell line transiently 
transfected with an AR expression vector and a PRE-E1b-CAT reporter plasmid 
(Garcia-Becerra et al., 2004). Interestingly, 5α-NET displayed a four-fold higher 
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androgenic activity than NET. Recently, a study has investigated agonist activity of 
MPA, NET and Prog for transactivation in the COS-1 cell line transiently co-
transfected with the AR and PRE2-tk-luc, and indicate EC50 values for agonist activity 
of MPA and NET of 56.8 and 19.6 nM, respectively, while no activity was observed 
for Prog (at 3 µM) (Sasagawa et al., 2008). These investigators also looked at the 
antagonist activity of MPA, NET and Prog for transactivation in the COS-1 cell line 
transiently co-transfected with the AR and PRE2-tk-luc, and indicated that, unlike 
Prog, neither MPA nor NET antagonized DHT-mediated transcription via the AR (up 
to 3 µM) (Sasagawa et al., 2008). 
 
Despite the established agonist activity of MPA, the mechanism whereby MPA acts 
as an AR agonist appears to differ from that for DHT. Kemppainen et al. (1999) 
investigated the mechanism of AR activation by MPA, using a mammalian two-hybrid 
assay in the CHO cell line, and showed that MPA (up to 1 µM) failed to promote the 
AR NH2-terminal and carboxy-terminal (N/C) interaction, which is usually induced by 
high-affinity agonists and believed to be inhibited by antagonists. Although not an AR 
antagonist, MPA was shown to be a potent antagonist of the DHT-induced AR N/C-
interaction in the same cells. In contrast, NET was able to induce the AR N/C-
interaction, and did not antagonize the DHT-induced AR N/C-interaction (Tamzin 
Tanner in Hapgood laboratory, MSc thesis). In addition, partial proteolytic digestion of 
in vitro translated AR, demonstrated that both NET and 5α-NET, induced a similar 
conformational change to each other, and to DHT, in the AR (Garcia-Becerra et al., 
2004). Recently, Birrell and co-workers (2007), formulated a molecular model in 
which MPA-bound AR forces the displacement of a critical amino acid residue, 
Phe874, thereby disrupting the well-defined AF-2 cleft observed for the DHT-bound 
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AR, taking on an atypical ligand binding domain structure distinct from that mediated 
by DHT. The authors thus hypothesized that this may explain divergent effects of 
MPA and DHT on AR-regulated gene expression. Indeed, a recent comparative gene 
expression profiling study in human breast cancer cell lines showed that MPA and 
DHT regulated distinct subsets of genes (Ghatge et al., 2005). However, they also 
showed that, unlike Prog, MPA at physiological (10 nM) and pharmacological (1 µM) 
doses, is as potent as DHT in regulating AR-mediated gene expression.  In 
agreement with its agonist activity for transactivation, MPA has been reported to act 
as an agonist for transrepression via the AR. For example, Bamberger et al. (1999) 
showed that MPA (at 2.5 x 10-7 M) transrepressed an IL-2 promoter-reporter 
construct stimulated with TPA and ionomycin, via co-transfected AR in the Jurkat T 
lymphoma cell line.  
 
In agreement with results showing that MPA acts as an AR agonist, there is evidence 
that several physiological effects of MPA administered to patients are mediated via 
the AR. Clinical studies indicate that the response of breast tumours to high-dose 
MPA therapy is dependent on the expression of the AR (Birrell et al., 1995). Further 
evidence that MPA acts via the AR in breast cancer cells has been provided by 
studies indicating inhibition of proliferation of AR-positive, but not AR-negative, cells 
by MPA, and the reversal of this inhibition with AR-specific antagonists (Hackenberg 
et al., 1993; Bentel et al., 1999). This argument for MPA effects being mediated by 
the AR, was strengthened by the study of Ghatge et al. (2005) showing that, in 
contrast to Prog, MPA is as potent as DHT in regulating AR-mediated gene 
expression in human breast cancer cell lines. In addition, the inability of some tumors 
in advanced breast cancer to respond to MPA therapy is related to reduced AR levels 
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or impaired AR function (Buchanan et al., 2005). Moreover, a recent study in an 
epithelial ovarian cancer cell line expressing endogenous AR indicated that MPA is 
more effective than DHT, in increasing the invasive potential of these cells via the AR 
(Gogoi et al, 2008). Consistent with the above-mentioned studies, an earlier study 
suggested that the significant inhibition of serum gonadotropin levels in 
postmenopausal women who had received either MPA or NET-EN, in contrast to 
Prog, was due to their actions via the AR (Perez-Palacios et al., 1981a). Additionally, 
it is postulated that the androgenic properties of MPA are responsible for the 
favourable decrease in the levels of the plasma proinflammatory markers, C-reactive 
protein and serum amyloid A protein, increased by estrogen, in postmenopausal 
women using the CEE/MPA HRT treatment (Wakatsuki et al., 2002).  
 
In contrast to the data available for MPA, much less is known about the biological 
activity of NET via the AR. Although the recent study by Sasagawa et al. (2008) has 
now characterized MPA and NET pharmacologically in terms of potency for 
transactivation, further work is still required to pharmacologically characterise effects 
of MPA vs. NET vs. Prog, in terms of potency and/or efficacy, on AR-mediated gene 
regulation, for transactivation and transrepression of various target genes in the 
same system. Furthermore, no direct comparison of the relative equilibrium 
dissociation constants of the two progestins has been reported. Further studies are 
therefore required to determine precise Ki values for both MPA and NET for the AR, 
as well as studies to characterise the mechanisms and effects of MPA vs. NET vs. 
Prog on AR-mediated gene regulation for both transrepression and transactivation of 
various target genes in the same system. 
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1.4.3.4 Mineralocorticoid Receptor (MR) 
Prog has a high affinity for the MR, displaying weak partial agonist2, transactivation 
activity, but potent antagonist3 activity for Ald, via the MR (Wambach et al., 1979; 
Rafestin-Oblin et al., 1992; Quinkler et al., 2002). In contrast, both MPA and NET-A 
are reported to bind weakly to the cytoplasmic MR in rat kidney (Wambach et al., 
1979), and their agonist activity for transactivation via the MR, as well as antagonist 
activity for Ald via the MR, is controversial. The RBA’s for the MR were obtained from 
EC50 curves and determined as 4% for MPA and <1% for both NET and NET-A, 
compared with 100% binding by Prog. A number of studies report that MPA and NET 
do not display any agonist or antagonist properties via the MR (Winneker et al., 2003 
and references therein, Palacios et al., 2006). In contrast, Sasagawa et al. (2008) 
showed that although MPA and NET have no agonist activity via the transiently 
transfected MR co-transfected with PRE2-tk-luc in the COS-1 cell line, both MPA and 
NET were able to antagonize Ald-mediated transcription via the MR, albeit to a much 
lesser extent than Prog. The difference in the antagonistic activity of MPA and NET 
relative to Prog via the MR may have serious implications for post-menopausal 
women using estrogen/progestin treatment for HRT, as they would not be able to 
antagonize the transcriptional activity of Ald via the MR, thus leading to side-effects 
such as weight gain and increased blood pressure. Since high blood pressure is a 
cardiovascular disease risk factor, using synthetic progestins, such as MPA and 
NET-A, that lack anti-mineralocorticoid activity in HRT, could lead to cardiovascular 
                                                    
2
 A drug or ligand that elicits a response less than the maximal response of the full agonist (See Appendix B1). 
3
 A drug or ligand that does not elicit a response itself, but inhibits agonist-mediated responses (See Appendix 
B1). 
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complications. In addition, it has not yet been established whether these progestins 
can transrepress target genes via the MR. Further work is thus required to 
characterise the effects of MPA vs. NET on MR-mediated gene regulation for both 
transrepression and transactivation of various target genes in the same system. 
Findings of such studies may result in an improved understanding of the relative 
effects of MPA and NET on blood pressure and in cardiovascular disease, as has 
been highlighted by the drive to find new progestins, such as trimegestone (Winneker 
et al., 2003) and drospirenone (Elger et al., 2003, Palacios et al. ,2006), with anti-
mineralocorticoid activity. 
 
1.4.3.5 Estrogen Receptor (ER) 
Evidence for activity of both MPA and NET via the estrogen receptor is contradictory. 
Two functional ERs, ERα and ERβ, transcribed from different genes, have been 
identified (Nilsson et al., 2001). Both MPA and NET-A have previously been reported 
to bind estrogen receptors both in vivo (in the rat uterus) and in vitro (Di Carlo et al., 
1983). Contrary to these studies, two other studies showed that MPA does not bind 
to the ER (Teulings et al., 1980; Bergink et al., 1983), while another study indicated 
that it does not have any estrogenic effects (Markiewicz and Gurpide, 1994). Reports 
on the estrogenic activity of NET are similarly contradictory. NET has been reported 
to have no binding or transactivation activities via the ER (Schoonen et al., 2000; 
Bergink et al., 1983). However, in other studies NET (Markiewicz and Gurpide, 1994) 
and its A-ring reduced metabolites (Mendoza-Rodriguez et al., 1999) have been 
reported to show intrinsic estrogenic activity. Furthermore, a 5α-reduced metabolite 
of NET (3β, 5α-NET), has been shown to selectively activate ERα at low 
concentrations, while ERβ agonistic activity was observed only at high concentrations 
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(1 µM) (Larrea et al., 2001). Interestingly, a recent study in the COS-1 cell line 
transiently transfected with the ERα or ERβ expression vectors and a synthetic 
promoter-reporter construct (ERE3-tk-luc), revealed that NET, but not MPA or Prog, 
showed preferential agonistic activity towards ERα (EC50 = 39.3 nM), and also 
minimal agonistic activity towards ERβ (EC50 = 1097.2 nM) (Sasagawa et al., 2008). 
In summary, data on the activity of MPA and NET via the ER is controversial. The 
differences in the results of the various studies may be due to different extents of 
metabolism of these progestins in different cells. Thus it may be that MPA and NET 
themselves do not bind to the respective ER isoforms, but that their metabolites do. 
However, it is hard to discriminate between the binding of the test compound vs. its 
metabolites. Further research is thus needed to determine the mechanisms and 
possible clinical implications of progestin activity via ER isoforms.  
 
1.5 Conclusion 
The synthetic progestins, MPA, NET-EN and NET-A, are widely used by millions of 
women in contraception and HRT. Although both progestins have been shown to 
exert a range of side-effects when used in vivo, little is known about their mechanism 
of action at the cellular level. The importance of investigating the mechanism of 
action of synthetic progestins at the molecular level, is highlighted by recent clinical 
evidence showing that MPA and NET increase the risk of the development of breast 
cancer in HRT users (Rossouw et al., 2002, Millions Women’s study collaborators). In 
contrast, Prog has been shown to have anti-proliferative, and anti-estrogenic effects 
on breast tissue. Whether MPA and NET, either alone or in combination with 
estrogen in HRT, have beneficial or deleterious cardiovascular effects, is still 
controversial. Certainly, the results of the WHI trial, and a number of other studies 
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(Rossouw et al., 2002; Register et al., 1998; Manson et al., 2003; Meendering et al., 
2008), seem to suggest that MPA is not cardioprotective. In contrast, some studies 
suggest that MPA does not have any detrimental cardiovascular effects (Taner et al., 
2006; Seeger et al., 2007). Similarly, a number of studies have indicated that NET 
has harmful cardiovascular effects (Rosano et al., 2001; Lokkegard et al., 2003; 
Fernandes et al., 2008), while other studies show that it does not (Mueck et al., 2002; 
Pedersen et al., 2004; Pedersen et al., 2006, Seeger et al., 2007). On the other 
hand, Prog has not been shown to have adverse cardiovascular effects (Ottoson et 
al., 1985; Saarikoski et al., 1990; Simoncini et al., 2004; Mishra et al., 2005). These 
conflicting data highlight a need for further research to clarify the role of MPA and 
NET on breast cancer and CVD markers at the cellular level. 
 
MPA used as contraception has also been shown to increase viral shedding (Mostad 
et al., 1997), which raises concern as to its impact on the spread of viral diseases. 
Several clinical studies have shown no link between MPA or NET-EN usage and HIV 
infection (Myer et al., 2007; Kleinschmidt et al., 2007). However numerous reports 
suggest there is a link between progestins and HIV infection (Martin et al., 1998, 
Lavreys et al., 2004; Morrison et al., 2007), highlighting the ongoing controversy in 
this area. More research is needed on the clinical effects, and mechanisms of action 
of these progestins, particularly with respect to HIV and other sexually transmitted 
infections (STIs). While MPA and NET are known to have varying effects on systemic 
immune function (reviewed above), their effect on local immune function in the 
cervicovaginal tract is likely to be most pertinent to unraveling their relative effects on 
early STIs. Clearly more research is required to investigate the relative effects of 
synthetic progestins on immune function in the reproductive tract.  
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As Prog and these synthetic progestins have different chemical structures, they may 
have different effects on target cells, depending on their dose, route of 
administration, bioavailability, effects on endogenous steroid metabolism in the target 
cell, their affinity for different steroid receptors or receptor isoforms, as well as the 
availability of steroid-responsive promoters and cofactors. Surprisingly, there is a 
paucity of research addressing the above-mentioned factors, particularly the relative 
binding affinity and relative agonist potency and efficacy (relative to each other and to 
Prog) of MPA and NET-EN (and NET-A) for transrepression and transactivation via 
various steroid receptors as well as their effects on intracellular signalling pathways, 
in the same system. Our recent work highlights the importance of such investigations 
as we have shown that MPA displays greater GR agonist potency and efficacy than 
either Prog or NET-A for both transactivation and transrepression of synthetic 
promoter-reporter constructs, and displays a higher affinity than Prog or NET-A for 
the GR (Koubovec et al., 2005). Furthermore, their interactions with serum-binding 
proteins as well as their effects on steroidogenesis require further investigation. 
These studies would be important in defining differences in mechanism of action of 
various synthetic progestins, and hence facilitate an informed choice of progestins, 
by women and their physicians, for reproductive intervention and therapy.  
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HYPOTHESES AND AIMS 
 
From the literature it is clear that Prog, MPA and NET-A differ in their structure, 
metabolites, bioavailability, affinity for different steroid receptors, and ultimately in 
their biological activity.  
 
To this end, the primary hypothesis of this thesis was that MPA and NET-A differ at 
least in some respects in their biological activity towards the hAR and hMR as 
compared to each other and Prog. Furthermore, it was hypothesized that MPA and 
NET-A would differ in their regulation of cytokine genes in the lower female genital 
tract. More specifically it was hypothesized that: 
 
1) MPA and NET-A (as compared to Prog), differentially regulate the cytokine and 
chemokine genes, in a cell-specific manner, in cervicovaginal epithelial cells; 
2)  different steroid receptors are responsible for the differential regulation of these 
genes; 
3) unlike Prog, MPA and NET-A are potent androgens; 
4) MPA and NET-A have weaker anti-MR activity than Prog; 
5) the aldosterone-induced upregulation of the Orm-1 (α-glycolytic protein or 
orosomucoid-1) gene via the hMR, is antagonized by progesterone, but not by 
MPA and NET-A;  
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The aims of this project were three-fold:  
 
Firstly, the regulation of TNFα-induced cytokine and chemokine genes, specifically 
IL-6, IL-8 and RANTES, in response to the endogenous female hormone, Prog, and 
the two synthetic progestins, MPA and NET-A, was investigated. These studies were 
performed in two immortalized cell lines from the lower female genital tract namely, 
Ect1/E6E7 (human ectocervical epithelial cell line) and Vk2/E6E7 (human vaginal 
epithelial cell line). Thereafter, the hypothesis that different steroid receptors are 
mediating the differential regulation of these genes, was tested by re-evaluating the 
expression of the genes when incubating cells with the progestins, in the presence 
and absence of the androgen receptor-specific antagonist hydroxyflutamide and 
RU486, the PR and GR antagonist.  
 
Secondly, using the COS-1 monkey kidney cell line, the mechanism of action of MPA 
and NET-A were directly compared to each other and Prog, via overexpressed 
human androgen receptor (hAR) and human mineralocorticoid receptor (hMR), 
respectively. Relative dissociation constants (Ki values) were determined for the 
progestins for each receptor, as well as the AR- and MR-mediated transcriptional 
activation and repression by MPA and NET-A in the COS-1 cell line.  
 
Thirdly, the MR-mediated transcriptional regulation of a gene that is a marker of 
cardiovascular disease (CVD), Orm-1, was investigated in a rat cardiomyocyte cell 
line, with a particular focus on the antagonistic role of MPA and NET-A, as compared 
to Prog. 
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Abstract 
Medroxyprogesterone acetate (MPA) and norethisterone (NET) and its derivatives 
are widely used in female reproductive therapy, but little is known about their 
mechanism of action at the cellular level. MPA used as a contraceptive, has been 
shown to increase HIV (Mostad et al., 1997) and HSV cervical shedding in HIV-
infected women (Mostad et al., 2000). Mucosal innate immune factors as well as 
proinflammatory cytokines are associated with elevated levels of HIV-1 shedding in 
the female genital tract (Gumbi et al., 2008).  Although use of MPA as a 
contraceptive has been implicated in effects on local immune function (IIdgruben et 
al., 2003), not much is known about the effects of MPA and NET-A in the female 
genital tract. In this study, we thus investigated the regulation of cytokine genes by 
MPA and NET-A, as compared to the endogenous hormone, progesterone (Prog), on 
mucosal immunity in an in vitro cell culture model of the female cervicovaginal 
environment, by comparing their effects on the regulation of the endogenous pro-
inflammatory cytokine/chemokine genes, interleukin (IL)-6, IL-8 and RANTES 
(Regulated on Activation, Normal T cell Expressed and Secreted). Two epithelial cell 
lines generated from normal human vaginal (Vk2/E6E7) and ectocervical 
(Ect1/E6E7) cells, immortalized by expression of the E6 and E7 genes of human 
papillomavirus type 16 (Fichorova et al., 1997), were used as model systems. Our 
study is the first to show that ligand-specific and cell-specific regulation of IL-6, IL-8 
and RANTES gene expression occurs with Prog, MPA and NET-A in the 
cervicovaginal environment. Moreover, we show that the repression of the TNFα-
induced RANTES gene by MPA in the Ect1/E6E7 cell line is mediated by the 
androgen receptor. Collectively, these data demonstrate that different anatomical 
sites of the female genital tract respond differently to Prog and the synthetic 
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progestins, possibly due to interaction with different steroid receptors. This may have 
important implications for women’s risk of susceptibility to infections.  
. 
 83 
Introduction 
The mucosal surface of the lower female genital tract (cervicovaginal environment) is 
a complex system that provides a barrier against pathogens. Epithelial cells lining the 
cervicovaginal mucosa are the point of entry for many viral, bacterial, and parasitic 
infections (Fichorova and Anderson, 1999). Therefore, these cells have features 
enabling them to combat infections, such as the expression of hormone receptors, 
hormone-dependent immune functions, and expression of genital tract-specific 
defensins (Press et al., 1986; Kutteh et al., 1998; Quayle et al., 1998). The 
cervicovaginal epithelial cells constitutively express a wide variety of pro- and anti-
inflammatory mediators, such as the cytokines, interleukin (IL)-1, IL-6, IL7, 
macrophage colony-stimulating factor, transforming growth factor beta, and the 
chemoattractant cytokines, IL-8 and RANTES (Regulated-upon-Activation, Normal T 
cell Expressed and Secreted), which are upregulated in response to tumor necrosis 
factor (TNF)-α (Fichorova and Anderson, 1999; Fichorova et al., 2001a). These cells 
thus execute a vital role in the innate and acquired immune systems present at the 
mucosal surfaces.  
 
IL-8 and RANTES (also termed CCL5) are chemotactic cytokines, or chemokines, 
involved in the early inflammatory response by recruiting specific leukocytes, 
particularly macrophages, to sites of ongoing inflammation and injury, while IL-6 is 
responsible for neutrophil priming to chemotactic factors (Kunkel et al., 1997). Thus, 
the cytokine milieu in the cervicovaginal mucosa is an important determinant of 
resistance and susceptibility to infections. Interestingly, increased levels of the 
cytokines IL-1, TNF-α, IL-6 and the chemokines RANTES, macrophage inflammatory 
protein (MIP)-1α and MIP-1β in cervicovaginal secretions, have been associated with 
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human immunodeficiency virus (HIV)-1 infection and bacterial vaginosis (Fichorova et 
al., 2001b).  
 
The transmission of- and susceptibility to infections in women may be better 
understood if factors affecting the immune response in the vagina and cervix are 
more clearly defined. Research in animal models and in women indicates that local 
and regional immune responses can influence the outcome of vaginal challenge with 
microbial pathogens (Rakasz and Lynch, 2002). Sex hormones are examples of 
factors that have been shown to influence susceptibility and disease predisposition to 
many genital tract infections (Brabin, 2002). Furthermore, there are indications that 
women using antibiotics, corticosteroids (immunosuppressive therapy), oral 
contraceptives and hormone replacement therapy, are more susceptible to fungal 
vaginal infections (Spinillo et al., 1995; Geiger and Foxman 1996; Magliani et al., 
2002).  
 
Medroxyprogesterone acetate (MPA) used as contraceptive, has been shown to 
increase HIV (Mostad et al., 1997) and HSV cervical shedding in HIV-infected 
women (Mostad et al., 2000). Although Mostad and co-workers did not investigate 
the molecular mechanism of these effects, they postulate that the effects may be 
mediated by factors such as direct effects on the virus, effects on local genital tract 
physiology or effects on immune modulation of viral replication, or a combination of 
these effects (Mostad et al., 1997). Interestingly, a recent animal study showed that 
MPA increased susceptibility to vaginal simian-human immunodeficiency virus (SHIV) 
transmission and suppressed the antiviral cellular immune response in SHIV-infected 
rhesus macaques (Trunova et al., 2006), indicating an immune- rather than 
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transmission-based mechanism. In another animal study, it was shown that MPA 
treatment at contraceptive doses rendered mice 100-fold more susceptible to genital 
HSV-2 infection compared to untreated mice (Kaushic et al., 2003). In addition, the 
use of MPA has been associated with increased acquisition of cervical chlamydial 
and gonococcal infections (Morrison et al., 2004).  
 
At the molecular level, MPA has been reported to modulate transcription of a number 
of genes via the glucocorticoid receptor (GR). For example, IL-2 in normal human 
lymphocytes (Bamberger et al., 1999), IL-6 and IL-8 in a mouse fibroblast cell line 
(Koubovec et al., 2004) and the nm-23 tumor suppressor gene in a breast cancer cell 
line (Ouatas et al., 2003). In contrast, MPA’s suppression of the RANTES gene in 
endometrial cells was progesterone receptor (PR)-mediated (Zhao et al., 2002). 
Furthermore, MPA has been shown to regulate a number of genes via both the PR 
and the androgen receptor (AR) in human breast cancer cell lines (Ghatge et al., 
2005). It is thus apparent that even though MPA and NET were developed for the 
similarity of their biological actions to those of progesterone (mediating their effects 
by binding to the PR), they can also initiate a diverse range of biological effects by 
cross-reacting with other members of the steroid receptor family such as the GR, the 
AR and possibly the mineralocorticoid receptor (MR) (Bentel et al., 1999; Philibert et 
al., 1999; Hapgood et al., 2004; Koubovec et al., 2005). 
 
An important question is thus whether, and to what extent, clinical doses of MPA, and 
also NET-A, regulate known pro-inflammatory mediators such as IL-6, IL-8 and 
RANTES, in the cervicovaginal mucosa. Understanding the mechanisms of this 
regulation and the receptors involved, would further our understanding of differential 
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gene regulation by different progestins and assist in the design of new progestins 
with fewer side effects. Investigating these mechanisms at a site relevant to 
infections, such as the cervicovaginal environment, is likely to be relevant to mucosal 
immunity. Factors that affect immunity in the cervicovaginal environment may be 
important determinants of transmission risk of pathogens such viruses, and 
understanding these factors may shed light on molecular events occurring during 
infections. In the light of the above, our strategy was to investigate the effects of MPA 
and NET-A relative to Prog on mucosal immunity in an in vitro cell culture model of 
the female cervicovaginal environment, by comparing their effects on the regulation 
of the endogenous pro-inflammatory cytokine/chemokine genes IL-6, IL-8 and 
RANTES. Two epithelial cell lines generated from normal human vaginal (Vk2/E6E7) 
and ectocervical (Ect1/E6E7) cells, immortalized by expression of the E6 and E7 
genes of human papillomavirus type 16 (Fichorova et al., 1997), were used as model 
systems.  
 
Materials and methods 
Inducing compounds 
4-pregnene-3, 20-dione (progesterone; Prog), 6α-methyl-17α-hydroxy-progesterone 
acetate (medroxyprogesterone acetate; MPA), 17α-ethynyl-19-nortestosterone 17β-
acetate (norethindrone acetate; NET-A), 5α-androstan-17β-ol-3-one 
(dihydrotestosterone; DHT), 11β-(4-dimethylamino)phenyl-17β-hydroxy-17-(1-
propynyl)estra-4,9-dien-3-one (mifepristone; RU486), 11β,16α-9-fluoro-11,17,21-
trihydroxy-16-methylpregna-1,4-diene-3,20-dione (dexamethasone; Dex), 11β,21-
dihydroxy-3,20-dioxo-4-pregnen-18-al (aldosterone; Ald), and recombinant TNF-α 
were obtained from Sigma-Aldrich, South Africa. NET-A, the acetate, was used as it 
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is soluble in water compared with the insoluble ester of NET-EN. In vivo, both NET-
EN and NET-A undergo hydrolysis and are converted to NET and its metabolites 
(Stanczyk and Roy, 1990). Hydroxyflutamide (OHF) was obtained from Dr C. Tendler 
(Schering Plough Research Institute, USA). Unlabelled 17β-hydroxy-7α,17α-
dimethylestr-4-en-3-one (mibolerone; MIB), [3H]-MIB (76.8 Ci/mmol), unlabelled 
R5020, 3[H]-R5020 (84.6 Ci/mmol) and [3H]-Ald (87.9 Ci/mmol) were purchased from 
PerkinElmer Life and Analytical Science, South Africa. [3H]-Dex (89 Ci/mmol) was 
purchased from AEC-Amersham (South Africa). All unlabelled test compounds were 
dissolved in absolute ethanol and stored at -20oC. These compounds were then 
added to serum-free culturing medium such that the final concentration of ethanol 
was 0.1%. Control incubations (no test compounds) were performed in the presence 
of 0.1% ethanol.  
 
Cell culture 
Ect1/E6E7 and Vk2/E6E7 cell lines (human ectocervical and vaginal epithelial cell 
lines, respectively) were purchased from American Type Culture Collection (ATCC), 
USA and maintained in keratinocyte serum-free medium (GibcoBRL, Paisley, UK) 
supplemented with 50 µg/ml bovine pituitary extract (GibcoBRL, Paisley, UK), 0.1 
ng/ml epidermal growth factor (GibcoBRL, Paisley, UK), 0.4 mM CaCl2, 50 IU/ml 
penicillin and 50 µg/ml streptomycin (GibcoBRL, Paisley, UK). Cultures were 
maintained in 75 cm2 culture flasks (Greiner Bio-One International, Austria) at 37°C, 
in an atmosphere of 90% humidity and 5% CO2. All cultures were regularly tested for 
mycoplasma infection by means of Hoechst staining (Freshney RI, 1987), and only 
mycoplasma-negative cell lines were used in experiments.  
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Plasmids 
Plasmids expressing the human mineralocorticoid receptor, pRShMR, and the 
human glucocorticoid receptor, pRS-hGRα were a kind gift from Prof. R. Evans 
(Howard Hughes Medical Institute, La Jolla, USA). A plasmid expressing the human 
androgen receptor, pSVARo (Brinkmann et al., 1989) was obtained from Frank 
Claessens, (University of Leuven, Leuven, Belgium). The plasmid expressing the 
human progesterone receptor, isoform B, pSG5hPR-B (Kastner et al., 1990), was 
obtained from Stoney Simons Jr (NIH, Bethesda, USA). The pGL2basic empty vector 
was obtained from Promega, Madison, USA. 
 
Isolation of total RNA and realtime quantitative RT-PCR (QPCR) analysis of 
representative genes 
Ect1/E6E7 and Vk2/E6E7 cell lines were maintained as described above. Cells were 
induced with 0.02 µg/µl TNF-α and 1 µM of the test compounds, in the absence and 
presence of 10 µM receptor-specific antagonists, for 24 hours. Total RNA was 
isolated from cells using Tri-reagent (Sigma-Aldrich, South Africa) according to the 
manufacturer’s instructions. The integrity of the RNA (presence of intact 18S and 28S 
ribosomal bands) was confirmed by denaturing agarose gel electrophoresis. Total 
RNA (1 µg) was reverse transcribed using the Transcriptor First Strand cDNA 
synthesis kit (Roche Applied Science, South Africa) according to the manufacturer’s 
instructions. Real-time PCR was performed by using a Light-Cycler, rapid thermal 
cycler system (Roche Applied Science, South Africa) according to the manufacturer’s 
instructions. Nucleotides, TaqDNA polymerase, and buffer used in the reaction were 
those included in the LightCycler-FastStart DNA MasterPLUS SYBR Green I system 
(Roche Diagnostics, South Africa). Agarose gel electrophoresis and melting curve 
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analysis was performed to confirm the generated amplicon in each sample. The 
amplification efficiency for each primer was determined by generating a standard 
curve from a cDNA dilution series. The efficiencies were 1.99, 1.92, 1.98 and 2.0 for 
IL-6, IL-8, RANTES and GAPDH, respectively. Relative IL-6, IL-8 and RANTES 
transcript levels were calculated with the Fit Points method described by Pfaffl 
(2001), and were normalized to relative glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) transcript levels. Primer sets are as described in Table 1.  
Table 2.1: QPCR primer sets  
 
 
Gene 
 
Primers 
(5’ - 3’) 
 
Strand 
Length 
of 
amplicon 
(bp) 
Annealing 
temperature 
(oC) 
 
Reference 
 
RANTES 
 
TACCATGAAGGTCTCCGC 
GACAAAGACGACTGCTGG 
 
Forward 
Reverse 
 
199 
 
60 
 
Wolf et al. 
(2002) 
 
 
IL-6 
 
TCTCCACAAGCGCCTTCG 
CTCAGGGCTGAGATGCCG 
 
Forward 
Reverse 
 
 
193 
 
60 
 
Wolf et al. 
(2002) 
 
 
IL-8 
 
TGCCAAGGAGTGCTAAAG 
CTCCACAACCCTCTGCAC 
 
Forward 
Reverse 
 
 
197 
 
60 
 
Wolf et al. 
(2002) 
 
 
GAPDH 
 
TGAACGGGAAGCTCACTGG 
TCCACCACCCTGTTGCTGTA 
 
Forward 
Reverse 
 
 
 
307 
 
 
55 
 
Ishibashi et 
al. (2003) 
 
 
Western blotting  
Ect1/E6E7 and Vk2/E6E7 cell lines were plated at 1 x 106 cells per well in 6-well 
plates and allowed to grow to confluency. Cells were washed with PBS and lysed in 
100 µl SDS-sample buffer (Sambrook et al., 1989). Lysates were boiled and 
subjected to electrophoresis on a 8% SDS polyacrylamide gel using β-actin 
expression as a loading control. Following electrophoresis, proteins were transferred 
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to nitrocellulose membranes. Blots were probed with an anti-AR (H-280, 1:1000), 
anti-GR (H300, 1:3000), anti-PR-B (sc-811, 1:500), anti-PR-AB (sc-810, 1:500) or 
anti-MR (H300, 1:1000) antibodies from Santa Cruz Biotechnology Inc. (Santa Cruz, 
CA, USA), as well as the anti-β-actin (1:1500) antibody from Cell Signalling 
Technology, Massachusetts, USA, for 16 hours at 4oC. Blots were subsequently 
incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit secondary 
antibody (1:10000, NA934VS, Amersham, South Africa) for 1 hour. Proteins were 
visualized using enhanced chemiluminescence (ECL) from Amersham, followed by 
exposure to Hyperfilm MP high performance autoradiography film (Amersham, South 
Africa). 
 
Whole cell binding assays to determine steroid receptor content in the 
Ect1/E6E7 and Vk2/E6E7 cell lines 
Competitive whole cell binding assays were performed essentially as described by 
Bamberger et al. (1995), with the following modifications. Ect1/E6E7 and Vk2/E6E7 
cell lines were maintained as described above. Cells were seeded into 12-well tissue 
culture plates (Nunc, Denmark) at 2 x 105 cells per well. On day 3, the cells were 
washed with phosphate-buffered saline (PBS) and incubated for 2 hours at 37°C with 
10 nM 3[H]-MIB (76.8 Ci/mmol) for AR, 3[H]-Ald (87.9 Ci/mmol) for MR, 3[H]-R5020 
(84.6 Ci/mmol) for PR (3[H]-MIB,  3[H]-Ald, and 3[H]-R5020 all from PerkinElmer Life 
and Analytical Science, South Africa) or 3[H]-Dex (89 Ci/mmol) for GR (AEC-
Amersham, South Africa), in the absence (total binding) and presence of 10 µM 
unlabelled MIB, aldosterone, R5020, or Dex (non-specific binding), respectively. 
Working on ice at 4oC, cells were washed three times with ice-cold 1X PBS 
containing 0.2% (w/v) bovine serum albumin (BSA) for 15 min. Cells were then lysed 
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with 200 µl reporter lysis buffer (Promega, Madison, USA). Total binding was 
determined by scintillation counting as counts per minute (cpm), while specific 
binding was determined by subtracting non-specific binding from total binding. 
Protein concentrations were determined using the Bradford protein assay method 
(Bradford, 1976). Specific binding was normalized to the protein concentration. The 
reported values are averages of at least three independent assays, with each 
condition performed in triplicate. The receptor numbers in ƒmol/mg protein were 
determined as follows:  
The specific activity of the tritium-labelled test compound (Ci/mmol) was converted to 
disintegrations per minute (dpm) per mmol, by multiplying by a factor of 2.22 x 1012 (1 
Curie equals 2.22 x 1012 dpm). The dpm was multiplied by the counting efficiency to 
get cpm per mmole, and divided by 1012 to get cpm/ƒmol. Counting efficiency was 
40% in our system. The specific activity was expressed as cpm/ƒmol. Dividing the 
specific binding cpm value by this value gives specific binding in ƒmol, which was 
divided by the protein content of the sample in mg, to yield the number of binding 
sites in ƒmol/mg protein. 
 
Luciferase reporter assays 
For transactivation assays, the Ect1/E6E7 and Vk2/E6E7 cells were maintained as 
above and seeded into 24-well tissue culture plates at 5 x 104 cells per well. On day 
2, cells in each well were transiently transfected with 330 ng of the pTAT-GRE-E1b-
luc construct and 33 ng of the expression vector for the hMR, hGR, hAR, hPR-B or 
the empty vector pGL2basic, using the FuGENE6 transfection reagent (Roche 
Molecular Biochemicals, South Africa) in accordance with the manufacturer’s 
instructions. On day 3, the cells were washed with PBS and induced with 10 µM of 
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either Ald, Dex, MIB, or R5020. After 24 hours, the cells were lysed with reporter lysis 
buffer (Promega, Madison, USA). Luciferase activity in the lysate was measured 
using the Luciferase Assay System (Promega, Madison, USA) and a Veritas 
microplate luminometer (Turner Biosystems, Sunnyvale CA, USA). The values 
obtained were normalised to expression of β-gal, which was measured using the 
GalactoStar Assay Kit from Tropix (Bedford MA, USA). The reported values are 
averages of at least three independent experiments, with each condition performed in 
triplicate.  
 
Data manipulation and statistical analysis 
The Graph Pad Prism software was used for data manipulations, graphical 
representations, and statistical analysis. One-way ANOVA analysis of variance and 
Bonferroni posttests (compares all pairs of columns) were used for statistical 
analysis. Statistical significance of differences is indicated by *, ** or ***, to indicate 
p<0.05, p<0.01 or p<0.001, respectively, whereas no statistical significance (ns) is 
indicated by p>0.05. The letters a,b,c etc. are also used to denote statistically 
significant differences, where all those values which differ significantly from others, 
are assigned a different letter.  
 
Results  
MPA and NET-A, unlike Prog, exhibit differential patterns of gene regulation on 
pro-inflammatory chemokines 
Human Ect1/E6E7 and Vk2/E6E7 cell lines were treated for 24 hours with 0.02 µg/µl 
TNF-α and 1 µM Prog, MPA or NET-A, followed by QPCR analysis for expression of 
the IL-6, IL-8 and RANTES genes, respectively. In both the Ect1/E6E7 and Vk2/E6E7 
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cell lines, results show that unlike Prog which upregulates IL-6 gene expression, both 
MPA and NET-A have no effect (figure 2.1A and 2.1B). In contrast, MPA and NET-A 
differentially regulate both the IL-8 (figure 2.2A) and RANTES (figure 2.3A) genes in 
the Ect1/E6E7 cell line. The results show that MPA, like Prog upregulates IL-8, (10.3- 
vs. 12-fold, respectively), while NET-A upregulates the gene to a significantly lower 
extent (2.8-fold) (figure 2.2A). Although not statistically different, Prog and NET-A 
seemed to upregulate the IL-8 gene in the Vk2/E6E7 cell line to a similar extent, 
while MPA showed the greatest level of upregulation (figure 2.2B). Unlike Prog which 
upregulates RANTES gene expression in the Ect1/E6E7 cell line, MPA 
downregulates the RANTES gene expression, while NET-A has no effect (figure 
2.3A). Conversely, both MPA and NET-A, like Prog, upregulate the expression of the 
RANTES gene in the Vk2/E6E7 cell line (figure 2.3B). Taken together, MPA and 
NET-A exhibit differential patterns of gene regulation on expression of the IL-8 and 
RANTES genes, as compared to Prog, in a promoter- and cell- specific manner. In 
addition, unlike Prog, MPA and NET-A do not upregulate IL-6 gene expression. 
 
The PR, AR and GR are expressed in both ectocervical and vaginal cell lines 
As these progestins are known to interact with the PR, GR, AR and possibly the MR 
(Philibert et al., 1999), we hypothesized that the differential regulation of genes by 
MPA and NET-A, particularly on the RANTES gene, was due to their action via 
different steroid receptors, or differing activities via the same steroid receptor. To test 
this hypothesis, we firstly investigated which members of the steroid receptor family 
were expressed in these cell lines using a combination of Western blotting (figure 
2.4A) and whole cell binding (figure 2.4B and 2.4C).  
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Figure 2.1: Effect of MPA and NET-A on the TNF-α-induced expression of the IL-6 gene in 
human ectocervical and vaginal epithelial cell lines. (A) Human Ect1/E6E7- and (B) Vk2/E6E7 cell 
lines were incubated with 0.02 µg/µl TNF-α in the presence of 0.1% EtOH or 1 µM Prog, MPA or NET-
A for 24 hours. Total RNA was extracted, cDNA synthesized and expression levels of IL-6 and 
GAPDH mRNA were determined by QPCR. Results shown (ratio of the specific target gene/GAPDH 
gene) are the averages (±SEM) of at least three independent experiments.  
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Figure 2.2: Effect of MPA and NET-A on the TNF-α-induced expression of the IL-8 gene in 
human ectocervical and vaginal epithelial cell lines. (A) Human Ect1/E6E7- and (B) Vk2/E6E7 cell 
lines were incubated with 0.02 µg/µl TNF-α in the presence of 0.1% EtOH or 1 µM Prog, MPA or NET-
A for 24 hours. Total RNA was extracted, cDNA synthesized and expression levels of IL-8 and 
GAPDH mRNA were determined by QPCR. Results shown (ratio of the specific target gene/GAPDH 
gene) are the averages (±SEM) of at least three independent experiments.  
 
(A) ECTOCERVICAL CELLS 
 
(B) VAGINAL CELLS 
EtOH Prog MPA NET-A
0
2
4
6
8
10
12
14
1 µM test compound
b
a
b
a
Ra
tio
 
IL
8/
G
AP
DH
 
ex
pr
es
si
o
n
EtOH Prog MPA NET-A
0
2
4
6
8
10
12
14
1µM test compound
a
a
a
a
Ra
tio
 
IL
8/
G
AP
DH
 
ex
pr
es
si
o
n
 96 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3: Effect of MPA and NET-A on the TNF-α-induced expression of the RANTES gene in 
human ectocervical and vaginal epithelial cell lines. (A) Human Ect1/E6E7- and (B) Vk2/E6E7 cell 
lines were incubated with 0.02 µg/µl TNF-α in the presence of 0.1% EtOH or 1 µM Prog, MPA or NET-
A for 24 hours. Total RNA was extracted, cDNA synthesized and expression levels of RANTES and 
GAPDH mRNA were determined by QPCR. Results shown (ratio of the specific target gene/GAPDH 
gene) are the averages (±SEM) of at least three independent experiments.  
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Whole cell binding results showed that the GR, AR, and PR, are expressed in both 
these cell lines, while relatively very low amounts of MR are expressed only in the 
Vk2/E6E7 cell line (figure 2.4C). Western blot analysis using an antibody specific for 
the MR (H-300), confirmed the absence of the MR in the Ect1/E6E7 cells (data not 
shown-Renate Louw, MSc student). However, the low levels of MR in the Vk2/E6E7 
cell line observed in the whole cell binding assay, could not be detected using 
Western blotting (data not shown-Renate Louw, MSc student).  
 
We subsequently determined the endogenous steroid receptor levels in both cell 
lines. The results show that there is significantly (p<0.001) more PR than AR or GR 
in the Ect1/E6E7 andVk2/E6E7 cell lines, respectively. Moreover, the levels of AR vs. 
GR are similar to each other in both cell lines (p>0.05), (figure 2.4B and 2.4C). The 
expression of the GR and AR in both cell lines was confirmed by Western blot 
analysis using antibodies specific for the GR and AR (figure 2.4A). As the GR is 
ubiquitously expressed (reviewed in Gross and Cidlowski, 2008), it is difficult to find a 
cell line that does not show low levels of GR. As expected, we detected low levels of 
endogenous GR in the untransfected COS-1 cell line (negative control). There are 
two functional isoforms of the PR, PR-A and PR-B (Kastner et al., 1990; Kraus and 
Katzenellenbogen, 1993). Western blot analysis using an antibody specific for the 
PR-B isoform showed that both these cell types did not express PR-B. We were 
unable to optimize the commercial antibody detecting the PR-A isoform (anti-PR-AB 
(sc-810), Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA)), and thus could not 
determine by Western blotting whether the PR-A isoform is expressed in these cell 
lines. Taken together, the results showing the expression of the PR, AR, and GR 
isoforms in both the Ect1/E6E7 and Vk2/E6E7 cell lines, support our hypothesis that 
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the differential effects of MPA and NET-A could be a consequence of their action via 
different steroid receptors.  
 
Receptor-specific antagonists indicate a role for the AR in the downregulation 
of the RANTES pro-inflammatory chemokine gene by MPA in the ectocervical 
cell line 
Having determined that these cell lines mostly express AR, GR and PR, our strategy 
was to determine which of these steroid receptors mediate the differential effects of 
MPA and NET-A on the RANTES genes in the Ect1/E6E7 cell line. Although 
differential effects were also observed for MPA and NET-A on the expression of the 
IL-8 gene, it was decided to continue the investigation only for the RANTES gene, as 
MPA and NET-A exhibited differential effects, not only to each, but also to Prog on 
this gene. For this reason, Ect1/E6E7 cells were incubated with 0.02 µg/ml TNF-α 
and 1 µM MPA or NET-A, in the absence and presence of 10 µM hydroxyflutamide 
(OHF), the classical androgen antagonist or mifepristone (RU486), the PR and GR 
antagonist. The addition of OHF prevented the inhibition by MPA, indicating that, in 
this cell line, the repression by MPA on the RANTES gene is mediated by the AR 
(figure 2.7A).  
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Figure 2.4: PR, AR and GR are expressed in human ectocervical and vaginal epithelial cell 
lines. (A) Whole cell extracts were prepared from human Ect1/E6E7 and Vk2/E6E7 cell lines, 
untransfected COS-1 cell line (negative control (-ve ctl)), COS-1 cell line transfected with pRS-hGRα, 
pSVARo, or pSG5hPR-B expression vectors (positive controls (+ve ctl)). Equal amounts of protein (20 
µg) were analyzed by Western blotting with the GR or AR or PR-B antibodies. (B) Human Ect1/E6E7- 
and (C) Vk2/E6E7 cell lines were incubated with 10 nM [3H]-R5020 or [3H]-Dex or [3H]-MIB or [3H]-
Ald in the absence (total binding) and presence of 10 µM unlabelled (non-specific binding) R5020 or 
Dex or MIB or Ald, respectively. Specific binding (total binding minus non-specific binding) is plotted. 
Results shown are the averages (±SEM) of at least three independent experiments with each 
condition performed in triplicate. The number of binding sites in ƒmol/mg protein was calculated from 
the specific activity of the radiolabelled ligands and the specific binding cpm value, as described in the 
materials and methods section. 
 
Only the GR was transcriptionally active in promoter-reporter transactivation 
assays in both ectocervical and vaginal cell lines 
Having established that the Ect1/E6E7 and Vk2 cell lines both express PR, GR, AR, 
and very low levels of MR in the Vk2/E6E7 cell line, we next determined whether 
these receptors are transcriptionally active by transiently transfecting these cells with 
a glucocorticoid response element (GRE)-driven reporter construct containing two 
copies of the rat tyrosine amino transferase (TAT) GRE.  The cells were 
subsequently exposed to 10 µM of the receptor-specific agonist Dex for the GR, MIB 
for the AR, R5020 for the PR and Ald for the MR. The results show that only the GR 
is transcriptionally active in the Ect1/E6E7 (figure 2.5) and Vk2/E6E7 (figure 2.6) cell 
lines. However, this does not mean that the other endogenously expressed receptors 
are not biologically active in other assays. Results from transrepression experiments 
via a synthetic NFκB-promoter have indicated transcriptionally active GR and AR, but 
not PR in the ectocervical cells (data not shown-Renate Louw, MSc student). In 
addition, it has previously been shown that the potency of a ligand for transactication 
via a GRE is less than the potency for transrepression via NFκB (Ronacher et al., 
2009). Thus the other endogenous receptors may still be active on other synthetic 
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and endogenous genes, such as in transrepression assays. These results with 
transfected receptors do however also show that the agonist used are active in these 
cell lines.  
 
Consistent with this result, dihydrotestosterone (DHT), the natural androgen, also 
repressed the RANTES gene in this cell line via the AR (figure 2.7A). Interestingly, 
the addition of OHF did not significantly inhibit the effects of Prog or NET-A, 
indicating that the effects of these compounds on the RANTES gene are not 
mediated via the AR. A similar experiment with OHF in the Vk2/E6E7 cell line 
indicated that the AR is not involved in any of the responses by Prog, MPA or NET-A 
on the RANTES gene (Appendix A1).  
 
RU486 did not inhibit the effects mediated by the positive controls: dexamethasone 
(Dex), a synthetic GR agonist, or promegestone (R5020), a synthetic PR agonist 
(figure 2.7B), indicating that RU486 is not working as a GR or PR antagonist in the 
Ect1/E6E7 cell line, but rather as an agonist. It has previously been reported that 
RU486 may act as an agonist in some cells and as an antagonist in others 
(Bamberger and Chrousos, 1995). The fact that the expression of the RANTES gene 
is enhanced when RU486 is added together with Prog, MPA or NET-A, is difficult to 
interpret. Taken together, conclusions cannot be drawn as to the role of the GR or 
PR in mediating the repression of the TNFα-induced RANTES gene by MPA. Using a 
PR antagonist, like Org31710, which has little anti-glucocorticoid activity compared to 
RU486 (Kloosterboer et al., 1994), or a GR-specific antagonist like DO6 (Miner et al., 
2003), was not possible since these antagonists are not commercially available.  
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Figure 2.5: Transactivation of a transiently transfected GRE-containing promoter-reporter 
construct via endogenous or expressed GR, AR, PR, or MR. Ect1/E6E7 cells (5x104 cells per well 
in a 24-well plate) were transiently transfected with 330 ng pTAT-GRE2-Elb-luc and 33 ng pRS-hGRα, 
pSVARo, pSG5hPRB , pRS-hMR or pGL2basic (empty vector control) as indicated, with Fugene 6 
transfection reagent according to the manufacturer’s instructions. Twenty-four hrs after transfection 
cells were induced for 24 hrs with vehicle (ethanol (EtoH)), 10 µM Dex, MIB, R5020 or Ald (receptor-
agonists).  
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Figure 2.6: Transactivation of a transiently transfected GRE-containing promoter-reporter 
construct via endogenous or expressed GR, AR, PR, or MR. Vk2/E6E7 cells (5x104 cells per well 
in a 24-well plate) were transiently transfected with 330 ng pTAT-GRE2-Elb-luc and 33 ng pRS-hGRα, 
pSVARo, pSG5hPRB , pRS-hMR or pGL2basic (empty vector control) as indicated, with Fugene 6 
transfection reagent according to the manufacturer’s instructions. Twenty-four hrs after transfection 
cells were induced for 24 hrs with vehicle (ethanol (EtoH)), 10 µM Dex, MIB, R5020 or Ald (receptor-
agonists).   
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Figure 2.7: Effect of the androgen receptor antagonist (OHF) (A) or 
glucocorticoid/progesterone receptor antagonist (RU486) (B) on the MPA inhibition of the TNF-
α-induced RANTES gene. The human Ect1/E6E7 cell line was incubated with 0.02 µg/µl TNF-α in the 
presence of 1 µM Prog, MPA, NET-A, DHT, DEX, or R5020, and absence or presence of 10 µM (A) 
hydroxyflutamide (OHF) or (B) RU486 for 24 hours. Total RNA was extracted, cDNA synthesized, and 
expression levels of RANTES and GAPDH mRNA were determined by QPCR. Results shown (ratio of 
the specific target gene/GAPDH gene) are the averages (±SEM) of at least two independent 
experiments. Open bars are compounds and vehicle only, while the black bars are compounds plus 
antagonist.  
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DISCUSSION  
Inflammation of the lower human female genital tract increases susceptibility to viral 
infections such as human immunodeficiency virus (HIV) (Kreiss et al., 1994; Hart et 
al., 1999) and human papilloma virus (HPV) (Castle et al., 2000). In addition, 
excessive release of proinflammatory cytokines may alter the mucosal immune 
function (Alfano and Poli, 2005). Thus, understanding factors that may influence the 
local mucosal immune response, such as endogenous hormones or hormonal 
contraception, is crucial, especially since the cervicovaginal mucosa is the primary 
site of HIV-1 infection during male to female transmission (reviewed in Pope and 
Haase, 2003). Although, the synthetic progestins medroxyprogesterone acetate 
(MPA) and norethindrone acetate (NET-A) are widely used in both contraception and 
hormone replacement therapy (HRT), little is known about their effects on the 
cervicovaginal environment, and whether they interfere with local epithelial immune 
function. In this study we investigated the effects of MPA, NET-A and Prog on two 
immortalized, morphologically and functionally different epithelial cell lines, one from 
a normal human ectocervix and the other from a normal human vagina (Fichorova et 
al., 1999). Although immortalized, the authors report that the morphological and 
immunocytochemical properties of these cell lines resemble not only their tissues of 
origin, but also those of primary cultures (Fichorova et al., 1997). Notably, this is not 
the case for the HeLa cervical cell line, which is probably the most frequently used 
cell line derived from the human female lower genital tract mucosa (Fichorova et al., 
1997). The Ect1/E6E7 and Vk2/E6E7 cell lines express characteristics of stratified 
squamous nonkeratinizing epithelia, and constitutively express IL-8, while IL-6 and 
RANTES are produced when the cell lines are stimulated with either TNFα or 
interferon gamma (IFNγ) (Fichorova and Anderson, 1999). 
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Prog increases the expression of IL-6, IL-8 and RANTES, in both the Ect1/E6E7 and 
Vk2/E6E7 cell lines, while NET-A had little to no effect. We found that Prog 
upregulated the TNFα-induced proinflammatory cytokine interleukin (IL)-6 in both cell 
lines, while MPA and NET-A had no effect (figure 2.1A and 2.1B). This is inconsistent 
with previous studies that have shown the repression of IL-6 by MPA in other cell 
types (Mantovani et al., 1997; Koubovec et al., 2004). Similarly, NET-A has 
previously been shown to either upregulate (Zitzmann et al., 2005) or downregulate 
(Wessel Kriek, MSc thesis) IL-6. In contrast, NET-A in combination with estrogen, like 
estrogen only, had no effect on IL-6 levels in healthy postmenopausal women 
(Žegura et al., 2006). In the Ect1/E6E7 cell line, the IL-8 gene was upregulated by 
Prog, MPA and NET-A, albeit to different extents, and statistical analysis showed that 
while the extent of upregulation by Prog and MPA is similar (p>0.05), NET-A’s 
upregulation is significantly different from both Prog (p<0.001) and MPA (p<0.01) 
upregulation (figure 2.2A). A similar pattern was observed for the compounds on the 
IL-8 gene in the Vk2/E6E7 cell line (figure 2.2B). However, due to variability in the 
extent of the response between experiments, when the results from different 
independent experiments were combined, the changes in IL-8 mRNA levels were not 
statistically significant. However, these results follow a similar trend between 
experiments, and are most likely physiologically relevant. Consistent with our results, 
both Prog and MPA have previously been shown to upregulate IL-8 mRNA levels in 
human endometrial stromal cells (Arici et al., 1996). As Prog has previously been 
shown to have a protective role in the vagina (Beaver, 1960), our results showing 
that MPA and NET-A are similar to Prog in upregulating IL-8, albeit to different 
extents, in the Ect1/E6E7 and Vk2/E6E7 cell lines, could indicate that these 
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progestins may provide an enhanced local defense mechanism against infections in 
the vaginal mucosa.  
 
MPA substantially and significantly downregulates the expression of the 
proinflammatory RANTES gene in the Ect1/E6E7 cell line, (figure 2.3A), while it is 
upregulated by MPA in the Vk2/E6E7 cell line (figure 2.3B). Thus, the same 
compound, MPA, exhibits differing effects on the same gene (RANTES), in different 
cell types, indicating cell-specific effects of MPA. In addition, NET-A had no 
statistically significant effect on the RANTES gene in both cell types, indicating 
differential regulation of RANTES by the two synthetic progestins thought to have 
similar biological activity. Trying to understand the physiological implications of this 
result on the RANTES gene is not easy. In epithelial cells, RANTES recruits immune 
cells into the reproductive tract, in this manner contributing to inflammation. Inhibition 
of RANTES by MPA would thus be expected to suppress inflammation, thereby 
blocking infiltration of immune cells (Cho et al., 2006). This lack of recruitment of 
immune cells into the reproductive tract may have implications for women using 
MPA. In terms of HIV-1 infection, which has been associated with increased 
RANTES in cervicovaginal secretions (Behbahani et al., 2007), these implications 
may be positive in terms of less HIV-infection due to decreased inflammation 
(Cummins et al., 2006). However, women using MPA in contraception and HRT are 
also at risk of other infections, and thus the suppression of RANTES may prevent the 
mounting of an effective response to combat these infections in the ectocervical 
environment. In addition, it is important to remember that the defense function in the 
cervicovaginal environment is dependent on number of regulatory factors in different 
anatomical sites, with a constant release of pro- and anti-inflammatory mediators. 
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Thus the observed effects of MPA on RANTES should be considered in the light of 
the fact that there may be a balance between pro- and anti-inflammatory molecules 
produced in the cervicovaginal environment.  It would be of interest to look at the 
expression of RANTES in cervicovaginal lavage samples from healthy-, and HIV-1 
infected- women using MPA and NET as injectable contraception, as compared to 
women not using these contraceptives. 
 
In summary, the general trend that was observed for the effect of Prog, MPA and 
NET-A on endogenous cytokine genes in the cervicovaginal environment, is that 
Prog upregulates the expression of IL-6, IL-8 and RANTES, while NET-A either 
upregulates these genes, or has no effect. In contrast, MPA either has no effect (e.g. 
IL-6 gene), or upregulates (e.g. IL-8 gene), or downregulates (e.g. RANTES gene) 
expression of these genes. Furthermore, Prog shows regulation different to both 
MPA and NET-A on the RANTES gene in the Ect1/E6E7 cell line (figure 2.3A), as 
well as on the IL-6 gene in both the Ect1/E6E7 and Vk2/E6E7 cell lines (figure 2.1A 
and 2.1B). Taken together, these results show that cytokine genes in the 
cervicovaginal environment are regulated in a ligand-specific and cell-specific 
manner by Prog, MPA and NET-A.  
 
We hypothesized that the ligand-specific and cell-specific effects regulation of 
cytokine genes in the cervicovaginal environment are due to ligands acting via 
different steroid receptors, or differing activities via the same steroid receptor. Using 
a combination of whole cell binding and Western blotting, we showed that the PR, AR 
and GR are expressed in both cell lines (figure 2.4A-C). Whole cell binding 
experiments showed that the amount of GR and AR in the Ect1/E6E7 and Vk2/E6E7 
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cell lines is similar (figure 2.4B and 2.4C). Since the whole cell binding experiments 
showed the presence of a large amount of PR, one would expect that the progestins 
would predominantly act via this receptor. However, we did not observe any PR-
mediated effects in our study. In fact, the potent synthetic PR agonist, R5020, 
displayed no activity for transactivation or transrepression via the PR. A possible 
explanation for this intriguing result may be explained by the expression levels of 
different PR isoforms. We were unable to detect the PR-B isoform in any of the cell 
lines, and thus we postulate that it is the transcriptionally less active PR-A isoform 
that is present in these cell lines. Indeed, variation in the expression of PR-A and PR-
B has previously been reported in the eutopic endometrium during the menstrual 
cycle (Mangal et al., 1997), with no PR-B detectable during the secretory and early 
proliferative phases. Similarly, Attia et al. (2000) did not detect any PR-B protein in 
endometriotic tissue, and they ascribe the clinically observed resistance of 
endometriosis to treatment with progestins, to this absence of PR-B, and presence of 
PR-A. 
 
We next determined which steroid receptor(s) are involved in the response of MPA 
on the RANTES gene in the Ect1/E6E7 cell line, by using receptor-specific 
antagonists. As we had shown that this cell line expresses AR, GR and PR (figure 
2.4B), we looked at the expression of the RANTES gene in the presence of OHF, the 
AR-specific antagonist, as well as RU486, the PR and GR antagonist. The results 
show that in the Ect1/E6E7 cell line, RU486 behaves as an agonist, rather than an 
antagonist (figure 2.7B). RU486 had previously been shown to act as both an agonist 
and as an antagonist, depending on receptor density (Zhao et al., 2003). 
Furthermore, it has been reported that RU486 is a partial agonist for both PR and GR 
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when selective coregulators are recruited (Jackson et al., 1997; Schulz et al., 2002). 
This approach of using RU486 as a receptor antagonist in this cell line is thus limited. 
Interestingly, the results using OHF showed that the repression of MPA on the 
RANTES gene was lifted when the AR is antagonised, revealing a possible role for 
the AR (figure 2.7A). The fact that OHF could lift the repression of MPA on the 
RANTES gene to similar levels as the control (EtOH), suggests that the PR, despite 
being the most abundant receptor, as well as the GR, are not involved in the MPA-
mediated downregulation of the RANTES gene in the Ect1/E6E7 cell line. 
Considering that both MPA and NET-A have previously been reported to have 
androgenic properties (Bentel et al., 1999; Teulings et al., 1980; Bamberger et al., 
1999; Kemppainen et al., 1999; Hackenberg et al., 1993; Perez-Palacios et al., 1983; 
Perez-Palacios et al., 1981a; Perez-Palacios et al., 1981b; Bergink et al., 1983; 
Schoonen et al., 2000; Deckers et al., 2000), it was surprising that NET-A did not act 
via the AR in this cell line. However, as it is known that NET-A can be metabolized 
(Stanczyk and Roy, 1990), the possibility exists that NET-A is metabolized in this cell 
line, and that the metabolite(s), are less efficacious AR agonists than NET-A itself.  
 
In summary, results from our study are the first to indicate not only differential 
regulation of the cytokine genes by Prog, MPA and NET-A, but also cell-specific 
effects. Moreover, we showed that the effect of MPA on the RANTES gene in the 
Ect1/E6E7 cell line is AR-mediated.  
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Abstract 
Medroxyprogesterone acetate (MPA) and norethisterone enanthate (NET-EN) are 
used by millions of women as contraceptives and in hormone replacement therapy 
(HRT). Surprisingly, even though both progestins are widely used, very little is known 
about their mechanism of action at the molecular level. The importance of 
investigating these mechanisms, and comparing them to those of progesterone 
(Prog), has recently been highlighted by clinical evidence showing that MPA and 
NET increase the risk of the development of breast cancer in HRT users. MPA is also 
implicated in increased risk of coronary heart disease in HRT users. The aim of this 
study was to investigate and compare the androgenic activities of these two clinically 
important progestins. Competitive binding in whole cells revealed that Prog, MPA and 
NET-A have a similar binding affinity for the androgen receptor (AR) to that of the 
natural androgen dihydrotestosterone (DHT) (Ki’s for DHT, Prog, MPA and NET-A 
are 29.4, 36.6, 19.4 and 21.9 nM, respectively). Moreover, in both transactivation and 
transrepression transcriptional assays we demonstrate that, unlike Prog, MPA and 
NET-A are efficacious AR agonists, with activities comparable to DHT. The finding 
that both MPA and NET-A have strong androgenic effects when compared to 
endogenous Prog, may have important implications for women using these 
progestins in HRT or contraception, as it may lead to side-effects such as weight 
gain, lipid profile modifications or increased breast cancer risk. Furthermore, we show 
that MPA and NET-A exert their androgenic actions by different mechanisms, as 
NET-A, like DHT and other well-characterised androgens, induces the ligand-
dependent interaction between the NH2- and COOH-terminal domains (N/C-
interaction) of the AR independent of promoter-context, while MPA does this in a 
promoter-dependent manner.  
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Introduction 
The synthetic progestins, medroxyprogesterone acetate (MPA) and norethisterone 
enanthate (NET-EN) are widely used in contraception and in hormone replacement 
therapy (HRT). MPA itself is the major progestogenic compound, while NET-EN and 
norethisterone acetate (NET-A) are hydrolysed to norethisterone (NET) and its 
metabolites, which together have progestogenic action (Stanczyk and Roy, 1990). 
The Women’s Health Initiative (WHI) trial showed healthy postmenopausal women  
using combined estrogen and MPA therapy in HRT have an increased risk of breast 
cancer and cardiovascular complications (Rossouw et al., 2002). A similar trial on the 
use of estrogen alone was only terminated two years later and its analysis, although 
indicating an increased risk for stroke, showed no increase in breast cancer risk 
(Anderson et al., 2004). MPA and NET have both been shown to substantially 
increase the risk of breast cancer in longterm HRT users in the “Million Women 
study” (Beral, 2003). Surprisingly, very little information is available about the 
molecular mechanism of action of MPA and NET, in particular their comparative 
properties (Hapgood et al., 2004). 
 
Notably, a few studies have recently started investigating these mechanisms, but 
focus mostly on MPA, and not NET-A. MPA has been reported to modulate 
transcription of a number of genes via the glucocorticoid receptor (GR), such as IL-2 
in normal human lymphocytes (Bamberger et al., 1999), IL-6 and IL-8 in a mouse 
fibroblast cell line (Koubovec et al., 2004) and the nm-23 tumor suppressor gene in a 
breast cancer cell line (Ouatas et al., 2003). Interestingly, MPA has a greater affinity 
than NET-A for the GR, and acts as a partial agonist for transactivation (Koubovec et 
al., 2005), while NET-A is a GR antagonist (Appendix C6). This demonstrates that 
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MPA and NET do not have the same activity, nor do they act the same as Prog, via 
the GR. It is thus apparent that even though MPA and NET were developed so that 
their biological actions mimicked that of progesterone (mediating their effects by 
binding to the PR), they can also initiate a diverse range of biological effects by 
cross-reacting with other members of the steroid receptor family such as the GR and 
possibly the mineralocorticoid receptor (MR) (Hapgood et al., 2004; Koubovec et al., 
2005; Philibert et al., 1999). In this way, MPA and NET may exert side-effects via any 
of these receptors, such as the observed immunosuppressive effects of MPA via the 
GR. This highlights the importance of understanding the interactions of these 
compounds with different steroid receptors. 
 
Both MPA and NET-A have previously been reported to have androgenic properties 
(Bentel et al., 1999; Teulings et al., 1980; Bamberger et al., 1999; Kemppainen et al., 
1999; Hackenberg et al., 1993; Perez-Palacios et al., 1983; Perez-Palacios et al., 
1981a; Perez-Palacios et al., 1981b; Bergink et al., 1983; Schoonen et al., 2000; 
Deckers et al., 2000; Bergink et al., 1983; Bergink et al., 1985). In addition, MPA has 
been shown to regulate a number of genes via the AR in human breast cancer cell 
lines (Ghatge et al., 2005). Our own work in human ectocervical cells (Ect/E6E7), 
indicates involvement of the AR in the downregulation of the proinflammatory 
RANTES (Regulated-upon-Activation, normal T cell Expressed and Secreted) gene 
by MPA (Chapter 2). Little research has been done to directly compare the relative 
androgenic activities of MPA and NET-A, as compared to the activity of Prog, and the 
precise mechanisms involved.  
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Like all members of the steroid receptor family, the AR is a ligand-dependent 
transcription factor which mediates the response of cells to androgens, and is 
structurally organized in three domains (depicted in Figure 1): the ligand binding 
domain (LBD) at the C-terminus of the protein, the highly conserved and centrally 
located DNA-binding domain (DBD) which consists of two zinc finger elements and 
which directly interacts with specific DNA sequences called androgen response 
elements (AREs), and the variable N-terminus or N-terminal domain (NTD), which is 
involved in transactivation. These receptors possess transcriptional activation 
functions located in the NTD (AF1 domain) and the LBD (AF2 domain) (Simental et 
al., 1991; Brinkmann et al., 1999). 
 
 
 
 
 
 
 
Figure 1. A schematic representation of the structural and functional domains of the 919 amino 
acid residue human androgen receptor. The N-terminal domain (NTD) contains the AF-1 (activation 
function 1), the ligand-binding domain (LBD) contains the AF-2 (activation function 2). Also indicated is 
the central DNA-binding domain (DBD) and the positions of the FxxLF motif. (redrawn from Trapman 
and Dubbink, 2007). 
 
The first step in the process of transcriptional regulation is binding of the hormone to 
the AR, which promotes dissociation of the mostly cytoplasmic AR from heat-shock 
proteins. The liganded-AR translocates to the nucleus where it binds to AREs as a 
dimer, and subsequently activates (transactivation) gene expression (Evans, 1988; 
Beato, 1989). The liganded-AR translocates to the nucleus where it binds to AREs as 
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a dimer, and subsequently activates gene expression (transactivation) (Evans, 1988; 
Beato, 1989). The liganded-AR can also cause repression of gene expression 
(transrepression). This involves the ligand-activated AR binding via protein-protein 
interactions to promoter-bound transcription factors such as nuclear factor-kappa B 
(NFκB) and activator protein-1 (AP-1). Furthermore, in the presence of a classical AR 
agonist, the transactivation capacity of the AR is mediated primarily by an interaction 
between the N-terminal transactivation domain (AF-1) and the AF-2 cleft in the C-
terminal LBD. Studies to further reveal the subdomains mediating this so-called “N/C 
interaction” implicate the FXXLF motif, 23FQNLF27, in the NTD (He et al., 2000). In 
addition, the N-terminal WXXLF binding motif, 433WHTLF437, has also been reported 
to bind to the AF-2 domain, thereby contributing to the N/C-interaction (He et al., 
2000). This N/C interaction takes place both within one molecule (intramolecular), 
and between two AR molecules (intermolecular) (Schaufele et al., 2005). 
Interestingly, it has previously been shown that both Prog and MPA cannot induce 
the AR N/C-interaction (Kemppainen et al., 1999), but to the best of our knowledge, 
this has not been investigated for NET.  
 
In this study we investigated the mechanism of action of MPA and NET-A via the AR 
and compared it to that of Prog, by evaluating and comparing binding affinities for the 
AR. Although a number of studies have looked at the relative binding affinities of 
MPA and NET-A to the AR, the data from these studies may be misleading as many 
performed their experiments in cell lines that express, not only endogenous AR, but 
also other steroid receptors to which these compounds can bind (Hackenberg et al., 
1993; Zhao et al., 2000). Thus, we performed whole cell binding assays in the COS-1 
cell line, that have negligible levels of endogenous steroid receptors, and determined 
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the Kd’s of Prog, MPA and NET-A for the AR. In addition, we compared the 
transcriptional activation and repression of these compounds via the AR, as well as 
their ability to induce the N/C-interaction of the AR. The androgenic properties were 
compared with those of the synthetic androgens, mibolerone and R1881, the native 
ligand, 5α-dihydrotestosterone (DHT), and the synthetic progestin, mifepristone 
(RU486), a derivative of norethindrone, that has previously been shown to have 
androgenic and anti-androgenic properties (Kemppainen et al., 1992; Song et al., 
2004) (refer to figure 2 for the chemical structures of the androgens, progesterone, 
and the synthetic progestins).  
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Figure 2. The chemical structures of natural (endogenous) and synthetic androgens (white boxes) and 
progestins (light grey boxes). The natural androgen, dihydrotestosterone (DHT); synthetic androgens, 
mibolerone (MIB) and methyltrienolone (R1881); natural progesterone (Prog), synthetic progestins 
medroxyprogesterone acetate (MPA), norethisterone enanthate (NET-EN) and mifepristone (RU486). 
Adapted from Ronacher et al., 2009. 
 
 
Dihydrotestosterone Mibolerone Metyltrienolone
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Materials and methods 
Inducing compounds 
5α-androstan-17β-ol-3-one (dihydrotestosterone; DHT), 11β-(4-dimethylamino) 
phenyl-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one) (mifepristone; RU486), 4-
pregnene-3, 20-dione (progesterone; Prog), 6α-methyl-17α-hydroxy-progesterone 
acetate (medroxyprogesterone acetate; MPA), 17α-ethynyl-19-nortestosterone 17β-
acetate (norethindrone acetate; NET-A), 11β,16α-9-fluoro-11,17,21-trihydroxy-16-
methylpregna-1,4-diene-3,20-dione (Dexamethasone; Dex), recombinant TNF-α and 
phorbol 12-myristate-13-acetate (PMA) were obtained from Sigma-Aldrich, South 
Africa. NET-A, the acetate, was used as it is soluble in water compared with the 
insoluble ester NET-EN. In vivo, both NET-EN and NET-A undergo hydrolysis and 
are converted to NET and its metabolites (Stanczyk and Roy, 1990). 
Hydroxyflutamide (OHF) was obtained from Dr C. Tendler (Schering Plough 
Research Institute, USA). Unlabelled 17β-hydroxy-7α, 17α-dimethylestra-4-en-3-one 
(mibolerone; MIB), 17β-17-hydroxy-17-methyl-estra-4,9,11-trien-3-one 
(methyltrienolone; R1881) and [3H]-Mibolerone ([3H]-MIB) (76.8 Ci/mmol) were 
purchased from (PerkinElmer Life and Analytical Science, South Africa). All 
unlabelled test compounds were dissolved in absolute ethanol and stored at -20oC. 
These compounds were then added to serum-free culturing medium such that the 
final concentration of ethanol was 0.1%. Control incubations (no test compounds) 
were performed in the presence of 0.1% ethanol.  
 
Plasmids 
The plasmid pTAT-GRE-E1b-luc, driven by the E1b promoter that contains two 
copies of the rat TAT-GRE, has been described previously (Sui et al., 1999). The 
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cytomegalovirus (CMV)-driven-β-galactosidase expression vector (pCMV-β-gal) was 
obtained from Prof. G. Haegeman (University of Gent, Belgium). The 5xNFκB-luc and 
7xAP-1-luc plasmids were from Stratagene (Houston, Texas, USA). A plasmid 
expressing the human androgen receptor, pSVARo (Brinkmann et al., 1989), the 
human AR (hAR) DBD-LBD expression vector, pSG5-hAR(DBD-LBD) (Alen et al., 
1999), the hAR NTD-VP16 fusion protein expression vector, pSNATCH-II(hAR-NTD)  
(Alen et al., 1999), as well as the reporter constructs for selective androgen response 
elements (AREs), 4xSC-ARE1.2 and 4xSLP-HRE2 (Schauwaers et al., 2007), were 
obtained from Prof. Frank Claessens (University of Leuven, Leuven, Belgium). 
 
Cell culture 
COS-1 cell lines (monkey kidney cells) were purchased from American Type Culture 
Collection (ATCC), USA and maintained in high glucose (4.5 g/ml) Dulbecco’s 
Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, South Africa), supplemented with 
10% fetal calf serum (FCS) (Delta Bioproducts, Johannesburg, South Africa), 50 
IU/ml penicillin and 50 µg/ml streptomycin (GibcoBRL, Paisley, UK). Cultures were 
maintained in 75 cm2 culture flasks (Greiner Bio-One International, Austria) at 37°C, 
in an atmosphere of 90% humidity and 5% CO2. All cultures were regularly tested for 
mycoplasma infection by means of Hoechst staining (Freshney RI, 1987), and only 
mycoplasma-negative cell lines were used in experiments.  
 
Whole cell binding assays 
Competitive whole cell binding assays were performed essentially as described by 
Bamberger et al. (1995), with the following modifications. The COS-1 cell line was 
maintained in DMEM as described above. Cells were seeded into 24-well tissue 
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culture plates (Nunc, Denmark) at 1 x 105 cells per well. On day 2, cells were 
transfected with 0.375 µg pSVARo expression vector and 0.0375 µg of the pCMV-β-
gal expression vector (Stratagene, Houston, Texas, USA), using the FuGENE6 
transfection reagent (Roche Molecular Biochemicals, South Africa) according to the 
manufacturer’s instructions. On day 3, the cells were washed with phosphate-
buffered saline (PBS) and incubated for 16 hours (time taken to reach equilibrium; 
Appendix B2) at 37°C with 0.2 nM [3H]-MIB (PerkinElmer Life and Analytical Science, 
South Africa) in the absence and presence of increasing concentrations of unlabelled 
MIB, R1881, DHT, Prog, MPA, NET-A or RU486. Working on ice at 4oC, cells were 
washed three times with ice-cold 1X PBS containing 0.2% (w/v) bovine serum 
albumin (BSA) for 15 min. Cells were then lysed with 200 µl reporter lysis buffer 
(Promega, Madison, USA). Total binding ([3H]-MIB in the absence of added 
unlabelled ligand) was determined by scintillation counting and expressed as 100%. 
Specific bound [3H]-MIB was calculated as the difference between total and non-
specific binding, the latter determined by incubating cells in the presence of [3H]-MIB 
plus 10 µM unlabelled MIB and expressed as a relative % of total binding. The β-
galactosidase chemiluminescent reporter gene assay system (Tropix Inc., U.S.A.) 
was used to determine β-galactosidase activity, to correct for differences in 
transfection efficiencies. Binding data were analyzed using GraphPad Prism 
software, with nonlinear regression and assuming competitive binding to one class of 
binding sites. Ki values for DHT, R1881, Prog, MPA, NET-A and RU486 were 
determined from the heterologous displacement curves using the EC50s, Kd for MIB 
and concentration of radiolabelled MIB, according to the method of Cheng and 
Prusoff (1973). The reported values are averages of at least three independent 
assays, with each condition performed in triplicate. 
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Transient transfection assays 
For transactivation assays, the COS-1 cell line was maintained as above and seeded 
into 96-well tissue culture plates (Nunc, Denmark) at 1 x 104 cells per well. On day 2, 
cells in each well were transfected with 100 ng of the appropriate luciferase reporter 
constructs, 10 ng of the appropriate expression vectors for either a human steroid 
receptor or relevant fusion proteins, and 10 ng of the pCMV-β-gal expression vector 
(Stratagene, Houston, Texas, USA), using the FuGENE6 transfection reagent 
(Roche Molecular Biochemicals, South Africa) in accordance with the manufacturer’s 
instructions. On day 3, cells were washed with PBS and induced with increasing 
concentrations of MIB, R1881, DHT, Prog, MPA, NET-A or RU486. After 24 hours, 
cells were lysed with 25 µl reporter lysis buffer (Promega, Madison, USA). Luciferase 
activity in the lysate was measured using the Luciferase Assay System (Promega, 
Madison, USA) and a Veritas microplate luminometer (Turner Biosystems, Sunnyvale 
CA, USA). The values obtained were normalised to expression of β-galactosidase, 
which was measured using the GalactoStar Assay Kit from Tropix (Bedford MA, 
USA). 
 
For transrepression assays, the COS-1 cell line was seeded into 24-well plates at a 
density of 5 x 104 cells per well. The following day the cells were transfected with 
0.045 µg of pSVARo, 0.09 µg of 5xNFκB-luc or 7xAP-1-luc plasmids, and 0.0225 µg 
of pCMV-β-Gal using the FuGENE6 transfection reagent (Roche Molecular 
Biochemicals) in accordance with the manufacturer’s instructions. Twenty four hours 
after transfection the cells were washed with PBS and incubated with serum-free 
medium containing 10 ng/ml PMA and 1 µM of the test compounds. Luciferase 
activity in the lysate was measured as described above. The values obtained were 
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normalised to expression of β-galactosidase, which was measured using the 
GalactoStar Assay Kit from Tropix (Bedford MA, USA). The reported values are 
averages of at least three independent experiments, with each condition performed in 
triplicate. Where normalising to β-galactosidase is absent, transfection efficiency was 
previously determined to be highly reproducible. The reported values are averages of 
at least three independent experiments, with each condition performed in triplicate.  
 
Mammalian two-hybrid assays 
The COS-1 cell line was cultured in DMEM as described above. The cells were 
plated at a density of 5 x 104 cells/well in 24-well plates. Cells were transfected using 
FuGENE6 transfection reagent (Roche Molecular Biochemicals, South Africa) in 
accordance with the manufacturer’s instructions. A total of 0.868 µg DNA was 
transfected per well as follows: 0.067 µg pSNATCH II-hAR (hAR-NTD), 0.067 µg of 
pSG5-hAR (DBD-LBD), 0.067 µg of pCMVβ-gal and 0.667 µg of pTAT-GRE-E1b-luc 
or 4xSC ARE1.2-luc or 4xSLP HRE2-luc, respectively. Twenty four hours after 
transfection the cells were washed with PBS and incubated for 24 hours with serum-
free medium containing increasing concentrations of the test compounds. Luciferase 
activity in the lysate was measured as described above. 
 
Data manipulation and statistical analysis 
The Graph Pad Prism software was used for data manipulations, graphical 
representations, and statistical analysis. One-way ANOVA analysis of variance and 
Bonferroni (compares all pairs of columns) posttests were used for statistical 
analysis. Non-linear regression and one site competition were used in whole cell 
binding assays, whereas non-linear regression and sigmoidal dose response were 
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used in transactivation (antagonist) experiments. Statistical significance of 
differences is indicated by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001, 
respectively, whereas no statistical significance is indicated by p>0.05. The letters 
a,b,c etc. are also used to denote statistically significant differences, where all those 
values which differ significantly from others, are assigned a different letter.  
 
Results 
MPA and NET-A have a similar binding affinity for the AR 
The COS-1 cell line was transiently transfected with a full-length hAR expression 
vector, and in order to obtain accurate Kd and Ki values, a range of experiments were 
first performed to establish two important parameters, namely concentration of 
radiolabelled ligand to use and time to reach equilibrium. An explanation for the 
relevance of these parameters can be found in Appendix D1. An appropriate 
concentration of [3H]-mibolerone ([3H]-MIB), in the range two to ten times lower than 
the EC50, was established as 0.2 nM (Appendix B1), and the incubation time required 
for equilibrium to be reached for 0.2 nM [3H]-MIB binding to the AR was determined 
as sixteen hours (Appendix B2). Homologous/heterologous curves with unlabelled 
steroids show that R1881, DHT, Prog, MPA, NET-A and RU486 are able to compete 
with [3H]-MIB for binding to the AR (figure 3). The curves for all the test compounds 
are consistent with competitive binding to the same site as mibolerone (MIB). These 
homologous/heterologous displacement curves were analysed and the Kd value 
determined for MIB, while Ki values were determined for R1881, DHT, Prog, MPA, 
NET-A and RU486 (Table 1). Both the synthetic androgens, MIB (Kd = 0.38 ± 0.15 
nM) and R1881 (0.217 ± 0.62 nM), have similar affinity for the AR, which is 
significantly higher than that of DHT, MPA and NET-A Prog (p<0.01). The results 
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indicate that MPA (Ki = 19.4 ± 0.04 nM), NET-A (Ki = 21.9 ± 0.10 nM) and Prog (36.6 
± 0.20 nM) bind to the AR with a similar affinity as that of the natural androgen DHT 
(Ki = 29.4 ± 0.01 nM). DHT showed a 77-fold lower affinity for the AR than MIB 
whereas MPA and NET-A displayed a 51-fold and 57-fold lower affinity than MIB, 
respectively (Table 1). Interestingly, RU486 has a higher affinity for the AR than the 
other progestins, and the natural androgen, DHT. It displays an approximately 10-fold 
lower affinity than MIB and R1881, compared to about a 100-fold lower affinity shown 
by the other ligands in this study. 
 
MPA and NET-A display androgen agonist activity that is similar to that of DHT 
for transactivation 
The finding that both Prog, MPA and NET-A bind to the AR with the same affinity as 
the natural androgen, DHT, raised the question whether once bound, these three 
ligands could activate the AR in a manner similar to DHT. We thus investigated the 
relative agonist and antagonist potency and efficacy of the test compounds for 
transcriptional regulation via the classical androgen response element (ARE). Due to 
the high degree of structural and functional conservation within the DBD of steroid 
receptors, most steroid receptors can bind the same DNA response element 
(reviewed in Beato, 1989). The classical ARE thus also serves as a response 
element for the GR, PR and MR (reviewed in Beato, 1989), and is then termed 
glucocorticoid response element (GRE), progesterone response element (PRE) and 
mineralocorticoid response element (MRE), respectively. Thus, the COS-1 cell line 
was transiently transfected with a glucocorticoid response element (GRE)-driven 
reporter construct containing two copies of the rat TAT-GRE-luc (a promoter-reporter 
construct containing a simple promoter linked to the luciferase reporter gene, and 
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referred to as the “classical” ARE), a full-length hAR expression vector, as well as the 
pCMV-β-gal expression vector. The cells were subsequently exposed to increasing 
amounts of MIB, R1881, DHT, Prog, MPA, NET-A or RU486. Figure 4A clearly 
indicates that MPA and NET-A have similar, and relatively strong, agonist potencies 
compared to each other, and to the natural androgen DHT, for the AR. Although the 
levels of maximal induction displayed by DHT appear to be higher than that of MPA 
and NET-A, this difference is not statistically significant (p>0.05), indicating that these 
compounds probably have a similar efficacy for agonist activity via the hAR. The 
transcriptional activity of these compounds in the absence of transfected receptor 
was negligible (Appendix D3). The potencies and efficacies of these compounds for 
the AR are summarised in Table 2. Although Prog has a similar binding affinity as 
DHT, MPA and NET-A, it displays relatively weak agonist activity (EC50 = 601.2 nM, 
with maximal induction of ~34%). Similarly, despite the high binding affinity of RU486, 
it displays very weak agonist activity. In addition, we confirmed the previously 
reported AR antagonist activity of RU486 (Kemppainen et al., 1992; Song et al., 
2004), and Prog (Fuhrmann et al., 1996; Kemppainen et al., 1999) (figure 4B). The 
determined antagonist potency (EC50 values) for RU486 (29.5 nM ± 0.12) and Prog 
(12.3 nM ± 0.17) were not significantly different (p>0.05). Thus, although Prog, MPA 
and NET-A bind to the AR with similar binding affinity, MPA and NET-A differ from 
Prog in their transcriptional activity.  
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Figure 3: MPA and NET-A both compete with [3H]-mibolerone ([3H]-MIB) for binding to the 
human androgen receptor. The COS-1 cell line was transiently transfected with the pSVARo and 
pCMV-β-gal expression vectors. Twenty-four hours later the cells were incubated with 0.2 nM [3H]-MIB 
in the absence and presence of increasing concentrations of either unlabelled mibolerone (MIB) (), 
R1881 (▼), DHT (▲), Prog (♦), MPA (●), NET-A (○) or RU486 (◊) for 16 hours. Results are plotted as 
% specific binding where total specific binding of [3H]-MIB in the absence of unlabelled ligand is set as 
100% and binding of unlabelled ligand is set as a % binding relative to MIB, after normalization for 
transfection efficiency with β-galactosidase levels. Competition for binding is illustrated by the total 
percentage of [3H]-mibolerone bound to the hAR. Result shown is representative of three independent 
experiments with each condition performed in triplicate (±SEM). 
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Table 1: Relative binding affinities of the ligands for the AR (Kd / Ki values)a 
Ligand Kd or Ki (M) ± SEM Fold differences 
MIB 3.83 x 10-10 ± 0.15 1 
R1881 2.17 x 10-10 ± 0.62 0.57 
DHT 2.94 x 10-8 ± 0.01 76.76 
Prog 3.66 x 10-8 ± 0.20 95.56 
MPA 1.94 x 10-8 ± 0.04 50.65 
NET-A 2.19 x 10-8 ± 0.10 57.18 
RU486 
 
4.66 x 10-9 ± 0.55 12.17 
 
a
 Binding data of three independent experiments were analyzed using GraphPad Prism software, with 
nonlinear regression and assuming competitive binding to one class of binding sites. Ki values ± SEM 
for R1881, DHT, Prog, MPA, NET-A and RU486 were determined from the heterologous displacement 
curves using the EC50s, Kd ± SEM for MIB, and concentration of radiolabelled MIB, according to the 
method of Cheng and Prusoff (1973) that is described in Appendix D1. Fold differences calculated by 
setting the Kd for MIB in M as 1, and expressing the Ki in M for the other ligands as a fraction thereof. 
Statistical analysis of the Kd / Ki values using Bonferroni (compares all pairs of columns) posttests, 
indicated the following: MIB vs. DHT (p< 0.01); MIB vs. DHT, MPA, NET-A (p< 0.01); MIB vs. Prog 
(p<0.001); MIB vs. RU486, R1881 (p>0.05); DHT vs. Prog, MPA, NET-A, RU486 (p>0.05); DHT vs. 
R1881 (p<0.01); MPA vs. NET-A (p>0.05); MPA, NET-A vs. RU486 )p>0.05); MPA, NET-A vs. R1881 
(p<0.01); Prog vs. MPA, NET-A, RU486 (p>0.05); Prog vs. R1881 (p<0.01); RU486 vs. R1881 
(p>0.05).  
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Figure 4: (A) MPA and NET-A display androgen agonist activity similar to DHT. The COS-1 cell 
line was transiently transfected with the pTAT-GRE-E1b-luc reporter, pSVARo and pCMV-β-
galactosidase expression vectors. Subsequently, the cells were incubated in the absence and 
presence of increasing concentrations of either mibolerone (MIB) (), DHT (), R1881 (), Prog (♦), 
MPA (), NET-A (○) or RU486 (◊) for 24 hours. Induction is shown as % luciferase (luc) activity 
expressed in relative light units (rlu). Result shown is one representative figure with each condition 
performed in triplicate (±SEM). (B) Prog and RU486 display androgen antagonist activity. The 
COS-1 cell line was transiently transfected as above. Subsequently, the cells were incubated with 0.1 
nM MIB alone (100%) or with increasing concentrations of Prog (♦) or RU486 (◊) for 24 hours. Result 
shown is the average of at least four independent experiments with each condition performed in 
triplicate (±SEM).  
 
Table 2: Potencies (agonist and antagonist activity) for transactivation of the 
ligands via the AR expressed as EC50 in nM, as well as efficacy (maximal 
agonist activity expressed as %.b  
 
b
 Data from experiments depicted in figure 4A and 4B were analysed to obtain EC50 ± SEM values, 
and figure 4A to obtain maximal values ± SEM for each test compound. Maximal values are expressed 
as a percentage of 10-5 MIB=100%. N/A = no activity up to 10-5 M test compound. Statistical analysis 
of the EC50 values for agonist activity, indicated MIB vs. DHT, MPA and NET-A (p< 0.001); DHT vs. 
MPA, NET-A (p>0.05); MPA vs. NET-A (p>0.05), whereas there were no statistically significant 
differences observed for the MAX values. 
Agonist activity Antagonist activity 
LIGAND 
EC50 (M) ± SEM MAX (%) ± SEM EC50 (M) ± SEM 
MIB 1.318 x 10-12 ± 0.19 100 ± 0.0 - 
DHT 1.416 x 10-9 ± 0.18 98.77 ± 7.19 - 
R1881 5.012 x 10-11 ± 0.02 90.46 ± 7.62 - 
Prog N/A 33.89 ± 6.45 1.23 x 10-8 ± 0.17 
MPA 1.365 x 10-9 ± 0.18 86.54 ± 7.56 - 
NET-A 2.333 x 10-9 ± 0.19 78.37 ± 5.82 - 
RU486 N/A 6.97 ± 0.35 2.95 x 10-8 ± 0.12 
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MPA, but not NET-A, induces the ligand-dependent interaction between the 
amino- and carboxyl-terminals of the androgen receptor in a promoter-
dependent manner 
The functional, in vivo, androgen-dependent interaction between the NTD and LBD of 
the AR, the so-called N/C-interaction, has been well-described for the AR (Langley et 
al., 1995; Doesburg et al., 1997; Kemppainen et al., 1999; He et al., 2000). It has 
been shown that the AR N/C-interaction is important for agonist activity for 
transactivation via the AR (He and Wilson, 2002). Here we used a mammalian two-
hybrid assay to compare the potential of MPA and NET-A to induce the N/C-
interaction of the hAR. The COS-1 cell line was co-transfected with a GRE-driven 
reporter construct, an expression vector encoding the DBD and LBD of the hAR, as 
well as an expression vector encoding the NTD of the hAR fused to a VP16 
activation domain.  
 
In figure 5A we show that NET-A has the ability to induce the N/C-interaction of the 
AR on the classical ARE with an efficacy similar to R1881, but weaker than MIB and 
DHT. Although DHT, MPA and NET-A have similar potencies for transactivation on 
the classical ARE, MPA is not able to induce the N/C-interaction of the AR. To 
investigate whether the inability of MPA to induce the N/C-interaction may depend on 
the DNA binding sequence, reporter assays were performed in parallel using the 
classical ARE construct (pTAT-GRE-E1b-luc) as well as constructs containing two 
AR-specific androgen response elements (AREs), 4xSC-ARE1.2 and 4xSLP-HRE2 
(Schauwaers et al., 2007). These binding motifs, which resemble a direct rather than 
a palindromic repeat of the 5’-TGTTCT-3’ hexamer are termed AR-specific, as the 
AR but not GR is able to transactivate via these DNA motifs. Dose response curves 
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for all the ligands on the three individual promoters were plotted (figure 5), and the 
efficacies for each ligand (maximal response at 10 µM), are shown in figure 6 (A-C), 
and summarized in Table 3. The results indicate that when using the AR-specific 
sequences, the ability of all the ligands to induce the AR N/C-interaction increases. 
For example, MPA’s ability increases from 7% to 36% (SLP-HRE2) and 59% (SC-
ARE1.2), respectively. This suggests that MPA can induce the AR N/C-interaction in 
a promoter-specific way. In contrast, NET-A induces the AR N/C-interaction 
regardless of promoter context. This suggests that the induction of the AR N/C-
interaction by MPA is promoter-dependent, while this is not true for NET-A. 
Interestingly, DHT, MPA and NET-A also have similar potencies for transactivation on 
the AR-specific SC-ARE1.2 promoter (figure 7). 
 
As it is thought that the androgenic agonist potency of a ligand is dependent on the 
ability of the AR to induce the N/C-interaction (Alen et al., 1999; Berrevoets et al., 
1998, He et al., 2000), we correlated the agonist potencies (EC50 values) for 
transactivation on the classical ARE with the potencies for N/C-interaction on the 
same promoter. The results indicate a positive linear correlation between potency of 
N/C interaction and potency for transactivation, indicating a good (r2 > 0.59) and 
significant (p<0.05) correlation (figure 8A). In contrast, no linear correlation was 
detected between efficacy (maximal responses) for transactivation and efficacy for 
N/C-interaction (figure 8B), indicating that the two processes are unrelated. This 
suggests that the induction of the AR N/C interaction by the ligands in this study does 
not determine efficacy for transactivation.  
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Figure 5: MPA induction of the AR N/C-interaction is promoter dependent. COS-1 cells were 
transiently transfected with the pSG5-hAR(DBD-LBD), the pSNATCH-II(hAR-NTD) and the pCMV-β-
galactosidase expression vectors and (A) pTAT-GRE-E1b-luc or (B) 4xSLP HRE2-luc or (C) 4xSC 
ARE1.2-luc. Cells were incubated in the absence and presence of increasing concentrations of either 
mibolerone (MIB), DHT, R1881, Prog, MPA, or NET A for 24 hours. Induction is shown as % luciferase 
(luc) activity relative to MIB=100%. Result shown is one representative figure of three independent 
experiments with each condition performed in triplicate (±SEM). Higher basal activity is characteristic 
of these ARE-specifc constructs (Frank Claessens, personal communication).  
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Figure 6: In contrast to DHT and NET-A, MPA does not induce the ligand-dependent N/C-
interaction of the hAR on a pTAT-GRE. The COS-1 cell line was transiently transfected with the 
pSG5-hAR(DBD-LBD), the pSNATCH-II(hAR-NTD) and the pCMV-β-galactosidase expression vectors 
and (A) pTAT-GRE-E1b-luc or (B) 4xSC ARE1.2-luc or (C) 4xSLP HRE2-luc. Cells were subsequently 
exposed to 10 µM of MIB, DHT, R1881, Prog, MPA, NET-A or RU486 for 24 hours. Results are 
averages of at least three independent experiments with each condition performed in triplicate 
(±SEM). 
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Table 3: Maximal AR N/C-induction (at 10 µM of each ligand).c 
 
cRelative responses for AR transactivation on pTAT-GRE-E1b-luc and for induction of AR N/C-
interaction on pTAT-GRE-E1b-luc or 4xSLP-HRE2 or 4xSC-ARE 1.2-luc reporter plasmids at 10 µM 
ligand, were determined in the transiently transfected COS-1 cell line. Values were obtained from at 
least three independent experiments, each performed in triplicate, after which the ± SEM was 
calculated for each ligand. MIB activity was taken as 100% and all other values are expressed as a % 
relative to this.  
 
MAXIMAL N/C-INDUCTION (%) ± SEM 
 
 
LIGAND 
(Classical) 
 
pTAT-GRE-E1b 
(AR-selective) 
 
4xSLP-HRE2 
(AR-selective) 
 
4xSC-ARE1.2 
 
MIB 
 
100 ± 0.0 
 
100 ± 0.0 
 
100 ± 0.0 
 
DHT 
 
128.70 ± 7.72 
 
136.0 ± 18.37 
 
147.2 ± 1.54 
 
R1881 
 
47.97 ± 7.42 
 
74.6 ± 5.31 
 
105.9 ± 22.73 
 
Prog 
 
13.51 ± 2.0 
 
34.41 ± 1.19 
 
78.77 ± 19.2 
 
MPA 
 
7.19 ± 0.10 
 
35.89 ± 3.30 
 
58.82 ± 11.58 
 
NET-A 
 
41.6 ± 4.10 
 
57.59 ± 4.62 
 
88.73 ± 25.48 
 
RU486 
 
0.81 ± 0.16 
 
16.35 ± 3.67 
 
62.19 ± 14.03 
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Figure 7: MPA and NET-A display androgen agonist activity similar to DHT on an AR-specific 
ARE. COS-1 cells were transiently transfected with the 4xSC ARE1.2-luc reporter, pSVARo and 
pCMV-β-galactosidase expression vectors. Subsequently, the cells were incubated in the absence and 
presence of increasing concentrations of either mibolerone (MIB) (), DHT (), Prog (♦), MPA (), 
RU486 (◊), or NET-A (○) for 24 hours. Induction is shown as % luciferase (luc) activity expressed in 
relative light units (rlu). Result shown is one representative figure with each condition performed in 
triplicate (±SEM).  
 
MPA and NET-A display similar androgenic properties for transrepression. 
Having shown that both MPA and NET-A can transactivate an ARE-containing 
promoter via the AR, albeit via a different mechanism, we were interested in 
comparing the androgenic properties of MPA and NET-A for transrepression. We 
thus evaluated the transrepressive ability of MPA and NET-A via the AR by 
transfecting the COS-1 cell line with luciferase reporter plasmids linked downstream 
of either five copies of a nuclear factor kappa-B (NFĸB) site or seven copies of an 
activator protein-1 (AP-1) site, both in the absence and presence of a transfected AR 
expression vector (Appendix B3). Cells were stimulated with phorbol 12-myristate 13-
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acetate (PMA) and incubated for 24 hours with 1 µM of each test compound. To 
correct for any low level responses via endogenous steroid receptors by the different 
test compounds, the response without AR was subtracted from the response with 
transfected AR. The resulting plots in figure 9, show the AR-dependent repression 
calculated as a percentage of the MIB-dependent repression via the AR 
(MIB=100%). 
 
Using the NFĸB promoter-reporter construct, results showed greatest, and similar, 
transrepression of PMA-mediated induction with DHT, MPA and NET-A, whereas 
Prog and RU486 showed virtually no repression (figure 9A). These responses are 
similar to those seen on the synthetic ARE promoter-reporter construct. In contrast to 
similar to responses by MPA and NET-A on the synthetic classical ARE and NFĸB 
promoter constructs, AR-mediated repression on the AP-1 promoter-reporter 
construct (figure 9B) by both MPA and NET-A, was significantly different from that of 
DHT (summarized in Table 4). In addition, AR-mediated maximal repression of the 
AP-1 promoter-reporter construct by Prog and RU486 was 59% and 38% 
respectively, while on the NFĸB promoter-reporter construct, it was only 7% and 13% 
respectively. This indicates promoter-specific repression by Prog and RU486. 
Interestingly, although the repression by MPA and NET-A on the NFκB promoter 
reporter is similar to MIB and DHT, it is significantly different to DHT on the AP-1 
promoter-reporter. In summary, the transrepressive activities of Prog and RU486 are 
similar, while the transrepressive activities of Prog are significantly different to MPA 
and NET on both promoters.  
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Figure 8: (A) Correlation analysis of potency for GRE transactivation versus GRE N/C- 
interaction. Relative potencies for transactivation (Table 2) were compared to relative potencies for 
N/C-interaction as determined by mammalian two hybrid assay (figure 5A) using Pearson correlations. 
Results showed p<0.05 and r2=0.59. (B) Correlation analysis for efficacy for GRE transactivation 
versus GRE N/C- interaction. Relative efficacies for transactivation (Table 2) were compared to 
relative efficacies for N/C-interaction as determined by mammalian two hybrid assay (figure 5A) using 
Pearson correlations. Results showed no statistical significance and r2=0.49. 
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Figure 9: Transrepression activity via the hAR. The COS-1 cell line was transiently transfected with 
pSVARo, pCMV-β-galactosidase expression vectors and (A) NFĸB- or (B) AP-1-containing promoter-
luciferase reporter constructs. Subsequently, the cells were stimulated with PMA and incubated with 1 
µM of either MIB, DHT, Prog, MPA, NET-A or RU486 for 24 hours. Once the repressive abilities of the 
test compounds were determined, in the absence and presence of transfected AR (Appendix B3), 
repression in the absence of AR was subtracted from the repression in the presence of transfected 
AR. The resulting plots show repression of the individual ligands calculated as a percentage of 
repression by MIB (100%), thus indicate the transrepression dependent on the expression of AR. 
Result shown is the average of three independent experiments with each condition performed in 
triplicate (±SEM). 
 
Table 4: Relative efficacies for transactivation and transrepression via the AR 
at 1 µM ligandd 
 
Ligand 
GRE (from Table 2) 
Relative response 
NFĸB 
Relative response 
AP-1 
Relative response 
 
MIB 
 
100 100 100 
 
DHT 
 
108 ± 11 99 ± 12 108 ± 12 
 
Prog 
 
13 ± 2 7 ± 4 59 ± 8 
 
MPA 
 
78 ± 3 84 ± 10 79 ± 3 
 
NET-A 
 
73 ± 7 85 ± 16 87 ± 4 
 
RU486 
 
12 ± 2 13 ± 9 38 ± 12 
d Relative responses for transactivation via pTAT-GRE-E1b-luc and for transrepression via either 
NFĸB or AP-1-luc reporter plasmids at 1 µM ligand, were determined in a transiently transfected COS-
1 cell line. Values were obtained from at least three independent experiments, each performed in 
triplicate, after which the ± SEM was calculated for each ligand. MIB activity was taken as 100% and 
all other values are expressed as a % relative to this. 
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DISCUSSION 
MPA and NET-A bind with similar relatively affinity as DHT to the hAR 
To the best of our knowledge, a detailed comparison of the relative equilibrium 
dissociation constants, and relative efficacy for transactivation and transrepression, 
by Prog, MPA and NET-A (or NET) for the AR, in the same system, has not been 
reported previously. We show that these compounds bind to the same site as that of 
MIB, and that Prog, MPA and NET-A bind to the AR with a similar affinity to that of 
DHT, the endogenous ligand of the AR (figure 3), and that in the context of this series 
of experiments, there is no significant difference in the binding affinities of DHT, Prog, 
MPA and NET-A for the hAR (Table 1). Moreover, we determined accurate 
equilibrium dissociation constants for these compounds. 
 
The determined Kd / Ki of MIB and R1881 for the AR in our system (Kd / Ki = 0.383 
and 0.22 nM, respectively), is similar to that reported in a previous study for MIB 
(0.53 nM; Schilling et al., 1984) and R1881 (0.6 nM; Bonne and Raynaud, 1975). 
Consistent with our results, a study by Kemppainen et al. (1999), also in the COS-1 
cell line, showed that DHT and MPA have similar relative binding affinities. We also 
demonstrate, in accordance with Kemppainen and co-workers, that Prog binds with a 
similar relative binding affinity to the AR as DHT and MPA (Kemppainen et al., 1999). 
In addition, a previous report in intact MCF-7 cells, showing that MPA and NET bind 
with a similar relative affinity to the endogenously expressed AR (Bergink et al., 1983 
and references therein), is in agreement with our results. In contrast, a study by 
Hackenberg et al. (1993) determined a Kd of MPA for the AR as 3.6 nM in the MFM-
223 human mammary cancer cell line compared with a Kd of 0.18 nM for 
dihydrotestosterone (DHT). In addition, the Kd / Ki values reported in the literature for 
 143 
DHT of 0.5 nM (Zhao et al., 2000) differ from the values that we determined for DHT 
(Ki = 29.4 nM). As the cell lines used in the studies by Hackenberg et al. (1993) and 
Zhao et al. (2000), breast- and prostate cancer cells, respectively, also express 
steroid receptors other than the AR, to which these progestins may bind, the 
possibility exists that the results reported in these studies may be inaccurate. Thus, 
to determine accurate Kd values of different ligands, it is best to use a system like the 
one in the present study, where the AR was overexpressed in COS-1 cells, with 
negligible levels of endogenous steroid receptors present. This allows a direct 
comparison of the relative binding affinities of ligands for the AR within a system 
where only the AR is present. Thus, the Ki-values of these compounds for the AR 
reported in the present study may better reflect the relative affinities of these 
compounds.  
 
To our knowledge, this study is the first to establish accurate Ki values for MPA, NET-
A and RU486 towards the human AR. Interestingly, RU486 has a higher affinity for 
the AR than all the other progestins used in our study, including DHT, but lower than 
MIB and R1881. Song et al. (2004) previously reported that the relative binding 
affinities of R1881 and RU486 differ by a factor of 12, and by 32 from data from 
Kemppainen et al. (2002). Our result indicates a factor of 22, which is similar to the 
result of Kemppainen et al. (2002). Taken together, our findings show that Prog and 
the synthetic progestins, MPA, NET-A and RU486, all bind the AR with relatively high 
affinity.  
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Unlike Prog, MPA and NET-A are potent agonists for the AR 
We subsequently demonstrated that, although Prog, MPA, NET-A and DHT bound 
the AR with similar binding affinities, Prog showed only weak partial agonist activity 
(figure 4A). In contrast, both MPA and NET-A are potent and efficacious AR agonists, 
with activity comparable to that of DHT (figure 4A). Notably, DHT, MPA and NET-A 
have a lower potency and efficacy in comparison to MIB. Kemppainen et al., 1999, 
showed that 100-fold more MPA is required to achieve the same agonist activity as 
DHT, MIB and R1881. This AR agonist activity was determined in the CV-1 cell line 
transiently transfected with a mouse mammary tumor virus (MMTV)-luciferase 
reporter and full-length hAR expression vectors. In a separate study, using the 
Chinese hamster ovary (CHO) cell line stably transfected with the MMTV-luciferase 
reporter and hAR expression vectors, the relative agonistic activity of NET for the AR 
was found to be only about 1% of that of DHT (Deckers et al., 2000). Thus, in these 
two aforementioned studies, due to the fact that MPA and NET both required 100-
fold greater concentrations to achieve similar agonist activity as DHT, MPA was 
described as a weak AR agonist whereas NET was said to have low androgenic 
activity. The discrepancies between our results and the aforementioned studies could 
be attributed to the different systems in which the agonist activities were measured. If 
this is the case, then contributing factors could be the cell line used and/or the 
sequence or context of the hormone response element used in the reporter 
construct. In addition, a very recent study also performed in the COS-1 cell line using 
a PRE2-tk-luc construct, reported EC50 values for Prog, MPA and NET-A of 
approximately 3000, 56.8 and 19.6 nM, respectively (Sasagawa et al., 2008), while 
we determined values of 601, 1.37 and 2.33 nM, respectively.  
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In accordance with our results indicating that MPA and DHT are equally potent AR 
agonists, a comparative study by Ghatge and co-workers (2005) recently showed 
that MPA is as potent as DHT in regulating AR-mediated gene expression in human 
breast cancer cell lines (Ghatge et al., 2005). Furthermore, we demonstrate that Prog 
and RU486 are potent antagonists of MIB induced AR-mediated transcription (figure 
4B), with minimal agonist activity (figure 4A). Similarly, Prog (Kemppainen et al., 
1999; Sasagawa et al., 2008) and RU486 (Song et al., 2004) have previously been 
reported to antagonize DHT-induced AR- mediated transcription. In contrast, MPA 
and NET-A did not antagonize MIB-induced AR-mediated transcription. Overall, 
these results indicate that Prog displays weak androgenic activity, while the synthetic 
progestins, MPA and NET-A, display potent androgenic activities similar to the 
natural androgen, DHT.  In addition, Prog has anti-androgenic activities, while the 
synthetic progestins do not. Interestingly, the synthetic progestin, RU486, has similar 
activities as Prog. 
 
MPA and NET-A activate the AR by different mechanisms 
A number of parameters contribute to the potency of a ligand such as its affinity for 
the receptor, rate of nuclear translocation, elicited receptor conformation, stabilisation 
of receptor-ligand complex, the recruitment of coregulators and transcription 
machinery, as well as DNA binding and rate of ligand dissociation. As we had already 
addressed the binding of ligands to the AR, we next investigated the effect of all the 
ligands in our study on another parameter. Considering that the N/C-interaction of the 
AR is well-described, we decided to investigate the N/C-interaction of the AR in 
response to ligand, as a measure of receptor conformation and stabilisation. To the 
best of our knowledge, the capability of MPA (Kemppainnen et al., 1999), but not 
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NET-A, to induce the N/C-interaction of the AR has been previously investigated. Our 
results indicate that MPA, in contrast to NET-A and DHT, does not induce the N/C-
interaction on a classical ARE-promoter (figure 6A), suggesting that MPA and NET-A 
activate the AR by different mechanisms. This difference between MPA and NET in 
inducing the AR N/C-interaction was first observed by Tamzin Tanner in the Hapgood 
laboratory (MSc thesis). These results suggest that the conformation of the AR 
attained by the N/C-interaction is not imperative to render the receptor 
transcriptionally active, since MPA still has the ability to activate an androgen-
responsive reporter. When comparing the ability of the two synthetic progestins to 
induce the AR N/C-interaction, it would appear that NET-A displays behaviour that is 
more characteristic of classical strong androgen agonists. An explanation for this 
difference in induction of AR N/C-interaction, could be the fact that MPA and NET-A 
are structurally different, with MPA being a 21-carbon series steroid, and therefore 
considered a true progestin, whereas NET-A is a 19-carbon series steroid structurally 
more closely related to the androgens. This difference in the structures could 
possibly account for the more typical androgenic profile of NET-A.  
 
The crystal structure analysis of the AR bound to DHT showed a conformational 
arrangement of the ligand binding domain (LBD), and the formation of the conserved 
cleft, AF-2, which is critical for interaction with coregulators (Sack et al., 2001). 
Recently, in a review by Birrell and co-workers (Birrell et al., 2007), a molecular 
model was presented, in which MPA forces the displacement of a critical amino acid 
residue, Phe874, in the AR, thereby disrupting this well-defined AF-2 cleft observed 
for the DHT-bound receptor. The authors hypothesized that this could cause MPA 
and DHT to have differing effects on AR-regulated gene expression. A recent study 
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of AR-regulated genes in breast cancer cell lines supports this hypothesis (Ghatge et 
al., 2005). This raises the possibility that NET-A-bound AR may have a similar 
conformation as the DHT-bound AR, and that MPA and NET-A, could therefore have 
divergent effects on AR-regulated genes.  
 
The ability of a compound to bind to the AR but not induce the N/C-interaction has 
previously been reported for the AR antagonists hydroxyflutamide and cyproterone 
acetate (Langley et al., 1995; Kemppainen et al., 1999). In accordance with these 
previously reported results, the two antagonists in our system, Prog and RU486 (see 
figure 8B), also did not induce the N/C-interaction of the AR (Kemppainen et al., 
1999; Song et al., 2004). Consistent with the previous finding that the degree of 
agonist potency at low physiological concentrations parallels the ability of a 
compound to induce the N/C-interaction (Kemppainen et al., 1999), we show that 
potency for transactivation via a synthetic GRE correlates with the potency for the 
induction of N/C-interaction (r2 = 0.59; p<0.05) for most of the ligands (figure 8A), 
barring MPA. Correlation of efficacy for transactivation versus efficacy for induction of 
N/C-interaction, showed no statistical significance (r2 = 0.49). In addition, it was 
previously reported that MPA is a potent antagonist of a DHT-induced N/C-interaction 
(Kemppainen et al., 1999; Birrell et al., 2007). This result was corroborated in our lab 
(MSc thesis of Tamzin Tanner), while we found that NET-A could not antagonize the 
DHT-induced N/C-interaction (Appendix B5), highlighting a potentially significant 
difference in the mechanism of action of the two progestins. Altogether, the findings 
indicate that Prog, MPA and NET-A activate the AR by different mechanisms. 
Notably, the mechanism of AR activation by RU486 is comparable to Prog. 
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Induction of the AR N/C-interaction is promoter-dependent 
The steroid receptor family has a high degree of structural and functional 
conservation. Thus, it is not surprising that they can recognize virtually the same 
DNA motifs, e.g. some androgen response elements (AREs), also function as 
glucocorticoid response elements (GREs) or progesterone response elements 
(PREs), or vice versa (Evans, 1988; Beato, 1989; Mangelsdorf et al., 1995). 
However, the AR can also interact with binding motifs that resemble direct rather 
than palindromic repeats of the 5’-TGTTCT-3’-hexamer. These motifs are termed AR-
specific, and have been described in several androgen-responsive genes, such as 
the sc-ARE1.2 in the far upstream enhancer of the human secretory component (SC) 
gene (Haelens et al., 1999), and the SLP-HRE2 from the upstream enhancer of the 
mouse sex-limited (SLP) gene (Adler et al., 1991). In addition, it has been shown that 
the AR N/C interaction is important for AR activation of the promoters of some 
androgen-regulated genes, but not others (He et al., 2002). We thus hypothesized 
that the inability of MPA to induce the N/C-interaction is dependent on the nature of 
the response element i.e. the DNA binding sequence. To this end, we tested whether 
MPA could induce the ligand-dependent N/C-interaction using two androgen-
selective AREs. We observed an overall increase in the ability of all ligands to 
increase the AR N/C-interaction on both promoters. These results support our 
hypothesis that the induction of the N/C-interaction by MPA is promoter-dependent 
(figure 5A-5C and figure 6A-C). He and co-workers (2002b) have previously shown 
that the AR N/C-interaction is important for some androgen-regulated promoters, but 
not others. Our finding that NET-A shows similar potency and efficacy to MPA in 
inducing transcription via the AR, but has a different effect on the N/C-interaction, 
even on selective AREs, suggests that the N/C-interaction is not essential for 
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transactivation activity on these synthetic promoters. This has previously been 
suggested by other groups (Shen et al., 2005). Other factors such as the dissociation 
of heat-shock proteins, nuclear translocation, DNA binding affinity and rate of ligand 
dissociation may also play a role in the transactivation activity. 
 
MPA and NET-A display similar androgenic properties for transrepression on 
synthetic promoters  
Many steroid receptors have been suggested to exert inhibitory effects on 
inflammatory response genes (transrepression) through direct interactions with 
transcription factors such as NFĸB and AP-1, thereby attenuating inflammatory 
responses. NFĸB and AP-1 have been shown to be crucial for the regulation of the 
inflammatory process through their direct activation of proinflammatory cytokines and 
chemokines (Karin, 2009; Xiao and Ghosh, 2005). By far the most best-studied in 
terms of transrepression is the GR (De Bosscher et al., 2003; Koubovec et al., 2005), 
but transrepression has also been reported for the ER (reviewed by Pascual and 
Glass, 2006). Interestingly, not much is known about transrepression mediated via 
the AR. On these grounds, we investigated the comparative effects of all the ligands 
on transrepression via both NFĸB and AP-1 on synthetic promoter-reporter 
constructs.  
 
The results of the transrepression assays (at 1 µM of each ligand) (figure 9A and 9B) 
as well as the effects observed for transactivation (figure 4A), are summarized in 
Table 4. Similar relative activity of the ligands on all three promoters was observed. 
Notably, both the weak partial agonist/potent antagonists, Prog and RU486, could 
transrepress more effectively via the AP-1 promoter than via NFκB. This increase in 
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transrepression on AP-1 via the AR, at least for Prog, was also observed for this 
ligand on the same promoter via the GR (Ronacher et al., 2009). Briefly, unlike Prog, 
the transrepressive activities of MPA and NET-A via the AR is similar to the natural 
androgen, DHT. 
 
Conclusion 
Although Prog, MPA and NET-A are structurally similar, relatively minor differences 
can cause profound alterations in their biochemical activity (Darney, 1995). The 
findings of our study highlight the fact that, although these compounds are designed 
to mimic the biological activity of natural Prog, they do not act similarly to Prog at the 
molecular level. Moreover, the ability of MPA and NET-A to exert similar effects 
through the AR, but via different mechanisms, implies that such compounds could 
then also exhibit very different effects via different steroid receptors in some target 
tissue. Additionally, MPA could also exert different effects on endogenous genes via 
the AR, in the same cell. Indeed, we have observed such differential effects by MPA 
and NET-A on the RANTES gene in a human ectocervical cell line (Ect1/E6E7) 
(Chapter 2).  
 
This finding that MPA acts differently to NET-A, and moreover does not mimic the 
effects of Prog, may have important implications for women’s health. By elucidating 
the mechanisms by which MPA and NET-A exert their effects, we could facilitate 
improved drug design for contraceptive and HRT agents, as well as help to unravel 
molecular mechanisms by which the compounds exert their side effects. 
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Abstract 
Progesterone (Prog) has a high affinity for the mineralocorticoid receptor (MR) and is 
a potent MR antagonist. The synthetic progestins, medroxyprogesterone acetate 
(MPA) and norethisterone derivatives, widely used as progestin-only injectable 
contraceptives and in hormone replacement therapy (HRT), have been reported to 
lack this anti-mineralocorticoid activity. This suggests that when they are used in 
combination with estrogen during HRT, they are unable to antagonize the salt-
retaining effects of estrogen, which may lead to weight gain and increased blood 
pressure. As the latter are causes of cardiovascular disease, this may explain the 
mechanism for the observed adverse cardiovascular outcomes associated with 
estrogen plus progestin therapy. In this study, we compared the binding affinity of 
Prog for the MR with that of MPA and NET-A, as well as with the known 
glucocorticoid and progesterone receptor antagonist, RU486. We also compared the 
relative antagonist potencies of the ligands for transactivation on a synthetic 
GRE/MRE via the MR, as well as their ability to transrepress MR-mediated NFĸB and 
AP-1 promoter-reporter genes. In addition, the effect on an endogenous gene, Orm-
1, shown to contain a GRE/MRE, was investigated. Competitive binding revealed that 
MPA and NET-A have similar binding affinities, but that their affinity is a 100-fold 
lower than that of Prog for the human MR (Kd of 0.153 nM for aldosterone (Ald) and 
Ki’s of 1.69, 197, and 229 nM for Prog, MPA and NET-A, respectively). Interestingly, 
RU486 has a very low affinity for the hMR (Ki of 2980 nM). Furthermore, on a 
synthetic mineralocorticoid response element (MRE)-containing promoter, we 
showed that MPA, NET-A and RU486 are all antagonists of the hMR, but that unlike 
Prog, they have weak antagonistic activity. However, on the endogenous MRE-
containing Orm-1 (α-glycolytic protein or orosomucoid-1) gene expressed in a rat 
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cardiomyocyte cell line, NET-A, but not MPA, has similar antagonistic activity as 
Prog, suggesting that NET-A may be partially cardioprotective while MPA is not. 
Interestingly, RU486 also has similar antagonist activity as Prog on the Orm-1 gene. 
In addition, we highlight the underappreciated fact that dexamethasone (Dex), the so-
called GR-specific agonist, is a partial agonist for MR transactivation, and show for 
the first time, that it is a full agonist for MR transrepression. Consistent with agonist-
induced interactions between the N- and C termini of steroid receptors (N/C-
interaction), our findings show that efficacy for transactivation via a synthetic GRE 
correlates with the efficacy for the induction of MR N/C-interaction (r2 = 0.9179; 
p<0.01), indicating that there is a relationship between transactivation and MR N/C-
interaction. Moreover, this study is the first to show that NET-A and RU486, but not 
MPA, can dissociate between transrepression (AP-1 promoter-reporter) and 
transactivation (GRE promoter-reporter) via the MR. These differences indicate that 
NET-A and RU486 may be promising therapeutics for the treatment of MR-mediated 
inflammation.  
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INTRODUCTION 
 
Synthetic progestins have been used for decades in female reproductive health. 
Although used in the treatment of a wide range of gynaecological disorders such as 
endometriosis, the two most frequent uses of progestins are for contraception, and 
for hormone replacement therapy (HRT) in postmenopausal women. These 
compounds are used to mimic the actions of the endogenous hormone progesterone 
(Prog), but have a longer plasma half-life and higher bio-availability than Prog 
(Speroff, 1996). Medroxyprogesterone acetate (MPA) and norethisterone enanthate 
(NET-EN) are two widely used progestins which are chemically derived from 17α-
hydroxy-progesterone and from 19-nortestosterone derivatives, respectively. MPA 
itself, rather than its metabolites, is the major progestogenic compound, while NET-
EN and norethisterone acetate (NET-A) are hydrolysed to norethisterone (NET) and 
its metabolites, which together have progestogenic action (Stanczyk and Roy, 1990).  
 
Both MPA and NET are reported to have side-effects for users. The side-effect profile 
when used as contraception includes irregular bleeding patterns, breast tenderness, 
headache, dizziness, and weight gain (Haider and Darney, 2007; Nur-Isterate 
package insert reg. no. J/21.8.2/136, Shering (Pty) Ltd). Recent studies suggest that 
MPA and NET used in HRT may increase the incidence of breast cancer (Rossouw 
et al., 2002; Beral, 2003). In addition to an increased risk of breast cancer, the 
Women’s Health Initiative (WHI) study on combined estrogen and MPA used in 
healthy postmenopausal women also showed increased risk of cardiovascular 
complications (Rossouw et al., 2002). As these progestins are designed to mimic the 
actions of progesterone, it is assumed that their biological effects, like progesterone, 
are mediated by the progesterone receptor (PR). However, these progestins cross-
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react with other members of the steroid receptor family and it is speculated that the 
observed side-effects are mediated in this way.  
 
The PR, androgen receptor (AR), glucocorticoid receptor (GR), estrogen receptor 
(ER) and mineralocorticoid receptor (MR) constitute the steroid receptor family. They 
are ligand-dependent transcription factors that display a high level of similarity with 
regards to their structure and mechanism of action, and they regulate gene 
expression of target genes by activating (transactivation) or repressing 
(transrepression) transcription (Evans, 1988; Beato, 1989). In general, for 
transactivation, the liganded-receptor translocates to the nucleus and binds hormone 
response elements (HREs) to activated genes, while during transrepression, the 
liganded-receptor binds to other transcription factors such as NFĸB and AP-1, 
thereby inhibiting gene activation (Evans, 1988; Beato, 1989). Both MPA and NET-A 
have been shown to have similar affinities for the AR, and are both potent agonists 
for transactivation like dihydrotestosterone (DHT), the native androgen (Chapter 3). 
Interestingly, MPA has a greater affinity than NET-A for the GR, and acts as a partial 
agonist for transactivation via the GR (Koubovec et al., 2005), while NET-A is a GR 
antagonist (supplementary material in Appendix C6). Interestingly, the activity of 
MPA and NET via the GR and AR differs from that of Prog, in that Prog is a weak 
partial agonist for the GR, and an antagonist for the AR. Collectively, this 
demonstrates that MPA and NET do not have the same activity, nor do they act the 
same as Prog, via different steroid receptors. 
 
Prog has a high affinity for the MR, displaying weak agonist transactivation activity, 
but potent antagonist activity (Wambach et al., 1979; Rafestin-Oblin et al., 1992; 
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Quinkler et al., 2002). In contrast, both MPA and NET-A have been reported to bind 
to the MR with low relative affinity and do not display any agonist or antagonist 
properties towards the MR (Winneker et al., 2003, Palacios et al., 2006). The 
difference in the activity of MPA and NET as compared to Prog, via the MR, may 
have serious implications for post-menopausal women using estrogen/progestin 
treatment for HRT. This is because the progestin used in HRT should be able to 
antagonize the salt-retaining and blood pressure raising effects of estrogens. 
Estrogen acts on the renin-angiotensin-aldosterone system (RAAS), leading to 
increased synthesis of angiotensinogen, which subsequently increases aldosterone 
levels thereby promoting sodium and water retention (Oelkers, 1996). Thus estrogen 
indirectly leads to increases in weight and blood pressure. Thus, if progestins used in 
combined HRT lack anti-mineralocorticoid activity, it could lead to side-effects such 
as weight gain and an increase in blood pressure. Since high blood pressure is a 
cardiovascular disease risk factor, using synthetic progestins, such as MPA and 
NET-A, that lack anti-mineralocorticoid activity in HRT, could lead to cardiovascular 
complications, as observed in the WHI study (Rossouw et al., 2002). However, the 
role of progestins such as MPA and NET-A, in cardiovascular disease remains poorly 
defined. 
 
Recently, Fejes-Tóth and Náray-Fejes-Tóth (2007) showed that Aldosterone (Ald), 
the natural MR ligand, regulates the expression of several genes that may contribute 
to the development of cardiovascular damage. Furthermore, it is known that Ald 
plays an important role in hypertension and heart failure, and MR antagonists are 
frequently prescribed to block MR activity in hypertensive patients (Pitt et al., 1999; 
Pitt et al., 2003). Thus, blocking Ald regulation of these genes by MR antagonists 
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could alleviate cardiovascular damage, and may be beneficial to patients with chronic 
heart failure. We were particularly interested in the Orm-1 (α-glycolytic protein or 
orosomucoid-1), an inflammation/acute phase-related gene, whose increased 
expression is associated with increased risk of cardiovascular disease (Engström et 
al., 2003). The promoter of Orm-1 contains a functional glucocorticoid response 
element/mineralocorticoid response element (GRE/MRE) (Klein et al., 1988). It has 
been reported that the effect of Ald on Orm-1 is direct, mediated by the binding of the 
liganded-MR to MREs in the promoter region (Fejes-Tóth and Náray- Fejes-Tóth, 
2007).  
 
In the current study, we determined the equilibrium constants (Kd or Ki’s) for the MR 
of Ald, Prog, MPA, NET-A, as well as RU486, the known PR and GR antagonist, and 
probable MR antagonist (www.nursa.org/10.1621/datasets.02001). We also 
compared the relative antagonist potencies of the ligands for transactivation on a 
synthetic GRE/MRE, as well as their ability to transrepress NFĸB and AP-1 promoter-
reporter genes via the MR. To further investigate the anti-mineralocorticoid activity of 
these compounds, we used rat cardiomyocytes transiently transfected with MR 
(Fejes-Tóth and Náray- Fejes-Tóth, 2007), and measured the expression of the 
endogenous Orm-1 gene in response to Ald, in the absence and presence of the 
synthetic progestins. Specifically, we hypothesized that MPA and NET-A, unlike 
Prog, would not antagonize the Ald-mediated MR transactivation. 
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MATERIALS AND METHODS 
Plasmids 
The plasmid, pTAT-GRE-E1b-luc, driven by the E1b promoter containing two copies 
of the rat TAT-GRE, has been described previously (Sui et al., 1999). The 
cytomegalovirus (CMV)-driven-β-galactosidase expression vector (pCMV-β-gal) was 
obtained from Prof. G. Haegeman (University of Gent, Belgium). The 5xNFκB-luc and 
7xAP-1-luc plasmids were from Stratagene (Houston, Texas, USA). A plasmid 
expressing the human mineralocorticoid receptor, pRShMR, was a kind gift from Prof. 
R. Evans and previously described (Arriza et al., 1987). Plasmids expressing human 
glucocorticoid receptor, pRS-hGRα were a kind gift from Prof. R. Evans (Howard 
Hughes Medical Institute, La Jolla, USA). A plasmid expressing the human androgen 
receptor, pSVARo (Brinkmann et al., 1989) was obtained from Frank Claessens, 
(University of Leuven, Leuven, Belgium). The plasmid expressing the human 
progesterone receptor, isoform B, pSG5hPR-B (Kastner et al., 1990), was obtained 
from Stoney Simons Jr (NIH, Bethesda, USA). The GAL4-MRC expression vector 
and the VP16-MRNT fusion protein expression vectors (provided by Prof’s Peter 
Fuller (Prince Henry’s Institute of Medical Research, Victoria, Australia) and Fraser 
Rogerson (University of Melbourne Department of Paediatrics, and Murdoch 
Childrens Research Institute, Royal Children's Hospital, Victoria, Australia), were 
previously described (Rogerson and Fuller, 2003). The reporter vector, pG5-luc, 
which contains the luciferase gene driven by a GAL4 responsive promoter, was 
obtained from Prof Douglas Stocco (Texas Tech University Health Sciences Center, 
Texas, USA). The pGL2basic empty vector was obtained from Promega, Madison, 
USA. 
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Inducing compounds 
11β,21-Dihydroxy-3,20-dioxo-4-pregnen-18-al (Aldosterone; Ald), 11β-(4-
Dimethylamino)phenyl-17β-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one 
(mifepristone; RU486), 7α-acetylthio-3-oxo-17α-pregn-4-ene-21,17-carbolactone 
(spironolactone), 4-pregnene-3, 20-dione (progesterone; Prog), 6α-methyl-17α-
hydroxy-progesterone acetate (medroxyprogesterone acetate; MPA), 17α-ethynyl-
19-nortestosterone 17β-acetate (norethindrone acetate; NET-A), (11β,16α)-9-fluoro-
11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione (Dexamethasone; Dex) 
and phorbol 12-myristate 13-acetate (PMA) were obtained from Sigma-Aldrich, South 
Africa. NET-A, the acetate, was used as it is soluble in water compared with the 
insoluble ester NET-EN. In vivo, both NET-EN and NET-A undergo hydrolysis and 
are converted to NET and its metabolites (Stanczyk and Roy, 1990). [3H]-Aldosterone 
([3H]-Ald) (87.9 Ci/mmol), unlabelled 17β-hydroxy-7α,17α-dimethylestr-4-en-3-one 
(mibolerone; MIB), and unlabelled R5020 were purchased from PerkinElmer Life and 
Analytical Science, South Africa. All unlabelled test compounds were dissolved in 
absolute ethanol and stored at -20oC. These compounds were then added to serum-
free culturing medium such that the final concentration of ethanol was 0.1%. Control 
incubations (no test compounds) were performed in the presence of 0.1% ethanol.  
 
Cell culture 
COS-1 cell lines (monkey kidney cells) were maintained in high glucose (4.5 g/ml) 
Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, South Africa). Medium 
was supplemented with 10% fetal calf serum (FCS) (Delta Bioproducts, South Africa), 
50 IU/ml penicillin and 50 µg/ml streptomycin (GibcoBRL, Paisley, UK). The H9C2 
cell line (rat cardiomyocyte cells) was a kind gift from Dr. Rob Smith (Physiology 
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Department, University of Stellenbosch, South Africa) and was maintained in high 
glucose (4.5 g/ml) DMEM (Sigma-Aldrich, South Africa). Medium was supplemented 
with 10% FCS (Delta Bioproducts, South Africa), 50 IU/ml penicillin and 50 µg/ml 
streptomycin (GibcoBRL, Paisley, UK). All cultures were maintained in 75 cm2 culture 
flasks (Greiner, Bio-One International, Austria) at 37°C, in an atmosphere of 90% 
humidity and 5% CO2, and were regularly tested for mycoplasma infection by means 
of Hoechst staining (Freshney, 1987), and only mycoplasma-negative cell lines were 
used in experiments.  
 
Whole cell binding assays 
Competitive whole cell binding assays were performed essentially as described by 
Bamberger et al. (1995), with the following modifications. The COS-1 cell line was 
maintained in DMEM as described. Cells were seeded into 24-well tissue culture 
plates at 1 x 105 cells per well. On day 2, cells were transfected with 0.375 µg 
pRShMR expression vector and 0.0375 µg of the pCMV-β-gal expression vector 
(Stratagene, Houston, Texas, USA), using the FuGENE6 transfection reagent 
(Roche Molecular Biochemicals, South Africa) according to the manufacturer’s 
instructions. On day 3, the cells were washed with phosphate-buffered saline (PBS) 
and incubated with 0.2 nM [3H]-Ald (PerkinElmer Life and Analytical Science, South 
Africa) in the absence (total binding) or presence of increasing concentrations of 
unlabelled Ald, Prog, MPA, NET-A or RU486 for 16 hours (time taken to reach 
equilibrium; Appendix C2) at 37°C. Working on ice at 4oC, cells were washed three 
times with ice-cold 1X PBS containing 0.2% (w/v) bovine serum albumin (BSA) for 15 
min. Cells were then lysed with 200 µl reporter lysis buffer (Promega, Madison, 
USA). Total binding ([3H]-Ald in the absence of added unlabelled ligand) was 
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determined by scintillation counting and expressed as 100%. Specific bound [3H]-Ald 
was calculated as the difference between total and non-specific binding, the latter 
determined by incubating cells in the presence of [3H]-Ald plus 10 µM unlabelled Ald 
and expressed as a relative % of total binding. The β-galactosidase 
chemiluminescent reporter gene assay system (Tropix Inc., U.S.A.) was used to 
determine β-galactosidase (β-gal) activity, to correct for differences in transfection 
efficiencies. Binding data were analyzed using GraphPad Prism software, with 
nonlinear regression and assuming competitive binding to one class of binding sites. 
Ki values for Prog, MPA, NET-A and RU486 were determined from the heterologous 
displacement curves using the EC50s, Kd for Ald, and concentration of radiolabelled 
Ald, according to the method of Cheng and Prusoff (1973) and described in Appendix 
D1. The reported values are averages of at least three independent assays, with 
each condition performed in triplicate.  
 
Luciferase reporter assays 
For transactivation assays in the COS-1 cell line: COS-1 cells were maintained as 
above and seeded into 96-well tissue culture plates at 1 x 104 cells per well. On day 
2, cells in each well were transiently transfected with 50 ng of the pTAT-GRE-E1b-luc 
construct, 5 ng of the expression vector for the human mineralocorticoid receptor 
(pRShMR), and 5 ng of the pCMV-β-gal expression vector, using the FuGENE6 
transfection reagent (Roche Molecular Biochemicals, South Africa) in accordance 
with the manufacturer’s instructions. On day 3, the cells were washed with PBS and 
induced with 1 or 10 µM of either Ald, Prog, MPA, NET-A, RU486 or Dex to 
investigate agonist activity, while for antagonist activity, the cells were incubated with 
1 nM Ald in the absence and presence of increasing concentrations of Prog, MPA, 
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NET-A or RU486. After 24 hours, the cells were lysed with reporter lysis buffer 
(Promega, Madison, USA). Luciferase activity in the lysate was measured using the 
Luciferase Assay System (Promega, Madison, USA) and a Veritas microplate 
luminometer (Turner Biosystems, Sunnyvale CA, USA). The values obtained were 
normalised to expression of β-gal, which was measured using the GalactoStar Assay 
Kit from Tropix (Bedford MA, USA). 
 
For transactivation assays in the H9C2 cell line: H9C2 cells were maintained as 
above and seeded into 24-well tissue culture plates at 5 x 104 cells per well. On day 
2, cells in each well were transiently transfected with 330 ng of the pTAT-GRE-E1b-
luc construct and 33 ng of the expression vector for the hMR, hGR, hAR, hPR-B or 
the empty vector pGL2basic, using the FuGENE6 transfection reagent (Roche 
Molecular Biochemicals, South Africa) in accordance with the manufacturer’s 
instructions. On day 3, the cells were washed with PBS and induced with 10 µM of 
either Ald, Dex, MIB, or R5020. After 24 hours, the cells were lysed with reporter lysis 
buffer (Promega, Madison, USA). Luciferase activity in the lysate was measured 
using the Luciferase Assay System (Promega, Madison, USA) and a Veritas 
microplate luminometer (Turner Biosystems, Sunnyvale CA, USA). 
 
For transrepression assays, the COS-1 cell line was seeded into 24-well tissue 
culture plates at a density of 5 x 104 cells per well. The following day the cells were 
transfected with 0.045 µg of pRShMR, 0.09 µg of 5xNFκB-luc or 7xAP-1-luc plasmids 
respectively, and 0.0225 µg of pCMV-β-Gal using the FuGENE6 transfection reagent 
(Roche Molecular Biochemicals, South Africa) according to the manufacturer’s 
instructions. Twenty four hours after transfection the cells were washed with PBS and 
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incubated with serum-free medium containing 10 ng/ml PMA and 1 µM of each test 
compound. Luciferase activity in the lysate was measured as described above. The 
values obtained were normalised to expression of β-gal, which was measured using 
the GalactoStar Assay Kit from Tropix (Bedford MA, USA). Where normalising to B-
galactosidase is not performed, transfection efficiency was previously determined to 
be highly reproducible. The reported values are averages of at least three 
independent experiments, with each condition performed in triplicate.  
 
Mammalian two-hybrid assays 
The mammalian two-hybrid assay was performed in the COS-1 cell line. The cells 
were maintained as described, and then plated in 24-well tissue culture plates at a 
density of 5 x 104 cells per well. On day 2, the cells were transfected with 0.1 µg/well 
GAL4-MRC, 0.5 µg/well VP16-MRNT and 0.5 µg/well pG5-luc, using the FuGENE6 
transfection reagent (Roche Molecular Biochemicals, South Africa) according to the 
manufacturer’s instructions. Twenty four hours after transfection, cells were induced 
with 1 or 10 µM Ald, Prog, MPA, NET-A, RU486 or Dex for 24 hours. Luciferase 
activity in the lysate was measured as described above. The reported values are 
averages of at least three independent experiments, with each condition performed in 
triplicate. The values obtained were normalised to expression of β-gal, which was 
measured using the GalactoStar Assay Kit from Tropix (Bedford MA, USA). 
 
Isolation of total RNA and real-time quantitative RT-PCR analysis of 
representative genes 
The H9C2 cell line was maintained as described above. Cells were seeded into 12-
well plates, transiently tranfected with the MR, and subsequenlty grown in the 
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absence of FCS for 48 h before treatment with test compounds. Cells were induced 
with 1 nM Ald in the absence and presence of 1 µM Prog, MPA, NET-A, RU486 or 
Spironolactone for 24 hours. Total RNA was isolated from cells using Tri-reagent 
(Sigma-Aldrich, South Africa) according to the manufacturer’s instructions. The 
integrity of the RNA (presence of intact 18S and 28S ribosomal bands) was 
confirmed by agarose gel electrophoresis. Total RNA (1 µg) was reverse transcribed 
using the Transcriptor First Strand cDNA synthesis kit (Roche Applied Science, 
South Africa) according to the manufacturer’s instructions. Real-time PCR was 
performed by using a Light-Cycler, rapid thermal cycler system (Roche Applied 
Science, South Africa) according to the manufacturer’s instructions. Nucleotides, 
TaqDNA polymerase, and buffer used in the reaction were those included in the 
LightCycler-FastStart DNA MasterPLUS SYBR Green I system (Roche Diagnostics, 
South Africa). β-actin was used as an internal control. Primer sets are as described in 
Table 1. The thermal cycling parameters were: initial denaturation at 95oC for 3 min, 
followed by 40 cycles at 95oC for 15 sec and 57oC for 30 sec. 
 
Table 1: QPCR primer sets (Orm-1 and β-actin sequences were obtained from Prof. 
Anikó Náray-Fejes-Tóth) (Fejes-Tóth and Náray- Fejes-Tóth, 2007). 
 
Gene Primers Strand Annealing 
temperature 
(oC) 
 
Orm-1 
 
TGCCCATTTGATAGTGCTGAAG 
CAGGCTGTCAAAGATGTGGGCA 
 
Forward 
Reverse 
 
60 
 
β-actin 
 
TTGTAACCAACTGGGACGATATGG 
GATCTTGATCTTCATGGTGCTAGG 
 
Forward 
Reverse 
 
 
60 
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Western blotting  
H9C2 cell lines were plated at 1 x 106 cells per well in 6-well plates and allowed to 
grow to confluency. Cells were washed with PBS and lysed in 100 µl SDS-sample 
buffer (Sambrook et al., 1989). Lysates were boiled and subjected to electrophoresis 
on a 8% SDS polyacrylamide gel using β-actin expression as a loading control. 
Following electrophoresis, proteins were transferred to nitrocellulose membranes. 
Blots were probed with an anti-MR (H300, 1:1000), anti-GR (H300, 1:3000), anti-AR 
(H-280, 1:1000), or anti-PR-AB (sc-810, 1:500) antibodies from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA, USA), as well as the anti-β-actin (1:1500) 
antibody from Cell Signalling Technology, Massachusetts, USA, for 16 hours at 4 oC. 
Blots were subsequently incubated with horseradish peroxidase (HRP)-conjugated 
goat anti-rabbit secondary antibody (1:10000, NA934VS, Amersham, South Africa) 
for 1 hour. Proteins were visualized using enhanced chemiluminescence (ECL) from 
Amersham, followed by exposure to Hyperfilm MP high performance autoradiography 
film (Amersham, South Africa). 
 
Data manipulation and statistical analysis 
The Graph Pad Prism software was used for data manipulations, graphical 
representations, and statistical analysis. One-way ANOVA analysis of variance and 
Bonferroni (compares all pairs of columns) posttests were used for statistical 
analysis. Non-linear regression and one site competition were used in whole cell 
binding assays, whereas non-linear regression and sigmoidal dose response were 
used in transactivation (antagonist) experiments. Statistical significance of 
differences is indicated by *, ** or ***, to indicate p<0.05, p<0.01 or p<0.001, 
respectively, whereas no statistical significance is indicated by p>0.05. The letters 
 167 
a,b,c etc. are also used to denote statistically significant differences, where all those 
values which differ significantly from others, are assigned a different letter. Fractional 
occupancy of the MR for each compound was calculated using the equation: 
Fractional occupancy = [ligand] / ([ligand]+Ki), using the Ki values summarized in 
Table 2. 
 
RESULTS 
MPA and NET-A have a similar binding affinity for the MR 
Competitive whole cell binding assays in the COS-1 cell line transiently transfected 
with a full-length human mineralocorticoid receptor (hMR) expression vector, were 
performed to determine Kd and Ki values. In order to obtain accurate Kd and Ki values 
using homologous and heterologous displacement curves, respectively, a range of 
experiments was first performed to establish an appropriate concentration of 
radiolabelled ligand and the time to reach equilibrium. An appropriate concentration 
of [3H]-Ald, in the range two to ten times lower than the EC50, was established as 0.2 
nM (discussed in Appendix D1), and the incubation time required for equilibrium to be 
reached for 0.2 nM [3H]-Ald binding to the MR, was determined as sixteen hours 
(discussed in Appendix D1).  
 
Homologous/heterologous curves with unlabelled steroids were then obtained and 
results show that MPA and NET-A bind to the MR with a similar affinity, but 
approximately 100-fold lower than that of Prog and 1000-fold lower than that of the 
natural mineralocorticoid, Ald (figure 1). Interestingly, RU486 also binds the MR but 
with an approximately 20 000-fold lower affinity than Ald. The curves for each 
competitor steroid indicate competitive binding to the same site as Ald (R2 values for 
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each MPA, NET-A, Prog and RU486 were 0.9453, 0.9452, 0.9837 and 0.9431 
respectively, for one site competitive binding curve). The Kd for Ald and Ki values for 
Prog, MPA, NET-A and RU486 are summarised in the Table 2. The Ki for Prog was 
determined as 1.69 nM, which is similar to a previously reported value of 1.2 nM 
(Quinkler et al., 2002). 
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Figure 1: MPA and NET-A both compete with [3H]-Ald for binding to the human 
mineralocorticoid receptor. The COS-1 cell line was transiently transfected with the pRShMR and 
pCMV-β-galactosidase expression vectors.Twenty-four hours later the cells were incubated with 0.2 
nM [3H]-Ald in the absence or presence of increasing concentrations of either unlabelled Ald (), Prog 
(♦), MPA (●), NET-A (▼), RU486 (◊) or Dex (▲) for 16 hours. Results are plotted as % specific binding 
where total specific binding of [3H]-Ald in the absence of unlabelled ligand is set as 100% and binding 
of unlabelled ligand is set as a % binding relative to Ald, after normalization for transfection efficiency 
with β-galactosidase levels. Result shown is representative of three independent experiments with 
each condition performed in triplicate (±SEM).  
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Table 2: Relative binding affinities of the ligands for the MR (Kd or Ki values)a 
Test compound Kd or Ki (M) ± SEM 
 
Fold differences 
Ald 
 
1.53 x 10-10 ± 0.04 
 
1 
Prog 
 
1.69 x 10-9 ± 0.07 
 
11.05 
MPA 
 
1.97 x 10-7 ± 0.04 
 
1287.58 
NET-A 
 
2.29 x 10-7 ± 0.07 
 
1496.73 
RU486 
 
2.98 x 10-6 ± 0.08 
 
19477.12 
Dex 
 
5.14 x 10-9 ± 0.07 
 
33.59 
 
a
 Binding data of three independent experiments were analyzed using GraphPad Prism software, with 
nonlinear regression and assuming competitive binding to one class of binding sites. Ki values ± SEM 
for Prog, MPA, NET-A, RU486 and Dex were determined from the heterologous displacement curves 
using the EC50s, Kd ± SEM for Ald, and concentration of radiolabelled Ald, according to the method of 
Cheng and Prusoff (1973) that is described in Appendix D1. Fold differences calculated by setting the 
Kd for MIB in M as 1, and expressing the Ki in M for the other ligands as a fraction thereof. Statistical 
analysis of the Kd / Ki values, indicated the following: Ald vs. Prog, MPA, NET-A, RU486, Dex (p< 
0.001); Prog vs. MPA, NET-A, RU486, Dex (p< 0.001); MPA, NET-A vs. RU486, Dex (p<0.001); MPA 
vs. NET-A (p>0.05); Prog vs. Dex (p<0.05). 
 
Unlike Prog, MPA and NET-A display weak MR antagonist activity and no 
mineralocorticoid agonist activity for transactivation 
Having shown that MPA, NET-A and RU486 bind to the hMR, albeit with low affinity, 
we directly compared their mineralocorticoid properties by transiently transfecting the 
COS-1 cell line with a glucocorticoid response element (GRE)/mineralocorticoid 
response element (MRE)-driven reporter construct containing two copies of the rat 
TAT GRE, a hMR expression vector and the pCMV-β-gal expression vector. The 
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cells were subsequently exposed to either 1 or 10 µM Ald, Prog, MPA, NET-A, 
RU486 or Dex. The results clearly show that 10 µM MPA, NET-A and RU486, unlike 
10 µM Prog, do not display agonist activity for the MR (figure 2A). A similar profile 
was observed at 1 µM of each compound (Appendix C4). The transcriptional activity 
of these compounds in the absence of transfected receptor was negligible (Appendix 
D3). Interestingly, Dex, the well-described potent GR-specific agonist (Honer et al., 
2003; Yu et al., 2004), displays partial agonist activity of about 37% of maximal 
activity relative to Ald via the MR, showing that Dex is a partial agonist for 
transactivation via the MR. Whole cell binding experiments showed that Dex binds to 
the MR with a significantly higher affinity than Prog (Table 2).  
 
In order to obtain additional information about the pharmacological profiles of these 
compounds, we investigated their antagonist activity by transfecting the COS -1 cell 
line as above, and incubating the cells with 1 nM Ald in the absence or presence of 
increasing concentrations of Prog, MPA, NET-A and RU486 (figure 2B). These 
results indicate that although, MPA, NET-A and RU486 can similarly antagonise the 
effects of Ald, they are much less potent than Prog (approximately 87-216 fold less 
potent). We determined potencies (EC50 values) for antagonist activity of 3.1, 310, 
270 and 670 nM for Prog, MPA, NET-A and RU486, respectively. Interestingly, our 
EC50 value for antagonist activity of Prog (3.1 nM) indicates that Prog is a more 
potent at antagonizing the effects of Ald than the well-known MR antagonist 
spironolactone (EC50 of 14 nM) (reviewed in Lu et al., 2006). Whether Dex has MR 
antagonist activity was not investigated. 
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Figure 2 legend on next page. 
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Figure 2: (A) Unlike Ald, Prog and Dex, MPA, NET-A and RU486 do not display 
mineralocorticoid agonist activity. The COS-1 cell line was transiently transfected with the pTAT-
GRE-E1b-luc reporter plasmid plus, pRShMR and pCMV-β-galactosidase expression vectors. 
Subsequently, the cells were incubated with 10 µM of either Ald (100%), Prog, MPA, NET-A, RU486 
or Dex for 24 hours. Results shown are the average of at least three independent experiments with 
each condition performed in triplicate (±SEM). (B) Prog, MPA, NET-A and RU486 can antagonize 
the agonist activity of Ald via the MR. The COS-1 cell line was transiently transfected as above. 
Subsequently, the cells were incubated with 1 nM Ald alone (100%) or with increasing concentrations 
of Prog (♦), MPA (), NET-A (▼) or RU486 (◊) for 24 hours. Result shown is a representative 
experiment of at least three independent experiments with each condition performed in triplicate 
(±SEM). Data from these experiments was analysed to obtain EC50 ± SEM values for each test 
compound. Statistical analysis of the EC50 values, indicated that Prog vs. MPA, NET-A and RU486 (p< 
0.001); MPA vs. NET-A, RU486 (p>0.05); NET-A vs. RU486 (p>0.05).  
 
Unlike MPA and NET-A, Prog and Dex induce the ligand-dependent interaction 
between the amino- and carboxyl-terminals of the mineralocorticoid receptor 
Interaction between the N-terminal domain and the C-terminal domain (N/C-
interaction) of liganded steroid hormone receptors has been described for other 
steroid receptors, and is best-described for the AR (Langley et al., 1995; Doesburg et 
al., 1997; Kemppainen et al., 1999; He et al., 2000). Recently, an Ald-dependent 
N/C-interaction was also reported for the MR using a mammalian-two-hybrid assay 
(Rogerson and Fuller, 2003). We thus used a similar approach to compare the 
capability of Prog, MPA, NET-A, RU486 and Dex to induce the N/C-interaction of the 
hMR. In transient transfection assays, the COS-1 cell line was co-transfected with 
GAL4-MRC (vector encoding amino acids 672-984 in the C-terminal region of the 
MR, containing the hinge region and LBD), VP16-MRNT (expression vector encoding 
amino acids 1-597 in the N-terminal domain of the MR) and the GAL4-responsive 
luciferase reporter vector pG5-luc. In figure 3 we show that the partial agonists, Prog 
and Dex, were able to induce the MR N/C interaction. However, Prog induced a very 
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weak N/C-interaction of about 5% (compared to 100% for Ald), while the observed 
transactivation activity was about 20% (figure 2A).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: In contrast to Ald, Prog and Dex, MPA, NET-A and RU486 do not induce the N/C-
interaction of the hMR. The COS-1 cell line was transiently transfected with the GAL4-MRC and 
VP16-MRNT expression vectors, as well as the GAL4-responsive luciferase reporter vector pG5-luc. 
The cells were exposed to 10 µM Ald (100%), Prog, MPA, NET-A, RU486 or Dex for 24 hours. Results 
are averages of at least three independent experiments with each condition performed in triplicate 
(±SEM).  
 
Interestingly, no N/C-interaction was observed for Prog at 1 µM (data not shown), 
even though it had transactivation activity of 6% at this concentration (Appendix C4). 
In contrast, Dex could induce the MR N/C-interaction at 1 and 10 µM (data not 
shown; figure 3). Nevertheless, the transactivation efficacy of the group of 
compounds (maximal induction at 10 µM ligand) showed a good (r2=0.9179), and 
significant (p<0.01) correlation with their efficacy for inducing the N/C-interaction 
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(figure 4). The effect of a given ligand depends on the fraction of receptors that are in 
fact occupied by the specific ligand. Thus, fractional occupancy describes the relative 
receptor occupancy for any ligand at equilibrium, as a function of the concentration of 
ligand and the Kd of the particular ligand. In Table 3, it is shown that 10 µM Ald, Prog 
and Dex saturates the MR, while MPA and NET-A both have a fractional occupancy 
of ~ 98%. In contrast, only 77% of the MR is occupied at 10 µM RU486. 
 
 
 
Figure 4: Correlation analysis of efficacy for transactivation versus N/C- interaction. Relative 
efficacies for transactivation (figure 2A) were compared to relative efficacies for N/C-interaction as 
determined by mammalian two hybrid assay (figure 3) using Pearson correlations. Results showed 
statistical significance (p<0.01) and r2 = 0.9179. *Strictly, it is not correct to do correlation analysis on 
data that has only one point with a great efficacy, whilst the other points are either 0 or close to 0. 
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Table 3: Fractional occupancy of the MR at 1 µM and 10 µM ligandc 
 Ligand 
Fractional occupancy (%) 
at 1 µM 
Fractional occupancy (%) 
at 10 µM 
 
Ald 
 
99.98 
 
100 
 
Prog 
 
99.83 
 
99.98  
 
MPA 
 
83.54  
 
98.07  
 
NET-A 
 
81.37  
 
97.76  
 
RU486 
 
25.13  
 
77.04  
Dex 
 
99.49  
 
99.95  
c
 The fractional occupancy was calculated according to the equation: Fractional occupancy = [ligand] / 
([ligand] + Ki). Kd for Ald and Ki values for Prog, MPA, NET-A, RU486 and Dex were from Table 2.  
 
 
MPA and NET-A display dissimilar mineralocorticoid properties for 
transrepression on an AP-1 promoter. 
Having shown that both MPA and NET-A cannot transactivate a simple GRE-
containing promoter via the MR, we were interested to compare their 
mineralocorticoid properties for transrepression. The COS-1 cell line was transiently 
transfected with luciferase reporter plasmids linked downstream of either five copies 
of a NFĸB site or seven copies of an AP-1 site, both in the absence and presence of 
a transfected MR expression vector. Cells were stimulated with PMA and incubated 
for 24 hours with 1 µM of each test compound. Figure 5 shows % repression with 
Ald.  
 
Surprisingly, results indicate that there is no statistically significant difference in the 
transrepression potential of Ald, Prog, NET-A, RU486 and Dex on the AP-1 promoter 
via the MR. However, the results indicate that unlike Prog and NET-A, MPA does not 
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transrepress the PMA-induced response on the AP-1 promoter via the MR (figure 
6A).  
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Figure 5: Transrepression activity of Ald on the AP-1 promoter in the presence of hMR. The 
COS-1 cell line was transiently transfected with the pRShMR, pCMV-β-galactosidase expression 
vectors and AP-1-containing promoter-luciferase reporter constructs. Subsequently, the cells were 
incubated with vehicle (EtOH), EtOH in the presence of 10 ng/ml PMA, or 10 ng/ml PMA in the 
presence of 1 µM Ald. β-galactosidase (β-gal) values were used to normalize for transfection 
efficiency. EtOH + PMA was set as 100% and Ald response calculated as a percentage of EtOH + 
PMA (100%). The % repression (indicated in red) was calculated by subtracting the % relative 
response of Ald from the % relative response of EtOH + PMA (100%). These calculations were also 
done for the Ald response on the AP-1 promoter in the absence of MR. Similar calculations were 
performed for MR-mediated responses on the NFκB-promoter in the absence and presence of 
transiently transfected MR. 
 
Using the NFĸB promoter-reporter construct, results showed similar but weak levels 
of transrepression of PMA-mediated induction with Prog, MPA, NET-A, RU486 and 
Dex (figure 6B). Although not statistically significantly different, MPA and RU486 
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appear to repress the NFĸB promoter to a slightly better extent (26% and 23%, 
respectively) than Prog and NET-A (12% and 5%, respectively). When comparing the 
transrepression activity of the different ligands on the AP-1 versus the NFĸB 
promoter-reporter, Prog, NET-A and RU486 all exhibit greater transrepression via 
AP-1 (51%, 74%, 60%, respectively) than via the NFĸB promoter (12%, 5%, 23%, 
respectively). The activities of the ligands (at 1 µM) on the three synthetic promoter 
constructs are summarized in Table 4. Given that MPA and NET-A bind to the MR 
with similar affinities, and that neither is an agonist for transactivation (GRE), it is 
noteworthy that they act differently on the AP-1 promoter.  
 
The transrepression/transactivation (AP-1/GRE) ratios for all the ligands were 
calculated, and are summarized in Table 5 in the discussion. Transrepression 
induced by NET-A for example was 74% of that caused by Ald (100%), while NET-A-
mediated transactivation is only 1.6%. The transrepression/transactivation ratio for 
NET-A is thus 46.3 (74% / 1.6%). It should be noted that at 1 µM of the ligands, the 
fractional occupancy for Ald, Prog and Dex are ~ 100%, while for MPA and NET-A it 
is ~84% and 81%, respectively (Table 3). Given that the fractional occupancy of 1 µM 
RU486 is only 25%, the 60% percent MR-mediated repression with RU486 on the 
AP-1 promoter is surprising, and difficult to explain. It may indicate that the affinity of 
a ligand for the MR, does not necessarily determine the efficacy of the ligand for 
transrepression.  
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Figure 6 legend on next page. 
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Figure 6: Transrepression activity via the hMR. The COS-1 cell line was transiently transfected with 
the pRShMR, pCMV-β-galactosidase expression vectors and (A) NFĸB- or (B) AP-1-containing 
promoter-luciferase reporter constructs. Subsequently, the cells were stimulated with 10 ng/ml PMA 
and incubated with 1 µM Ald, Prog, MPA, NET-A, RU486 or Dex for 24 hours. β-gal values were used 
to normalize for transfection efficiency. Once the repressive abilities of the test compounds were 
determined, in the absence and presence of transfected MR (Appendix C4), repression in the absence 
of MR was subtracted from the repression in the presence of transfected MR. The % repression for the 
other ligands was expressed as a % of Ald response which was set at 100%. The result shown is the 
average of three independent experiments with each condition performed in triplicate (±SEM). 
 
Unlike MPA, Prog, NET-A and RU486 do inhibit the aldosterone-induced 
upregulation of the endogenous Orm-1 gene 
To investigate whether the results observed on a synthetic promoter could be 
mimicked on an endogenous promoter, we transiently transfected a rat 
cardiomyocyte cell line (H9C2) with the full-length hMR or hGR expression vector. 
Western blot analysis confirmed the expression of the transfected MR and GR in 
these cells, as well as endogenous expressed MR and GR (figure 7A and 7B). To 
determine whether the endogenous MR and GR, as well as the overexpressed 
receptors are transcriptionally active, we assessed their transactivation potential in 
the presence of receptor agonists, using a promoter-reporter assay. The results in 
figure 7C-F indicate that the endogenous MR and GR, as well as the overexpressed 
MR, GR, PR and AR, are transcriptionally active. Consistent with the lack of 
transcrptional activity for endogenous PR and AR, Western blot analysis did not 
detect endogenous AR or PR protein levels in these cells (data not shown).  
 
We focussed our study on the inflammation/acute phase-related gene, Orm-1, known 
to be associated with increased risk of cardiovascular disease (Engström et al., 
2003), and previously reported to be upregulated by 1 nM Ald in a H9C2 cell line 
stably expressing the MR, via the suggested mechanism of binding of the liganded 
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MR to a MRE (Fejes-Tóth and Náray-Fejes-Tóth, 2007). In these cells, the 
investigators showed a 1000-fold induction of the Orm-1 gene by 1 nM Ald at 24 h, 
whereas we observed only a 6-fold induction at this time point (figure 8A and 8B). 
Although not significantly different to the control, MPA caused a 4.4-fold upregulation 
of the Orm-1 gene, while the other ligands displayed a 2-fold upregulation (figure 8A).  
We also investigated the antagonist activity of the progestins on the Ald-induced 
expression of Orm-1, by incubating the parent H9C2 cell line transiently transfected 
with the MR, with 1 nM Ald in the presence of 1 µM of each progestin, as well as the 
known MR antagonist, spironolactone, as a positive control. Our result on a synthetic 
GRE showing that Prog is a potent MR antagonist (EC50 = 3.1 nM) was corroborated 
on the endogenous Orm-1 gene. Although MPA, NET-A and RU486 showed a weak 
but similar antagonist potency for the MR on the synthetic promoter (EC50 of 310, 270 
and 670 nM, respectively), they acted differently on the endogenous promoter of the 
Orm-1 gene (figure 8B). Interestingly, NET-A and RU486 antagonized the Ald-
induced upregulation of the Orm-1 gene to similar extents as Prog. In contrast, MPA 
did not antagonize the upregulation of the Ald-induced Orm-1 gene (figure 8B). In 
fact, although not significant, MPA seemed to enhance the upregulation of the Ald-
induced Orm-1 gene (figure 8B). 
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Figure 7: MR (A) and GR (B) are expressed in the rat cardiomyocyte (H9C2) cell line. Whole cell 
extracts were prepared from the untransfected H9C2 cell line, the H9C2 cell line transfected with 
pRShMR or pRS-hGRα expression vectors, untransfected COS-1 cell line (negative control (-ve ctl)), 
COS-1 cell line transfected with pRShMR and pRS-hGRα expression vectors (positive controls (+ ctl)). 
Equal amounts of protein (20 µg) were analyzed by Western blotting with the MR or GR antibodies. 
(C) - (F) Transactivation of a transiently transfected GRE-containing promoter-reporter 
construct via MR, GR, AR, or PR. H9C2 cells were transiently transfected with pTAT-GRE2-Elb-luc 
and pRS-hMR, pRS-hGRα, pSVARo, pSG5hPRB, or pGL2basic (empty vector control) as indicated, 
with Fugene 6 transfection reagent according to the manufacturer’s instructions. Twenty-four hrs after 
transfection cells were induced for 24 hrs with solvent (ethanol), or 10 µM Ald (for MR), Dex (for GR), 
MIB (for AR) or R5020 (for PR). 
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Figure 8: (A) Agonist and (B) antagonist activity of Prog, MPA, NET-A and RU486 on the 
endogenous MRE-containing Orm-1 gene in the rat cardiomyocyte cell line transiently 
transfected with the MR. (A) Ald and MPA upregulate the Orm-gene to similar extents. Cells 
were incubated with 1nM Ald or 1 µM Prog, MPA, NET-A, or RU486, for 24 hours. (B) Prog, NET-A 
and RU486 antagonise the aldosterone-induced upregulation of the Orm-1 gene. Cells were 
incubated with 1 nM Ald in the absence and presence of 1 µM Prog, MPA, NET-A, RU486 or 
Spironolactone. Total RNA was extracted, cDNA synthesized and expression levels of Orm-1 and β-
actin mRNA were determined by QPCR. Ratios of the Orm-1/β-actin gene were calculated using the 
Fit Points method described by Pfaffl (2001). Results shown are the averages of three independent 
experiments.  
 
DISCUSSION 
For women with an intact uterus, the inclusion of progestin in continuous combined 
HRT is needed to counteract the proliferative effects of estrogen on the uterine 
endometrium, thereby decreasing the risk of cancer associated with unopposed 
estrogen therapy (Gambrell Jr et al., 1980; Palacios et al., 2006). However, the 
estrogen component in HRT can also cause water and sodium-retention mediated 
via the RAAS (Oelkers, 1996), leading to weight gain and increased blood pressure. 
Since hypertension (high blood pressure) increases cardiovascular risk in both men 
and women (Calhoun and Oparil, 1997), there may be an association between the 
use of menopausal HRT and an elevated risk for cardiovascular disease. 
Endogenous progesterone, however, has anti-MR effects on the RAAS (Oelkers, 
1996; Oelkers, 2004), thereby counterbalancing the estrogen-related water and 
sodium-retention and providing positive effects on body weight and also blood 
pressure. Thus, progestins used in HRT should ideally mimic these anti-
mineralocorticoid properties.  
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The MR belongs to the family of steroid hormone receptors, comprising structurally 
similar proteins such as the GR, AR, PR and ER. In general, they are ligand-
activated transcription factors that comprise four different domains namely the highly 
variable NH2-terminal domain (NTD), the highly conserved and centrally located 
DNA-binding domain (DBD), which directly interacts with the DNA response 
elements, the hinge region and the COOH-terminal (C-terminal) domain. The C-
terminal domain contains the ligand binding domain (LBD) to which the ligand binds. 
Furthermore, these receptors also possess transcriptional activation functions 
located in the NTD (AF1 domain) and the LBD (AF2 domain). Mineralocorticoids (or 
ligands binding to the MR) bind to the cytoplasmic MR in target tissues. Upon ligand 
binding, the receptor translocates to the nucleus where it regulates gene expression 
(Evans, 1988; Beato, 1989). An increase in gene transcription or positive regulation 
of target genes is termed transactivation, and occurs when ligand-activated MR binds 
to specific DNA sequences, called mineralocorticoid response elements (MREs) in 
the promoter regions of specific genes, resulting in gene activation (Evans, 1988; 
Beato, 1989). The steroid receptor family can also negatively regulate genes 
(transrepression), and this is mediated via the ligand-activated receptor not directly 
binding to DNA but via protein-protein interactions with other transcription factors 
such as nuclear factor-kappa B (NFĸB) and activator protein-1 (AP-1) (Lu et al., 
2006). AP-1 can be composed of either homodimers or heterodimers between 
members of the Jun and Fos families. This mechanism of transrepression is well-
described for the GR, but as yet the MR has not been shown to modulate AP-1- and 
NFκB-induced transcription by direct protein-protein interactions. 
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One of the aims of the present study was to evaluate the interactions with the MR of 
two synthetic progestins, MPA and NET-A, frequently prescribed for HRT and to 
provide a comparative biochemical profile of these progestins, as well as 
progesterone (the natural hormone), in the same model system. Although MPA and 
NET-A have been used clinically for more than 40 years (Westhoff, 2003), their 
apparent Ki values for the human MR in the same model system, have not been 
established. Furthermore, to our knowledge, our study is the first to investigate their 
ability to induce the MR N/C interaction, as well as their activity for transrepression of 
transcription via the MR.  
 
The Kd for Ald binding to the hMR determined in our system (0.153 nM) is similar to 
previously reported Kd’s of ± 0.8-3 nM (Arriza et al., 1987; Lombes et al., 1994; Lim-
Tio et al., 1997). We established Ki’s for Prog, MPA and NET-A of 1.69, 197 and 229 
nM, respectively (Table 1). In addition, we determined a Ki for RU486 (mifepristone), 
a known antagonist of the PR, GR and AR (Spitz and Bardin, 1993; Song et al., 
2004), of 2980 nM. RU486 has previously been reported to have no affinity for the 
MR (Leonhardt and Edwards, 2002). When comparing the binding affinities of MPA 
and NET-A as percentages relative to the native ligand Ald (100%), our values for 
MPA and NET-A (0.078% and 0.067%, respectively), are slightly lower than 
previously reported values of 3.1% and 2.7%, respectively (Philibert et al., 1999; 
Winneker et al., 2003 ). Furthermore, we show, as have others have (Arriza et al., 
1987; Rupprecht et al., 1993b; Grossmann et al., 2004), that the potent synthetic GR 
agonist, Dex, also binds the MR with relatively high affinity, although it does not 
activate the MR with the same potency as it does the GR (Arriza et al., 1987; 
Rupprecht et al., 1993b; reviewed in Rogerson et al., 2003; Grossmann et al., 2004). 
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In addition, we determined the agonist and antagonist properties of MPA and NET-A 
for transactivation via an MRE using promoter-reporter assays in the COS-1 cell line. 
Our results show that, while both MPA and NET-A are devoid of mineralocorticoid 
agonist activity via an MRE, Prog has very weak partial agonist activity at 10 µM 
(approximately 20% activity) (figure 2A), and only about 6% at 1 µM (Appendix C4). 
In contrast, a previous study reported agonist activity of Prog for transactivation via 
the MR as 27% at 1 µM (Quinkler et al., 2002). The discrepancy between our results 
and that study could be due to the different promoter and cell lines used, as they 
used a synthetic reporter gene containing an MMTV promoter in the CV-1 cell line, 
while we used the pTAT-GRE-E1b-luc vector in COS-1 cells. However, the observed 
differences could also be attributed to differences in MR levels. It has previously 
been shown that receptor levels affect the potency and efficacy of full GR agonists, 
partial agonists and antagonists (Zhao et al., 2003). Interestingly, a very recent study 
showed no agonist activity for up to 3 µM Prog in the COS-1 cell line co-transfected 
with a MR-expression vector and PRE2tk-luc promoter-reporter (Sasagawa et al., 
2008), which is more consistent with our results.  
 
To further investigate agonist potential of ligands via steroid receptors, much 
attention has focussed on agonist-induced interactions between the N- and C termini, 
an interaction termed the N/C-interaction. This N/C-interaction is best characterized 
for the AR and involves binding of the AF2 region of the LBD with specific sequences 
in the N-terminal domain (He et al., 2000), and has been shown to play a major role 
in AR transcriptional activity (Kemppainen et al., 1999; He et al., 1999; He et al., 
2000). An Ald-dependent N/C-interaction was also recently shown for the MR 
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(Rogerson and Fuller, 2003). Although the other physiological ligand of the MR, 
cortisol (Cort), has a higher potency than Ald in transactivation assays (Rogerson et 
al., 1999), a MR N/C-interaction was only weakly induced in its presence (Rogerson 
and Fuller, 2003). The authors hypothesize that their results showing that Ald, but not 
Cort, can induce the MR N/C-interaction, may explain why Ald and Cort have 
differential effects in some non-epithelial cells. However, that study only compared 
Ald and Cort up to 100 nM. At a concentration of 10 µM Ald and Cort, we find similar 
induction of the N/C-interaction by both ligands (supplementary material in Appendix 
C5). In addition, Prog, a very weak partial agonist for the MR in our system, could 
weakly induce the N/C-interaction at a concentration of 10 µM (figure 3), but not 1 µM 
(data not shown). Similarly to Rogerson and Fuller (2003) who showed no N/C-
interaction for the MR antagonist spironolactone, our results indicate that the 
antagonists in our system, that do not display partial agonist activity, such as MPA, 
NET-A and RU486, could not promote an N/C-interaction (figure 3). We show that 
efficacy for transactivation via a synthetic GRE correlates with the efficacy for the 
induction of N/C-interaction (r2 = 0.9179; p<0.01) (figure 4), indicating that there is a 
good relationship between transactivation and MR N/C-interaction. 
 
We determined considerable anti-mineralocorticoid activity of Prog (EC50 = 3.1 nM), 
which is in agreement with previously reported EC50 values in the range 2-10 nM 
(Rupprecht et al., 1993; Auzou et al., 2000; Geller et al., 2000), but lower than a 
recent study where the EC50 for Prog was determined as 11.4-18.1 nM (Sasagawa et 
al., 2008). The molecular basis of Prog MR antagonistic activity still needs to be 
researched, but it is speculated that it may be due to the destabilization of helix 12 of 
the MR binding domain (Elger et al., 2003). Surprisingly, although it has previously 
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been reported that MPA, NET-A and RU486 have no MR antagonist activity 
(Winneker et al., 2003 and references therein, reviewed by Rowlands 2003, Palacios 
et al., 2006; Zhang et al., 2006), we showed MR antagonist activity of these ligands, 
albeit to a lesser extent than for Prog (figure 2B). We determined potencies (EC50 
values) of 310, 270 and 670 nM for MPA, NET-A and RU486, respectively. 
Interestingly, in accordance with our results, a recent study also showed MR 
antagonist activity for MPA and NET-A, but reported much lower potencies (1108.6 
and 1100.9 nM for MPA and NET-A, respectively) (Sasagawa et al., 2008). The EC50 
values obtained in our study are higher than the peak serum level reached with HRT 
(MPA = 0.2 nM and NET-A = 17.7 nM) (Ghatge et al., 2005; Activelle package insert 
reg. no. 33/21.8.2/0532, Novo Nordisk Inc.) or contraception (MPA = 3.9 nM; NET-A 
= 59 nM) (Mishell, 1996; Fotherby et al., 1983), but the possibility that  higher 
concentrations may be present in vivo in target tissues compared with concentrations 
that are usually measured in the blood, should not be excluded.  
 
In general, not much is known about transrepression mediated via the MR. Early 
work by Pearce and Yamamoto (1993) showed that the MR could not repress AP-1 
activity in response to Ald. In contrast to that study, we have shown that Ald can 
repress AP-1 activity via the MR. In agreement with the study by Liden et al.  (1997) 
suggesting that the MR can repress transactivation of NFĸB, we also show that Ald 
can repress NFĸB activity via the MR. We investigated the comparative effects of all 
the ligands on transrepression via the MR on both NFĸB and AP-1 promoter 
constructs. The results of the transrepression assays (at 1 µM) (figure 6A and 6B) as 
well as the effects observed for transactivation (figure 2A), are summarized in Table 
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4. Figure 6B indicates that none of the ligands, except Ald, could significantly 
transrepress the NFĸB site via the MR. 
  
Table 4: Relative responses for transactivation and transrepression via the MR 
at 1 µM ligandc 
 
Ligand 
GRE 
Relative response 
(%) 
NFĸB 
Relative response 
(%) 
AP-1 
Relative response 
(%) 
 
Ald 
 
100 
 
100 
 
100 
 
Prog 
 
19 ± 0.7 
 
12 ± 11.3  
 
51 ± 17.1  
 
MPA 
 
2 ± 0.7  
 
26 ± 6.3  
 
1.8 ± 1.8  
 
NET-A 
 
1.6 ± 0.8  
 
5 ± 4.0  
 
74 ± 3.7  
 
RU486 
 
1.3 ± 1.0  
 
23 ± 12.8  
 
60 ± 14.2  
Dex 
 
27 ± 0.2 
 
21 ± 16.0 
 
103 ± 5.9  
c
 Relative responses for transactivation via pTAT-GRE-E1b-luc and for transrepression via either 
NFĸB or AP-1-luc reporter plasmids at 1 µM ligand, were determined in the transiently transfected 
COS-1 cell line. Results are averages of at least three independent experiments, each performed in 
triplicate. Ald activity was taken as 100% and all other values are expressed as a % thereof. 
 
One of the most important and novel findings of our study, is that both NET-A and 
RU486 can transrepress the PMA-induced response on the AP-1 promoter via the 
MR, without exhibiting agonist activity for MR transactivation via a GRE. MPA, on the 
other hand, cannot transrepress the PMA-induced response on the AP-1 promoter 
via the MR, or induce agonist activity for MR transactivation via a GRE. Ligands that 
can transrepress, but not transactivate, are referred to as dissociated ligands, and 
are well described for the GR (Vaysierre et al., 1997; De Bosscher et al., 2005). The 
transrepression by the ligands in this study is consistent with a MR-dependent 
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mechanism as the repression without transfected MR, was subtracted from the 
repression with transfected MR. However, elucidation of the mechanism behind this 
dissociative activity will require additional studies. Interestingly, Vaysierre et al. 
(1997) reported a similar ability for synthetic glucocorticoids that could differentiate 
between transactivation and AP-1 transrepression via the GR. Similarly, we show 
that while Dex is a partial agonist for MR transactivation on a GRE promoter, it is a 
full agonist for transrepression on the AP-1 promoter via the MR. An AP-1 
transrepression/transactivation ratio was calculated for all the ligands (Table 5). NET-
A and RU486 had an AP-1 transrepression/transactivation ratio of 46.3 and 46.2, 
respectively compared to 1.0 for Ald, indicating that NET-A and RU486 did not 
transactivate a GRE via the MR, but was able to repress AP-1 transactivation via the 
MR. As the fractional occupancy of the MR at 1 µM is only 25%, it is intriguing that 
RU486 could repress the AP-1 activity by 60%. This result may indicate that the 
affinity of a ligand for the MR, does not necessarily determine the efficacy of the 
ligand for transrepression, as has been shown for GR ligands via both NFĸB and AP-
1 (Ronacher et al., 2009). In contrast, MPA could not transactivate a GRE or repress 
AP-1 activity via the MR. The transrepression/transactivation ratio for MPA was thus 
0.9 indicating that MPA does not distinguish between transactivation and 
transrepression via the MR. In fact, MPA does not display any mineralocorticoid 
agonist properties. This ratio for Prog and Dex was 2.7 and 3.8, respectively, 
indicating that these ligands are better at transrepression than transactivation. MR 
actions via these transcription factors, NFĸB and AP-1, may play an important role in 
inflammation, typically associated with MR-mediated cardiovascular injury. 
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It has been reported that MR antagonism protects the cardiovascular system from 
damaging inflammation (Fejes-Tóth and Náray-Fejes-Tóth, 2007). For this reason, 
we next determined whether MPA, NET-A and RU486 could antagonize Ald-induced 
effects on a risk factor of cardiovascular disease. Using a rat cardiomyocyte cell line 
transiently transfected with the MR as a model for cardiovascular disease, we 
investigated the antagonistic properties MPA, NET-A and RU486, on the expression 
of the endogenous Ald-responsive gene, Orm-1. This gene is involved in 
inflammation, and elevated levels are considered a cardiovascular risk factor 
(Engström et al., 2003). Interestingly, patients with metabolic syndrome have 
elevated plasma Orm-1 levels, which may account for the increased prevalence of 
cardiovascular problems in this syndrome. Although MPA, NET-A and RU486 acted 
as weak antagonists of the MR in a GRE-reporter assay, we showed that NET-A and 
RU486, but not MPA, inhibit the effect of Ald on the expression of the endogenous 
MRE-containing gene, Orm-1, to a similar extent as Prog. MPA increased the 
expression of Orm-1 (figure 8A and 8B). However, the H9C2 cell line also expresses 
the GR (figure 7B) and it is known that glucocorticoids can induce Orm-1 (Vannice et 
al., 1984). Taking this into account, together with the fact that we show no MR 
agonist properties for MPA in a GRE-reporter assay, it is probable that MPA, known 
to have glucocorticoid agonist properties at a concentration of 1 µM (Koubovec et al., 
2004; Koubovec et al., 2005; Ronacher et al., 2009), would preferentially act via the 
GR, and it is thus likely that the agonist activity of MPA on the endogenous Orm-1 
gene is mediated by the GR rather than the MR.  
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Table 5: Transrepression/transactivation ratios (AP-1/GRE) via the MR at 1 µM 
ligandd 
 
Ligand 
GRE 
Relative response) 
(%) 
AP-1 
Relative response 
(%) 
Ratio 
 
Ald 
 
100 
 
100 
 
1.0 
 
Prog 
 
19 ± 0.7 
 
51 ± 17.1  
 
2.7 
 
MPA 
 
2 ± 0.7  
 
1.8 ± 1.8  
 
0.9 
 
NET-A 
 
1.6 ± 0.8  
 
74 ± 3.7  
 
46.3 
 
RU486 
 
1.3 ± 1.0  
 
60 ± 14.2  
 
46.2 
Dex 
 
27 ± 0.2 
 
103 ± 5.9  
 
3.8 
d
 Relative responses for transactivation via pTAT-GRE-E1b-luc and for transrepression via AP-1-luc 
reporter plasmids at 1 µM ligand, were determined in the transiently transfected COS-1 cell line. 
Results are averages of at least three independent experiments, each performed in triplicate. Ald 
activity was taken as 100% and other values are expressed as a % thereof. Ratios were calculated as 
% relative response on a GRE / % relative response on AP-1. This ratio is 1.0 for the standard 
mineralocorticoid Ald (100% transrepression / 100% transactivation = 1.0). A ratio of > 1 indicates that 
transrepression is preferred, while a ratio of < 1 indicates that transactivation is preferred. 
 
In summary, our results indicate that on an endogenous gene, considered to be a 
cardiovascular disease risk factor, MPA and NET-A act differently, which has 
implications for women using these progestins in HRT. As NET-A acts similarly to 
Prog, it may be the preferable progestin for women at risk of cardiovascular disease. 
Further investigation into the anti-mineralocorticoid properties of MPA, NET-A and 
RU486 is required, especially in vivo in animal experiments. In the meantime, 
however, it is important that physicians understand that progestins differ widely in 
their chemical structure, pharmacokinetics, and biological activity, and take 
cognizance of this when prescribing the optimum type and dose of progestin for HRT.  
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5. CONCLUDING DISCUSSION 
Although MPA and NET-A are widely used in female reproductive therapy, not much 
is known about their mechanism of action at the molecular level. Clinical evidence 
indicating that the use of MPA and NET-A in HRT increases the risk of breast cancer 
(Rossouw et al., 2002; Beral, 2003), and also that MPA increases the risk of CVD, 
has highlighted the importance of investigating these mechanisms. In addition to 
these studies implicating MPA in effects on cardiovascular function and breast 
cancer in HRT users, use of MPA as a contraceptive has also been implicated in 
effects on local immune function (Ildgruben et al., 2003). Little is known about the 
effects of MPA and NET-A, as compared to Prog, in the cervicovaginal environment, 
and whether they interfere with local epithelial immune function. In the first part of this 
thesis (Chapter 2), we thus investigated the regulation of cytokine genes by MPA and 
NET-A, as compared to the endogenous hormone Prog, in Ect1/E6E7 and Vk2/E6E7 
cell lines with a view to understanding the possible steroid receptor mediated effects 
of these synthetic progestins on immunity in the female genital tract. In addition, 
although it is known that both MPA and NET-A can bind the PR, GR, AR and MR, no 
thorough comparison exists on the binding affinity of MPA and NET-A, as compared 
to Prog, towards the AR and MR. Moreover, an accurate pharmacological 
characterisation of the relative efficacy and potency of the two progestins on gene 
regulation via these receptors is lacking. In the second and third part of the 
experimental work in this thesis (Chapter 3 and 4), we thus examined the mechanism 
of action of MPA and NET-A, relative to Prog, at the molecular level via 
overexpressed AR and MR in the COS-1 cell line. Additionally, we investigated the 
MR-mediated transcriptional regulation of the endogenous Orm-1 gene, a marker of 
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CVD, in a rat cardiomyocyte cell line, with a particular focus on the antagonistic role 
of MPA and NET-A, as compared to Prog. 
 
5.1 Comparing the regulation of endogenous pro-inflammatory 
cytokine genes, by MPA and NET-A, in the female reproductive tract 
In Chapter 2, specific genital tract cell types for the induction or upregulation of 
protective molecules were investigated. As a model for cervicovaginal mucosal 
immunity, we used epithelial cell lines derived from the female ectocervical and 
vaginal mucosa, and showed that ligand-specific and cell-specific regulation of the 
pro-inflammatory cytokine (IL-6) and chemokines (IL-8 and RANTES) gene 
expression occurs by Prog, MPA and NET-A. Chemokines initiate the immune 
response by controlling leukocyte migration and lymphocyte development. All three 
cytokines have been shown to be expressed and secreted by Ect/E6E7 and 
Vk2/E6E7 cell lines in response to activation by TNFα (Fichorova et al., 1999). Many 
inflammatory response genes containing NFĸB response elements, like the IL-6, IL-8 
and RANTES genes, are upregulated in response to proinflammatory cues initiated 
by cytokines like TNFα. IL-8 and RANTES are involved in the early inflammatory 
response, by recruiting specific leukocytes to sites of ongoing inflammation, while IL-
6 is responsible for neutrophil priming to chemotactic factors (Kunkel et al., 1997). 
These specific cytokines were chosen because they have previously been shown to 
be repressed by MPA in other cell types. For example, MPA has previously been 
shown to repress IL-6 and IL-8 promoter–reporter constructs at the transcriptional 
level (Koubovec et al., 2004), as well as the RANTES gene in endometrial cells 
(Zhao et al., 2002). Moreover, IL-6, IL-8 and RANTES have been reported to have 
distinct roles in HIV-1 pathogenesis (Fichorova et al., 2004). 
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Results showed that unlike Prog which upregulated TNFα-stimulated IL-6 gene 
expression in both the ectocervical and vaginal cell lines, MPA and NET-A had no 
effect. This is inconsistent with previous studies that have shown the repression of IL-
6 by MPA in other cell types (Mantovani et al., 1997; Koubovec et al., 2004; Wessel 
Kriek, MSc thesis). Similarly, NET-A has previously been shown to either upregulate 
(Zitzmann et al., 2005) or downregulate (Wessel Kriek, MSc thesis) IL-6. In contrast, 
NET-A in combination with estrogen, like estrogen only, had no effect on IL-6 levels 
in healthy postmenopausal women (Žegura et al., 2006).  
 
In contrast to the observed effects on the IL-6 gene, we show that MPA and NET-A 
upregulate the TNFα-induced IL-8 gene expression to different extents in both cell 
types, indicating pro-inflammatory activity of these progestins which is similar to that 
of Prog. Similarly, Prog and MPA have previously been shown to upregulate IL-8 
mRNA levels in human endometrial stromal cells (Arici et al., 1996). As IL-8 is a 
chemotactic factor for neutrophils and lymphocytes, the local concentration of IL-8 is 
important in determining whether either neutrophils or lymphocytes are primarily 
recruited. Prog has previously been shown to induce a neutrophil response in the 
vagina of germ-free mice, even in the absence of bacterial infection (Beaver, 1960), 
indicating a protective role for Prog in the vagina. Thus, our results demonstrating 
upregulation of IL-8 by natural Prog, MPA and NET-A, may indicate that in these cell 
lines, the synthetic progestins are similar to Prog, and that this may provide an 
enhanced local defense mechanism against infections in the vaginal mucosa.  
 
Interestingly, results indicated differential regulation of the TNFα-induced RANTES 
gene by MPA, NET-A and Prog in the Ect1/E6E7 cells, but similar regulation in the 
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Vk2/E6E7 cell line. As RANTES is a pro-inflammatory chemokine, the suppression of 
the RANTES gene by MPA indicates that MPA is anti-inflammatory. In epithelial cells, 
RANTES is responsible for recruiting immune cells into the reproductive tract (Kunkel 
et al., 1997) and thus inhibition of RANTES would suppress inflammation, thereby 
blocking infiltration of immune cells. As the transmission of viruses such as HIV, HSV 
and HPV occurs at the cervicovaginal environment (Tjiong et al., 2001), a lack of 
recruitment of immune cells into the reproductive tract may have negative 
implications for women using MPA, as they would not be able to effectively combat 
infections in the ectocervical environment. Consistent with this result, injectable 
hormonal contraceptive usage has previously been associated with increased risk of 
cervical cancer due to HPV (Castle et al., 2005). In contrast, a South African study 
investigating the link between use of MPA and NET-A as progestin-only injectable 
contraceptives, and the risk for cervical cancer due to HPV, indicated that these 
progestins did not contribute to the risk of cervical cancer (Shapiro et al., 2003).  
 
Downregulation of RANTES gene expression by MPA has previously been reported 
in endometrial stromal cells (Zhao et al., 2002), and the PR was shown to mediate 
the effect. In addition, MPA has previously been shown to repress the pro-
inflammatory chemokine, IL-8, via the GR (Koubovec et al., 2004). We thus 
investigated which steroid receptor is mediating the effects of MPA on RANTES in 
the Ect1/E6E7 cell line, by using receptor-specific antagonists. Our results using 
RU486, the antagonist for the PR and GR, was inconclusive as RU486 behaved as 
an agonist in this cell line. We were unable to exclude the involvement of the GR and 
PR, particularly the PR-A isoform, which is a weak activator of transactivation, but a 
strong activator of transrepression (Kalkhoven et al., 1996). However, when using the 
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AR-specific antagonist, hydroxyflutamide, we showed that the repression of the 
RANTES gene by MPA is mediated by the AR. Consistent with this result, the 
androgenic properties of MPA have previously been proposed to be responsible for 
the anti-inflammatory effects of MPA on plasma inflammatory markers, such as C-
reactive protein and serum amyloid A protein (Wakatsuki et al., 2002).  
 
Our study is the first to show ligand-specific and cell-specific effects on cytokine and 
chemokine genes in the cervicovaginal environment. In addition, we show that the 
observed repression of the TNFα-induced RANTES gene by MPA in the Ect1/E6E7 
cell line is mediated by the AR. Considering that NET-A was shown to have similar 
androgenic properties to MPA for transactivation and transrepression of synthetic 
promoters (see Chapter 3), it was surprising that NET-A did not act via the AR on the 
endogenous RANTES promoter, that contains NFκB-binding sites, in the Ect1/E6E7 
cell line. This difference indicates that the repression of the endogenous RANTES 
gene is more complex than repression on a synthetic NFĸB-promoter, and possibly 
involves more factors than just NFκB tethering. It is thus possible that there are other 
regulators or elements determining the response of NET-A on the endogenous gene, 
which are not present in the promoter-reporter construct used. Furthermore, as it is 
known that NET-A can be metabolized (Stanczyk and Roy 1990), the possibility thus 
exists that NET-A is metabolized in this cell line, and that the metabolite(s), are less 
efficacious AR agonists than NET-A itself. This could be investigated in future, by 
transfecting an ARE-luc or NFκB-luc into the Ect1/E6E7 cells, and determining 
whether NET-A can transactivate or transrepress via the AR.  
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In addition, the repression of RANTES by MPA via the AR was not observed in the 
Vk2/E6E7 cell line, indicating that MPA acts in a cell-specific manner. As the levels of 
AR in the Ect1/E6E7 and Vk2/E6E7 cell lines are similar, it is unlikely that these 
differences in responses are due to different levels of steroid receptors. It may be 
due to other factors such as different extent of metabolism or even different levels of 
coregulators. Using whole cell binding experiments, we showed that the amount of 
GR and AR in the Ect1/E6E7 cells line are similar to those in the Vk2/E6E7 cell line. 
The expression of AR in the human vagina and cervix has previously been reported 
(Ruizeveld de Winter et al., 1991), and it is known that the GR is ubiquitously 
expressed (reviewed in Gross and Cidlowski, 2008). A further complexity is the 
affinity of MPA and NET-A for the different steroid receptors, in particular the GR 
versus the AR, as there appear to be similar levels of these receptors in the 
Ect1/E6E7 cell line. MPA has a much higher affinity for the GR than NET-A (10.8 vs. 
270 nM, respectively) (Koubovec et al., 2005), while both MPA and NET-A have 
similar affinities for the AR (19.4 and 27.9 nM, respectively). Thus, in a cell where the 
AR and GR are expressed equally, it is assumed that MPA can act via either the GR 
or AR as its affinity for these receptors is similar. However, one would then assume 
that NET-A would act via the AR, which is not the case in this study.  
 
Nevertheless, this study is the first to show that MPA suppresses the RANTES gene 
via the AR in a human ectocervical cell line. Further work is necessary to assess the 
impact of this novel finding. Moreover, the finding that MPA acts differently to NET-A, 
and does not mimic the effects of Prog, has important implications for women’s 
health.  
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Finally, the immunoregulatory milieu of the genital mucosa is important in determining 
the response to antigenic challenge. Mucosal innate immune factors as well as 
proinflammatory cytokines are associated with elevated levels of HIV-1 shedding in 
the female genital tract (Gumbi et al., 2008). During male-to-female transmission, it is 
thought that virus in the semen enters the stratified squamous epithelium of the 
vagina or the columnar epithelium of the endocervix to infect cells within or below the 
epithelium (reviewed in Pope and Haase, 2003). It is not clear which cells are the first 
to interact with, and to be infected with the virus, whether environmental factors in the 
reproductive tract tissues may influence the infection, or whether there are local 
immune-system responses directed at the virus. Thus, a greater understanding of the 
immune responses at these different anatomical locations in the genital tract, and 
how MPA and NET used as contraceptives and in HRT regulate genes relevant to 
the cervicovaginal mucosal immune response, may have implications for the 
development of efficacious topical microbicide products for the prevention of sexually 
transmitted HIV-1 infection, or for the development of HIV-1 vaccines. This may thus 
also have important implications for women’s risk of susceptibility to infections. In 
addition, novel avenues may be identified both to protect against potential pathogens 
and to improve the quality of women’s reproductive health. 
 
 5. 2. Comparing the androgenic properties of Prog, MPA and NET-A 
in the COS-1 cell line  
In the second part of this thesis (Chapter 3), for the first time, equilibrium binding 
studies in the COS-1 cell line enabled the calculation of precise Ki values of Prog, 
MPA, NET-A and RU486 for the AR. RU486 was included as it is a synthetic 
progestin previously reported to bind the AR (Song et al., 2004). The COS-1 cell line 
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does not contain significant levels of endogenous steroid receptors and is thus an 
appropriate model cell line for comparing the activities of ligands via a specific 
transiently transfected receptor. Although saturation binding experiments are the 
conventional way in which Kd’s are determined, we determined Kd and Ki values by 
using the alternate method of homologous/heterologous competitive binding 
experiments, using the Cheng-Prusoff equation (Cheng and Prusoff, 1973). We 
optimized the concentration of 3H-[MIB] (two to ten times lower than the EC50) to use, 
and found 0.2 nM to be optimal. The time for 0.2 nM 3H-[MIB] to reach binding 
equilibrium was determined as 16 hours.  
 
The results showed that Prog, MPA, NET-A and RU486 were able to compete with 
MIB for binding to the AR. Prog, MPA and NET-A displayed similar binding affinity to 
each other (Ki = 36.6 nM, 19.4 nM and 21.9 nM respectively), and the natural 
androgen DHT (Ki = 29.4 nM). MPA and NET have previously been shown to bind to 
the endogenously expressed AR in the MCF-7 breast cancer cell line with a similar 
relative affinity to each other, albeit with a much lower relative binding affinity than 
that found in our study (Bergink et al., 1983 and references therein). In addition, our 
results for Prog, MPA and DHT are consistent with a previous study in the COS-1 cell 
line (Kemppainen et al., 1999). Previous studies have reported that RU486 has low 
binding affinity for the AR in rat prostate cytosols (Philibert et al., 1999; Cabeza et al., 
2007). Interestingly, the study by Cabeza and co-workers (2007) shows a 23-fold 
lower relative binding affinity of RU486 compared to MIB. Indeed, in our study when 
compared to MIB, RU486 has a 12-fold lower affinity, which is in the same order of 
magnitude as the results by Cabeza et al. (2007). However, when compared to the 
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natural androgen DHT, RU486 (synthetic progestin) has a 6-fold higher binding 
affinity for the hAR. 
 
We demonstrated that unlike Prog, MPA and NET-A are potent and efficacious AR 
agonists, with activity comparable to that of DHT. Furthermore, consistent with other 
studies, we show that Prog (Kemppainen et al., 1999; Sasagawa et al., 2008) and 
RU486 are potent antagonists (Song et al., 2004; Cabeza et al., 2007) with minimal 
agonist activity. We show that in contrast to DHT and NET-A, MPA does not induce 
the N/C-interaction of the AR on the classical ARE, which also serves as a response 
element for the GR, PR and MR (reviewed in Beato, 1989). In addition, we show that 
MPA can induce the N/C-interaction on two selective AREs, suggesting a promoter-
dependent induction of the AR N/C interaction by MPA. Indeed, it has been shown 
that the AR N/C interaction is important for AR activation of some androgen-
regulated promoters, but not others (He et al., 2002). However, we cannot exclude 
the possibility that the reason for these quantitative differences in the ability of MPA 
to induce the N/C interaction via the promoter-reporter-constructs used in this study 
is due to different expression levels of the promter-reporter constructs or the AR. 
Taken together, these results suggest that MPA and NET-A activate the AR by 
different mechanisms on the classical ARE, but by similar mechanisms on selective 
AREs.  
 
It is well-known that the anti-inflammatory effects of glucocorticoids are mediated by 
the GR interacting with transcription factors, such as NFĸB and AP-1, thereby 
repressing the activity of the transcription factor and the target genes (De Bosscher 
et al., 2003). Considering that the AR and GR belong to the same superfamily and 
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are closely related, the question arose whether the AR could transrepress NFĸB and 
AP-1 containing genes in a similar manner. Indeed all the AR agonists used in this 
study could transrepress NFĸB and AP-1 synthetic promoter-reporter constructs via 
the AR. In addition, a comparison of the effects of all the ligands on transactivation 
on the classical ARE versus transrepression on both NFĸB and AP-1 synthetic 
promoter-reporter constructs, showed similar activity of the ligands on all three 
promoters. Interestingly, the RANTES gene promoter has four potential NFĸB 
response elements (Lebovic et al., 2001), thus the possibility exists that the AR-
mediated repression of the RANTES gene by MPA (Chapter 2) occurs via NFĸB.  
 
In summary, our results indicate that the synthetic progestins, MPA and NET-A, but 
not natural Prog, display binding affinities and biological activity comparable to the 
native androgenic ligand, DHT, via the AR. It has been proposed that the androgenic 
effects of MPA may reverse the protective effects of endogenous androgen signaling 
in the breast (Birrell et al., 2007). Our results showing similar potent androgenic 
activity of MPA and NET-A suggest that NET-A would do the same. Indeed, both 
MPA and NET were shown to substantially increase the risk of breast cancer in long-
term HRT in the ‘Million Women Study’ (Beral, 2003).  
 
5. 3. Comparing the anti-mineralocorticoid properties of Prog, MPA 
and NET-A in the COS-1 and cardiomyocyte cell lines  
In the third part of this thesis (Chapter 4), we used the same model system (COS-1 
cell line) to evaluate MR activity induced by MPA and NET-A, relative to Prog. The 
results from our study are the first to determine accurate apparent Ki values for MPA, 
NET-A and RU486 towards the human MR in COS-1. As in Chapter 3, we first 
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optimized the appropriate concentration of 3H-[Ald] to use and the time needed to 
attain binding equilibrium. The Ki’s values established for Prog, MPA and NET-A 
indicate that MPA and NET-A bind to the MR with similar affinity, but with a 
significantly lower affinity than Prog (1288-fold, 1497-fold and 11-fold compared to 
Ald). In addition, the binding affinity of RU486 was 19 477-fold lower than Ald. 
Previous reports on whether RU486 binds the MR or not are contradictory, as it has 
been reported to have no affinity for the MR (Leonhardt and Edwards, 2002), while 
on the Nuclear Receptor Signaling Atlas webpage it is classified as an MR 
antagonist, the Ki of which still needs to be curated 
(www.nursa.org/10.1621/datasets.02001). In addition, we show that the synthetic GR 
agonist Dex also binds the MR with relatively high affinity (7-fold less compared to 
Ald). Although this is not a novel result (Arriza et al., 1987; Rupprecht et al., 1993b; 
Grossmann et al., 2004), it is one that is under-appreciated in the current literature, 
which refers to Dex as a GR-specific ligand. In fact, in rabbit reticulocyte lysates, Dex 
has previously been shown to have a similar relative binding affinity as Ald (Hellal-
Levy et al., 1999). Thus, experiments performed in cell lines expressing both 
endogenous GR and MR, should not exclude a role for the MR on the basis that Dex 
is GR-specific.  
 
Our results show that, while both MPA and NET-A are devoid of mineralocorticoid 
agonist activity via an MRE, Prog has very weak partial agonist activity at 10 µM. 
Other in vitro studies have demonstrated agonist activity of 1 µM Prog for 
transactivation via the MR (Quinkler et al., 2002), while one recent study showed no 
agonist activity up to 3 µM (Sasagawa et al., 2008). Consistent with previous reports 
 206 
(Hellal-Levy et al. 1999; Grossmann et al., 2004), Dex showed partial agonist activity 
for transactivation via the hMR.  
 
As investigated and discussed in Chapter 3, studies have shown that the ligand-
induced N/C-interaction of the AR plays a major role in AR transcriptional activity 
(Kemppainen et al., 1999; He et al., 1999; He et al., 2000). Similarly, an Ald-
dependent N/C-interaction has been shown for the MR (Rogerson and Fuller, 2003). 
When investigating the ability of the ligands used in this study to induce the MR N/C 
interaction, we show that both of the partial agonists for transactivation, Prog and 
Dex, could marginally induce the N/C-interaction at 10 µM. Consistent with previous 
results for the MR antagonist spironolactone (Rogerson and Fuller, 2003), we found 
no N/C-interaction for MPA, NET-A and RU486, the antagonists in our system. Our 
findings show that efficacy for transactivation via a synthetic GRE correlates with the 
efficacy for the induction of N/C-interaction on the same GRE, indicating that the MR 
N/C-interaction is important for MR transcriptional activity (r2=0.9179; p<0.01). When 
investigating the MR antagonist activity of the ligands, we show that MPA, NET-A 
and RU486 are weak antagonists (EC50 values of 310 nM, 270 nM, and 670 nM, 
respectively) relative to the reported values for the well-known MR antagonist 
spironolactone (EC50 of 14 nM) (reviewed in Lu et al., 2006). This is in contrast to 
previous reports showing no MR antagonist activity (Winneker et al., 2003 and 
references therein, reviewed by Rowlands 2003, Palacios et al., 2006; Zhang et al., 
2006).  
 
MR antagonism has been reprted to protect the cardiovascular system from 
damaging inflammation (Fejes-Tóth and Náray-Fejes-Tóth, 2007). Orm-1, an Ald-
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responsive gene, is involved in inflammation, and high levels are associated with 
increased risk of CVD (Engström et al., 2003). Our results investigating the 
antagonist properties of MPA, NET-A and RU486, relative to Prog, on the expression 
of the endogenous Orm-1 gene in a rat cardiomyocyte cell line transiently transfected 
with the MR, showed that Prog, NET-A and RU486 inhibited the Ald-induced 
upregulation on Orm-1 mRNA expression. In contrast, MPA increased the expression 
of the Ald-induced upregulated Orm-1 gene. Moreover, when examining the 
expression of endogenous Orm-1, an MRE-containing gene, in response to Prog, 
MPA, NET-A and RU486 on their own, we showed that, in contrast to MPA Prog, 
NET-A and RU486 could not increase Orm-1 expression significantly. However, since 
we show that the H9C2 cell line also expresses endogenous GR, it may be that MPA, 
at a concentration of 1 µM, would act preferentially via the GR. Thus we cannot 
exclude the possibility that the agonist activity of MPA on the endogenous Orm-1 
gene (figure 8A) is mediated, at least in part, by the GR. Future studies to delineate 
the role of the GR would include studies in the presence of a GR antagonist and/or 
knockdown of the GR by siRNA technology.  
 
Given that MR antagonism is known to protect the cardiovascular system from 
damaging inflammation, it is interesting to see that, not only does MPA not 
antagonize the Ald-effects on Orm-1, but it may increase its expression. These 
results may provide an explanation for the observed adverse effects of MPA on CVD 
in the WHI study. On the other hand, NET-A partially inhibits the Ald-upregulated 
Orm-1 expression, indicating that NET-A could have cardioprotective properties.  
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Little is known about MR-mediated transrepression of genes, and similarly to the AR 
discussed in Chapter 3, this receptor is very closely related to the GR with a similar 
mechanism of action. Our findings show that only the natural ligand, Ald, and none of 
the progestins tested, could significantly elicit MR transrepression via NFκB. In 
contrast, this study demonstrates that Prog, NET-A and RU486 cause 
transrepression via AP-1 tethering. In addition, we show that even though MPA and 
NET-A are similar in most assays, NET-A but not MPA, can transrepress the PMA-
induced response on the AP-1 promoter via the MR. The 
transrepression/transactivation ratio for MPA is 0.9, which is similar to that of Ald 
used as the standard (transrepression / transactivation = 1.0) indicating that MPA 
cannot dissociate between transrepression and transactivation. In fact, under these 
experimental conditions, MPA is not an agonist for transactivation or transrepression 
via the MR. In contrast, to our knowledge, our study is the first to show that NET-A 
and RU486 can discriminate between transrepression and transactivation 
(transrepression/transactivation ratio for is 46.3 and 46.2, respectively) via the MR. 
For the GR, such compounds that can dissociate between transrepression and 
transactivation mechanisms are called dissociated glucocorticoids. These 
compounds are thought to retain the beneficial anti-inflammatory activities 
(transrepression mechanism) without the negative side-effects (transactivation 
mechanism) (Vayssière et al., 1997). Thus NET-A and RU486 may be referred to as 
dissociated mineralocorticoids. This result indicates that NET-A and RU486 may be 
promising agents for the treatment of certain inflammatory conditions, such as the 
inflammation associated with MR-mediated cardiovascular injury. However, 
elucidation of the mechanism behind this dissociative activity will require additional 
studies.  
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Taken together, the results from this study indicate that MPA and NET-A act 
differently to each other and Prog for transactivation and transrepression of synthetic 
promoters (GRE vs. AP-1) via overexpressed hMR in COS-1 cells. In addition, 
differential effects are also observed on an endogenous GRE/MRE-containing gene 
considered to be a cardiovascular disease risk factor. Although these results 
elucidate only a single step in the complex pathophysiological process of CVD, it may 
have implications for women using these progestins in reproductive therapy. As NET-
A antagonizes the Orm-1 gene to a similar extent as Prog, it may offer 
cardioprotection, and thus be the preferable progestin for women at risk of 
cardiovascular disease. Similarly, the dissociative mineralocorticoid property of NET-
A, makes it a candidate for therapeutic use that would combat inflammation, while 
displaying few side-effects. However, it has been reported that progestins displaying 
high androgenic potency (as shown for MPA and NET-A in Chapter 3), may not 
protect women against heart attacks (Sitruk-Ware, 2000). 
 
Collectively, the results from our study show that sometimes MPA and NET-A act in a 
similar manner, but different from Prog. For example, MPA and NET’s agonist 
transactivation and transrepression activity via expressed AR in COS-1 cells 
(Chapter 3), their lack of regulation of the IL-6 gene in the Ect1/E6E7 and Vk2/E6E7 
cell lines (Chapter 2), as well as their lower binding affinity for the MR, lack of agonist 
activity, and weaker antagonistic activity on a synthetic MRE promoter (Chapter 4), 
are similar, but different from Prog. However, sometimes they act like Prog, for 
example in having similar binding affinities to the AR (Chapter 3), and in upregulating 
the IL-8 and RANTES genes in the Vk2/E6E7 cell line (Chapter 2). Sometimes MPA 
and NET-A act differently from each other, and from Prog. For example, in the 
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regulation of the endogenous RANTES gene in the Ect1/E6E7 cell line (Chapter 2). 
Finally, there are circumstances under which MPA and NET differ in their actions, but 
one of them displays actions similar to that of Prog. These circumstances include 
similar activities of Prog and NET-A, but not MPA, for transrepression on the AP-1 
promoter via the MR (Chapter 4), similar regulation of the IL-8 gene by Prog and 
MPA, but not NET, in the Ect1/E6E7 cells (Chapter 2), and similar antagonist 
activities by Prog and NET-A, but not MPA, on the Orm-1 gene (Chapter 4).  
 
Our results clearly suggest that making an informed decision about the specific 
progestin to use clinically, is not a trivial matter. Finally, it is thus important that 
physicians understand that progestins differ widely in their chemical structure, 
pharmacokinetics, and biological activity, and take cognizance of this when 
prescribing the optimum type and dose of progestin for contraception or HRT. 
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5.4 Future Perspectives 
In the first part of this thesis (Chapter 2), the differential regulation of pro-
inflammatory cytokines by MPA and NET-A, as well as cell-specific effects were 
demonstrated, to our knowledge, for the first time in human ectocervical and vaginal 
epithelial cell lines. Previous reports indicate that different cells may respond 
differently to a particular ligand, depending on several factors, such as the relative 
levels and different isoforms of different steroid receptors, and the receptor 
conformation induced by the ligand which subsequently affects the recruitment of co-
regulators (co-activators and co-repressors) (Turgeon et al., 2004; reviewed by 
Hapgood et al., 2004).  
 
To gain insight into the differential and cell-specific effects of MPA and NET-A, a 
number of factors may thus be addressed. We have already determined the relative 
expression levels of PR, GR, AR, and ER (Renate Louw and Dewald Noeth, MSc 
students) in these cell lines. Moreover, it would be interesting to determine PR 
isoform is expressed in these cell lines, and whether they might be involved in any of 
the observed responses, as these isoforms are known to be transcriptionally different 
(Shyamala et al., 1990; Kastner, et al., 1990).  
 
We hypothesized that the differential effects of MPA and NET-A on the RANTES 
gene is as a result of the ligands acting via different steroid receptors. Although 
experiments using the AR antagonist, hydroxyflutamide indicate a role for the AR in 
mediating the repression of RANTES in the Ect1/E6E7 cell line, the possible role for 
the other steroid receptors, particularly the GR, has not been excluded. Thus these 
possibilities remain to be investigated. Specific steroid receptors may be knocked 
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down by using siRNA technology, in the quest to determine which steroid receptors 
play a role, and to what extent, in the responses of MPA and NET-A on the IL-8 and 
RANTES genes in the Ect1/E6E7 versus the Vk2/E6E7 cell lines. Furthermore, as 
MPA and NET-A are also used in combination with estrogen in HRT, it would be of 
interest to determine not only the direct effects of MPA and NET-A on these genes, 
but also their modulation of the effect of estrogen.  
 
In addition, we have compared the Ki for MPA and NET-A via overexpressed AR in 
the COS-1 cell line (Chapter 3). It would be interesting to perform binding 
experiments in the Ect1/E6E7 and Vk2/E6E7 epithelial cell lines, and compare the Ki 
values for MPA and NET-A via endogenous AR, GR or PR, so as to provide insights 
into the relationship between binding parameters and biological activity. Furthermore, 
the co-regulator (co-factor and co-repressor) expression and/or recruitment leading 
to gene transcription may be different in the Ect1/E6E7 versus Vk2/E6E7 cell lines. 
The expression levels can be investigated by preparing whole cell lysates from both 
cell lines, and assessing the levels of co-regulators such as SRC-1, GRIP-1, p300, 
NCor and Smrt using Western blotting, while the differential recruitment of co-
regulators to promoters could be determined by chromatin immunoprecipitation 
(ChIP) assays.  
 
In the literature, there is a paucity of data thoroughly comparing the binding affinities 
of MPA and NET-A via specific steroid receptors. To date, only one study has 
addressed this, specifically for the GR, and performed a thorough pharmacological 
characterization of the relative efficacy and potency of MPA versus NET-A on gene 
regulation (Koubovec et al., 2005). Our study has now addressed this for the AR and 
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MR (Chapters 3 and 4). However, it would also be interesting to do these 
experiments for the PR isoforms, as well as isoforms of the GR, AR and MR. Work in 
this area has already been started in our laboratory, showing that both MPA and 
NET-A have a similar affinity for overexpressed human PR-A and PR-B in COS-1 
cells (Renate Louw, BSc(Hons)). Further investigation into their PR isoform-specific 
agonist and antagonist activity are currently in progress.  
 
The AR N/C-interaction was initially shown to be crucial for transactivation 
(Kemppainen et al., 1999). However, recent evidence shows that the AR N/C-
interaction enhances AR transactivation activity but that transactivation can proceed 
without N/C-interaction (Shen et al., 2005). Indeed, we have also shown a disparity 
between the MPA-induced AR N/C-interaction and AR transactivation activity in the 
presence of MPA. In addition, it has recently been shown that the p160 co-activator, 
GRIP-1, mediates the DHT-induced AR N/C-interaction (Shen et al., 2005). Thus, to 
provide insight into the reason for the lack of N/C-interaction on a classical ARE by 
MPA, but not NET-A, it would be interesting to determine whether GRIP-1 is involved 
in AR N/C-interaction and AR transactivation in the presence of MPA and NET-A. It is 
likely that GRIP-1 would also mediate NET-A induced N/C-interaction, while it would 
not interact with MPA-bound AR. 
 
We characterized the interaction between the N-terminal domain of the AR and the 
ligand-bound ligand binding domain in vitro using a mammalian two-hybrid assay. A 
recent study however used the quantitative fluorescence resonance energy transfer 
(FRET) assay to investigate AR N/C-interaction in living cells, and showed that the 
N/C-interaction is initiated rapidly following the addition of DHT, before transport to 
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the nucleus (Schaufele et al., 2005). To confirm our results obtained with the 
mammalian two-hybrid assay, we could perform similar experiments to look at the 
conformation of the AR in the presence of MPA and NET-A, using ARs double 
tagged at the N and C termini with the FRET couple cyano fluorescent protein (CFP) 
and yellow fluorescent protein (YFP).  
 
A limitation of our study may be that we used only promoter-reporter constructs and 
overexpressed AR to investigate the mechanisms of transcriptional regulation of 
MPA and NET-A via the AR. However, our results for the repression by MPA on the 
RANTES gene via the AR suggest that the effects seen with synthetic promoter-
reporter genes are reflected on endogenous genes. In contrast, the result with NET 
on the endogenous RANTES gene differs to the effect found with synthetic promoter-
reporters, and it is thus possible that promoter-reporters may not reflect the 
regulation on full-length endogenous promoters in the context of the native chromatin 
structure. However, a study by Ghatge and co-workers (2005), showing that MPA 
and DHT are equally potent in regulating endogenous genes in breast cancer cell 
lines, supports our findings showing similar potent androgenic activity of MPA and 
DHT in the COS-1 cell line transiently transfected with an AR expression vector and 
promoter-reporter constructs. We thus conclude that the approach of using promoter-
reporter constructs, as well as using the COS-1 cell line, devoid of steroid receptors, 
are appropriate methods for directly comparing the mechanism of action of MPA and 
NET via different steroid receptors. This approach is also useful as cells expressing 
physiologically relevant genes are often found in cells that contain several different 
steroid receptors, making it difficult to identify which receptor is mediating a specific 
response. However, it would still be interesting to demonstrate the relevance of our 
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results obtained with transfected promoter-reporter constructs by verifying these 
results on an endogenous promoter, particularly for NET-A. 
 
In the third part of this thesis (Chapter 4), we show that MPA, NET-A and RU486 are 
devoid of MR agonist activity for transactivation and are weak MR antagonists. For 
the GR it has been shown that receptor density can change the biocharacter of MPA 
and RU486 (Zhao et al., 2003). At high receptor density, both MPA and RU486 
behaved as full agonists for transrepression, while at low receptor density, the 
ligands behaved as full antagonists. It would thus be interesting to see whether MPA, 
NET-A and RU486, can also change their agonist versus antagonist activities for 
both transactivation and transrepression at varying concentrations of MR, and also 
other steroid receptors. Furthermore, as we only determined the efficacy of ligands 
for MR transrepression on AP-1, it would be useful to also determine the potency of 
these ligands. 
In addition, the MR N/C-interaction was shown only for the agonists used in this 
study. It is thus possible that disruption of the N/C-interaction is one mechanism by 
which antagonists inhibit activation of the MR. It would be interesting to see whether 
MPA, NET-A and RU486 can antagonize the Ald-induced MR N/C-interaction. Our 
results on the expression of the endogenous Orm-1 gene were determined in H9C2 
cells with transiently transfected MR. Furthermore, the hypothesis that the MR plays 
a role in the antagonism of NET-A and RU486 may be strengthened by knocking 
down the MR using siRNA technology. Similar experiments may also be performed to 
exclude the role of the GR.  
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Finally, the studies with overexpressed AR and MR, as well as synthetic promoters, 
in the COS-1 cell line shed light on the putative role of steroid receptors in mediating 
the responses of MPA and NET-A in different cell types, such as the ectocervical and 
vaginal epithelial cell lines, as well as the cardiomyocyte cell line.  
 
5.5 Conclusion 
In summary, the results presented in this thesis show that in agreement with our 
hypothesis Prog, MPA and NET-A differentially regulate IL-8 and RANTES gene 
expression in the female genital tract, in a cell-specific manner. The differential 
effects of the progestins as compared to each other and Prog, was most striking on 
the RANTES gene. Prog upregulated TNFα-induced RANTES gene expression, 
NET-A had no effect, and MPA repressed this gene. This result implies that the use 
of MPA in vivo may either exert local immunosuppressive side-effects, or positive 
effects in terms of inflammation and HIV, while NET-A and natural Prog, will not 
exhibit these effects. Interestingly, both MPA and NET-A act differently to Prog, 
which had previously been shown to have a protective role in the vagina. This could 
in fact indicate that both MPA and NET-A may impact on the risk of susceptibility to 
infections in the cervicovaginal environment. It was further shown that the repression 
of TNFα-induced RANTES gene expression by MPA in the ectocervical cell line is 
mediated by the AR. In contrast, the effect of MPA in the vaginal cell line was not 
mediated by the AR. As hypothesized, the results investigating the activity of MPA 
and NET-A via overexpressed AR in COS-1 cells, show that both these synthetic 
progestins, unlike Prog, are potent androgens. This suggests that women using 
these progestins therapeutically could have androgenic side-effects such as negative 
impact on fetal or neonatal development when contraceptives are inappropriately 
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used (Kemppainen et al., 1999) or effects on hepatic endocrine function in HRT 
users (Nugent et al., 2003). In addition, the use of these potent androgens may 
reverse the protective effects of natural androgens in breast tissue, leading to 
increased risk of breast cancer in women, as was seen in the ‘Million Women Study’ 
(Million women study collaborators, 2003). Furthermore, our results show that both 
MPA and NET-A are weak partial antagonists of Ald-mediated MR transactivation on 
a synthetic GRE promoter. However, MPA, unlike Prog and NET-A, cannot 
antagonize the Ald-upregulated expression of the endogenous GRE-containing Orm-
1 gene. This may have adverse implications for cardiovascular side-effects when 
MPA is clinically used. Moreover, our results indicate that MPA on its own may 
directly enhance the expression of genes that are cardiovascular risk markers. The 
combined results from this thesis, together with the existing physiological and 
molecular information available on MPA and NET-A, relative to natural Prog, may 
improve our understanding of the physiological outcomes of these progestins in vivo.  
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APPENDIX A: DATA NOT INCLUDED IN CHAPTER 2 
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A1: Hydroxyflutamide does not inhibit the effects of Prog, MPA or 
NET-A on RANTES gene expression in the human vaginal cell line 
(Vk2/E6E7)  
 
 
 
Figure A1: Effect of the androgen receptor antagonist (OHF) on the upregulation of the TNF-α-
induced RANTES gene expression by Prog, MPA or NET-A. The human Vk2/E6E7 cell line was 
incubated with 0.02 µg/µl TNF-α in the presence of 1 µM Prog, MPA, NET-A, or DHT, and absence or 
presence of 10 µM hydroxyflutamide (OHF) for 24 hours. Total RNA was extracted, cDNA 
synthesized, and expression levels of RANTES and GAPDH mRNA were determined by QPCR. 
Results shown (ratio of the specific target gene/GAPDH gene) are representative of two independent 
experiments. Open bars are compounds and vehicle only, while the black bars are compounds plus 
antagonist. 
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B1: Optimisation of [3H]-MIB concentration for the determination of 
Kd or Ki values of ligands via overexpressed hAR 
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Figure B1: Determining the optimal concentration of [3H]-MIB. COS-1 cells (1x105 cells per well in 
a 24-well plates) were transiently transfected with 0.375 µg pGL2 basic vector (-AR) or pSVARo and 
0.0375 µg pCMV-β-gal expression vectors, using the FUGENE 6 transfection reagent according to the 
manufacturer’s instructions. Twenty-four hours later the cells were incubated with 0.2 nM or 1 nM [3H]-
MIB in the absence or presence of 1000 fold excess unlabelled MIB for 90 minutes. Specific binding 
normalised to β-galactosidase expression is shown. 
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B2: Time course to establish equilibrium time for binding of 0.2 nM 
[3H]-MIB to overexpressed hAR 
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Figure B2: Equilibrium time for 0.2 nM [3H]-MIB to bind to overexpressed AR is 16 hours. COS-1 
cells (1x105 cells per well in a 24-well plate) were transiently transfected with 0.375 µg pSVARo and 
0.0375 µg pCMV-β-gal expression vectors, using the FUGENE6 transfection reagent according to the 
manufacturer’s instructions. Twenty-four hours later the cells were incubated with 0.2 nM [3H]-MIB in 
the absence and presence of 10 µM unlabelled MIB for varying times. Specific binding normalised to 
β-galactosidase expression is shown. 
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B3: Transrepression assay in COS-1 cells in the absence and 
presence of overexpressed hAR 
 
 
Figure B3: Transrepression activity in the absence and presence of overexpressed hAR. COS-1 
cells were transiently transfected with pCMV-β-galactosidase expression vectors and (A) pGL2basic 
empty vector and NFĸB-containing promoter-luciferase reporter construct or (B) pSVARo and NFĸB-
containing promoter-luciferase reporter construct or (C) pGL2basic empty vector and AP-1-containing 
promoter-luciferase reporter construct or (D) pSVARo and AP-1-containing promoter-luciferase 
reporter construct. Subsequently, the cells were stimulated with PMA and incubated with 1 µM of 
either MIB, DHT, Prog, MPA, NET-A or RU486 for 24 hours. The resulting plots show repression by 
the individual ligands calculated as a percentage of EtOH (100%). Result shown is the average of 
three independent experiments with each condition performed in triplicate (±SEM).  
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B4: MPA and NET-A lack AR antagonist activity  
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Figure B4: MPA and NET-A do no display androgen antagonist activity. COS-1 cells were 
transiently transfected with the pTAT-GRE-E1b-luc reporter, pSVARo and pCMV-β-galactosidase 
expression vectors. Subsequently, the cells were incubated with 0.1 nM MIB alone (100%) or in the 
presence of increasing concentrations of DHT (), Prog (), MPA (), NET-A (♦) or RU486 () for 
24 hours. Result shown is the average of at least four independent experiments with each condition 
performed in triplicate (±SEM). 
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B5: MPA, but not NET-A, antagonizes the DHT-induced N/C-
interaction of the AR 
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Figure B5: In contrast to MPA, NET-A does not antagonize the DHT-induced N/C-interaction of 
the hAR. COS-7 cells were transiently transfected with the pTAT-GRE-E1b-luc reporter, the pSG5-
hAR(DBD-LBD), the pSNATCH-II(hAR-NTD) and the pCMV-β-galactosidase expression vectors. 
Subsequently, the cells were exposed to increasing concentrations of DHT, or 10-7 M DHT in the 
presence of increasing concentrations of (A) MPA and (B) NET-A, for 24 hours. Result is shown as 
luciferase (luc) activity normalized to β-galactosidase (β-gal) activity. Results are averages of three 
independent experiments with each condition performed in triplicate (±SEM). 
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APPENDIX C: DATA NOT INCLUDED IN CHAPTER 4 
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C1: Optimisation of [3H]-Ald concentration for the determination of 
Kd or Ki values of ligands via overexpressed hMR 
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Figure C1: Determining the optimal concentration of [3H]-MIB. COS-1 cells (1x105 cells per well in 
a 24-well plates) were transiently transfected with 0.375 µg pGL2 basic vector (-MR) or pRShMR and 
0.0375 µg pCMV-β-gal expression vectors, using the FUGENE 6 transfection reagent according to the 
manufacturer’s instructions. Twenty-four hours later the cells were incubated with 0.2 nM, 0.5 nM, 1 
nM or 2 nM [3H]-Ald in the absence or presence of 1000 fold excess unlabelled Ald for 90 minutes. 
Specific binding normalised to β-galactosidase expression is shown. 
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C2: Time course to establish equilibrium time for binding of 0.2 nM 
[3H]-Ald to overexpressed hMR 
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Figure C2: Equilibrium time for 0.2 nM [3H]-Ald to bind to overexpressed MR is 16 hours. COS-1 
cells (1x105 cells per well in a 24-well plate) were transiently transfected with 0.375 µg pRShMR and 
0.0375 µg pCMV-β-gal expression vectors, using the FUGENE 6 transfection reagent according to the 
manufacturer’s instructions. Twenty-four hours later the cells were incubated with 0.2 nM [3H]-Ald in 
the absence and presence of 10 µM unlabelled Ald for varying times. Specific binding normalised to β-
galactosidase expression is shown. 
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C3: Transrepression assay in COS-1 cells in the absence and 
presence of overexpressed hMR  
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Figure C3: Transrepression activity in the absence and presence of overexpressed hMR. COS-1 
cells were transiently transfected with pCMV-β-galactosidase expression vectors and (A) pGL2basic 
empty vector and NFĸB-containing promoter-luciferase reporter construct or (B) pRShMR and NFĸB-
containing promoter-luciferase reporter construct or (C) pGL2basic empty vector and AP-1-containing 
promoter-luciferase reporter construct or (D) pRShMR and AP-1-containing promoter-luciferase 
reporter construct. Subsequently, the cells were stimulated with PMA and incubated with 1 µM of 
either Ald, Prog, MPA, NET-A, RU486, or Dex for 24 hours. The resulting plots show repression by the 
individual ligands calculated as a percentage of EtOH (100%). Result shown is the average of three 
independent experiments with each condition performed in triplicate (±SEM). 
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C4: Prog displays weak partial agonist activity for transactivation 
via overexpressed MR in COS-1 cells 
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Figure C4: Unlike Ald and Prog, MPA and NET-A do not display mineralocorticoid agonist 
activity. COS-1 cells were transiently transfected with the pTAT-GRE-E1b-luc reporter plasmid plus, 
pRShMR and pCMV-β-galactosidase expression vectors. Subsequently, the cells were incubated with 
1 µM of either Ald, Prog, MPA or NET-A for 24 hours. Luciferase (luc) activity was normalized to β-
galactosidase (β-gal) activity, and is shown as fold induction relative to EtOH set as 1. Results shown 
are the average of at least three independent experiments with each condition performed in triplicate 
(±SEM). 
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C5: Similar induction of the MR N/C-interaction by aldosterone and 
cortisol  
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Figure C5: Ald and Cort induce the N/C-interaction of the hMR to a similar extent. COS-1 cells 
were transiently transfected with the GAL4-MRC and VP16-MRNT expression vectors, as well as the 
GAL4-responsive luciferase reporter vector pG5-luc. The cells were exposed to 10 µM Ald or Cort for 
24 hours. Results are averages of at least three independent experiments with each condition 
performed in triplicate (±SEM), and are shown as fold induction relative to EtOH set as 1..  
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C5: Antagonist activity of NET-A via the hGR in COS-1 cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure C6: Relative antagonist activity of NET-A via the GR. COS-1 cells were transiently 
transfected with HA-hGR-pCMV and pTAT-GRE-E1b-luc. The cells were incubated with 0.1 nM Dex in 
the absence (100%) and presence of increasing concentrations of RU486 (A) or NET-A (B). 
Thereafter the lysates were assayed for luciferase activity. One representative experiment for each 
compound performed in triplicate (± S.E.M.) is shown.  
 
co
ntr
ol
-
10 -9 -8 -7 -6 -5
0
50
100
150
log [RU486] M
RL
U 
(10
0 
%
 
=
 
0.
1n
M
 
De
x
)A 
co
ntr
ol
-
10 -9 -8 -7 -6 -5
0
50
100
150
log [NET-A] M
R
LU
 
(10
0 
%
 
=
 
0.
1n
M
 
D
ex
)
B 
 284 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX D: DEFINITIONS AND EXTRA DATA NOT INCLUDED IN 
CHAPTERS 
 285 
D1: Binding parameters and calculations 
The relative binding affinity (RBA), also referred to as the EC50, is a measure of the 
concentration of ligand that competes for half the specific binding. It is used to 
estimate the binding affinity of a ligand for a receptor. The EC50 values obtained from 
competitive binding curves however, are not equivalent to Kd or Ki (equilibrium 
dissociation constant) values. The EC50 is a relative term, which is influenced by 
different experimental conditions, such as receptor number or concentrations of 
radiolabelled ligand, while the Kd or Ki is a constant value for a particular receptor, 
which is not influenced by experimental variations (GraphPad Prism software).Thus, 
like the EC50, the Kd or Ki, is a measure of the affinity of a ligand for a particular 
receptor, that reflects the concentration of ligand needed to bind to half the available 
receptors at equilibrium, but it represents a more accurate measure of binding affinity 
of a ligand for its receptor than EC50 values.  
 
Kd is typically determined in a saturation binding assay using varying concentrations 
of a radiolabelled ligand. A low Kd or Ki value means that a low concentration of 
ligand is needed to bind half the available receptors. Thus, a low Kd or Ki value 
indicates that the receptor has a high affinity for the ligand. Ki refers to the equilibrium 
constant of a ligand determined in inhibition studies, and is usually determined by the 
alternative method for determining Kd or Ki, which is a homologous/heterologous 
competitive binding assay. A homologous binding assay is one where the 
radiolabelled and unlabelled are chemically identical, while in the heterologous 
assay, they differ. In these experiments, the radioligand concentration remains 
constant, and competes with varying concentrations of unlabelled competitor ligand 
for the receptor.  
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Analysis of radioligand binding experiments is based on the law of mass action, 
which assumes that binding is reversible. The number of binding events per unit of 
time = [Ligand]. [Receptor].Kon, where Kon is defined as the association- or on-rate 
constant (GraphPad Prism software). Following binding, the ligand remains bound to 
the receptor for a random amount of time, and the possibility of dissociation is very 
similar, at every instant of time. The rate of dissociation is the number of dissociation 
events per unit time= [ligand.receptor]. Koff where Koff is defined as the dissociation- 
or off-rate constant. Equilibrium is reached when the rate at which new ligand-
receptor complexes are formed equals the rate at which the ligand-receptor 
complexes dissociate (GraphPad Prism software). Thus, at equilibrium, 
[Ligand].[Receptor].Kon = [Ligand.Receptor].Koff. If this equation is rearranged, the Kd 
is defined as Koff / Kon, which equals [Ligand].[Receptor] / [Ligand.Receptor] 
(GraphPad Prism software). 
 
To accurately analyse and interpret the results from competitive ligand binding 
experiments, it is crucial to determine the time to reach binding equilibrium to the 
receptor with the concentration of radiolabelled ligand used in the experiment. The 
concentration of radiolabelled ligand used was in the range of two to ten times lower 
than the EC50. In addition, the ligand depletion always needs to be considered. 
Ligand depletion measures the fraction of the ligand bound to the receptor (specific 
sites) vs. the fraction of the ligand bound to nonspecific sites. One would assume that 
only a small fraction of the added ligand binds to the receptor, so that the free 
concentration approximates to the concentration initially added. Less than 10% 
ligand depletion is considered acceptable.  
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As [3H]-MPA and [3H]-NET-A are not commercially available, Kd and Ki values were 
determined from pooled data of three independent experiments, by homologous and 
heterologous binding experiments, respectively (Chapter 3 and 4). Once the optimal 
concentration of radiolabelled ligand was established (0.2 nM for both [3H]-MIB 
(Chapter 3) and [3H]-Ald (Chapter 4)), the incubation time for equilibrium to be 
reached with 0.2 nM [3H]-MIB and [3H]-Ald was determined. The Kd was 
subsequently calculated from homologous binding experiments by GraphPad Prism 
software according to the following equation: Total binding = (Bmax.[Hot] / [Hot] + 
[Cold] + Kd +NS, where NS is nonspecific binding and Bmax is the maximum binding 
of ligand to receptors in cpm. Once the Kd for MIB was determined, heterologous 
binding experiments were performed, and the Ki values for Prog, MPA, NET-A, DHT, 
R1881, and RU486 were determined (Chapter 3) according to the Cheng- Prussoff 
equation: Ki = EC50 / 1 + ([ligand] / Kd), where the EC50 value is that determined for 
the competing ligand, the [ligand] is the radiollabelled igand concentration used, and 
the Kd determined from the homologous binding experiments. Ki can only be 
determined using the Cheng-Prussoff equation, provided that the EC50 is two to ten 
times lower than the concentration of radiolabelled ligand, and that binding 
equilibrium has been reached at that concentration. In the same manner, the Kd 
value for Ald, and Ki values for Prog, MPA, NET-A, RU486 and Dex were 
determined. All binding data were analysed using GraphPad Prism software, using 
the following parameters: Nonlinear regression curve fit, homologous competitive 
binding curve, one class of binding sites, weighting 1/y2 (this minimises relative 
distances squared), consider the mean y value of each point and a stricter (slower) 
criterion for convergence. In addition, run rest and residuals test were used to 
determine whether the curve differed systematically from the data.  
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D2: Pharmacological definitions 
To characterize the effects elicited in terms of transactivation and transrepression of 
genes when a ligand binds to its receptor, two parameters need to be determined, 
namely efficacy and potency (figure D2(i)).  
 
 
 
 
 
 
 
Figure D2(i): A schematic representation of a sigmoidal dose-response curve indicating potency 
(EC50 value) and efficacy (maximal effect).  
 
The efficacy of a ligand refers the maximal effect it can elicit in a given cell under 
specific experimental conditions. Efficacy is characterised as either a full agonist or 
partial agonist. A full agonist is a ligand that produces a maximal response, while a 
partial agonist is a ligand eliciting a response less than the maximal response of that 
of a full agonist (figure D2(ii)). In contrast, an antagonist is a compound that binds to 
a receptor but that does not elicit a response itself, but inhibits agonist-mediated 
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responses (figure D2(ii)). The potency of a ligand is commonly quantified as the 
EC50, which is the concentration that induces half the maximal response.  
 
 
 
 
 
 
 
 
Figure D2(ii): A schematic representation of a sigmoidal dose-response curves indicating a full and 
partial agonist, as well as an antagonist. (for ligands binding to a single site, with no co-operativity) 
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D3: Transactivation in COS-1 cells in the absence and presence of 
overexpressed MR, AR or GR 
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        (B) MR            C) AR        (D) GR 
 
Figure D3: Agonist activity for transactivation via possible endogenous receptors, MR, AR or 
GR in COS-1 cells. COS-1 cells were transiently transfected with 100 ng pTAT-GRE-E1b-luc reporter 
plasmid plus, 10 ng pGL2basic (A), pRShMR (B), pSVARo (C) or HA-hGR-pCMV (D), and 10 ng 
pCMV-β-galactosidase expression vectors in a 96-well plate. Subsequently, the cells were incubated 
with 10 µM Prog, MPA, NET-A, RU486, MIB, DHT, Ald, Dex or Cort for 24 hours. Induction is shown 
as fold induction relative to EtOH set as 1. Result shown is one representative figure with each 
condition performed in triplicate (±SEM).  
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D4: Effects of Dex, MPA and NET-A on IL-6 protein production in 
human monocytes 
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Figure D4: MPA and NET-A exert pro-inflammatory and anti-inflammatory properties. Peripheral 
blood was drawn from healthy volunteers. Peripheral blood mononuclear cells were isolated from 
peripheral blood from healthy volunteers using Ficoll-Histopaque density centrifugation. Cells were 
cultures in RPMI 1640 containing 10%FBS and antibiotics for one hour. Non-adherent lymphocytes 
were removed. Adherent monocytes were cultured for 20 hours in the absence (A) and presence (B) 
of 100mg/ml lipopolysaccharide (LPS), in the absence and presence of increasing concentrations of 
Dex, MPA or NET-A. Secretion of IL-6 was measured by ELISA. One representative experiment for 
each compound performed in triplicate (± S.E.M.) is shown. 
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